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SUMMARY
Chronic Fatigue Syndrome is an illness characterized by severe, disabling fatigue of sudden 
onset that is not alleviated by rest, has been present for at least six months and causes a 
reduction in premorbid activity by at least 50%. Accompanying symptoms usually include 
myalgia, mood and sleep disturbance. Patients often describe the sudden onset of fatigue 
following a flu-like illness leading a number of investigators to propose an infectious 
cause.
Early serological evidence from Glasgow suggested an association between the 
enteroviruses (members of the Picornaviridae) and CFS in a high proportion of cases 
(Fegan et al., 1983). This was followed by the use of PCR (polymerase chain reaction) 
assays to detect the highly conserved 5’ non-translated region (NTR). This technique can 
detect the majority of the enteroviruses with the exception of echovirus 22 and 23. Initial 
work on muscle biopsies showed that 53% of biopsies from CFS patients were positive for 
enteroviral sequences compared to 15% of controls (Gow et al., 1991). Obtaining muscle 
biopsies is not an easy task however and work prior to this thesis looked at testing semm 
samples as an alternative. In this initial group, 42% of CFS patients were positive by a 
nested PCR compared to 2% controls, demonstrating that serum samples were suitable to 
test for enteroviral sequences (Clements et al., 1995). It has been suggested that 
enteroviruses persist in CFS patients, thus contributing to the chronic nature of the 
syndrome, but studies have not actually looked at enteroviral persistence over time. 
Rather, evidence has been based on a positive result from one sample only obtained from 
patients with a long history of illness and this does not provide direct evidence of 
persistence.
A prospective study was thus initiated to form the basis of this thesis to follow a group of 
patients with CFS and examine their serum for evidence of enteroviral sequences over time 
and to compare any positive PCR products by sequence analysis. Additionally, a 
questionnaire was developed to determine the clinical nature of the illness and to try to 
correlate this with the enteroviral status of the patient at a particular time.
Initial phylogenetic analysis of sequence derived from twenty semm positive samples 
showed that the sequences derived from CFS patients grouped apart from the known 
enteroviruses and from sequences derived from other clinical cases on a phylogenetic tree
I(Galbraith et al., 1995). The sequences were approximately 69-84% similar to the closest
sequence of a coxsackievirus B3. However, the sequences could have been from known
enteroviruses with no sequence data available, from known enterovimses with variant 5’
NTRs or from previously unknown enterovimses. Further analysis at a later date with
other available sequence data showed that the sequences grouped within the
coxsackie/echo virus group although some were still 10-13% different. The variation
observed was of the order of that seen between clinical isolates of the same serotype, thus
the CFS patient sequences may have represented known enterovimses with variant 5’
• -NTRs. Without corroboration from other regions this tentative group could not be 
described further. The capsid region was chosen as an alternative target region since it is 
relatively conserved among the enteroviruses, containing the neutralizing regions which 
form the basis of the serotypes. Semi-nested priming could amplify the majority of the 
known enteroviruses to a sensitivity of 1 TCID50, which was 100-fold less than the standard 
PCR. Testing of 55 samples previously positive by the standard PCR did not generate any 
positives. The use of other techniques (inverse PCR, long PCR and production of a cDNA 
library) to acquire additional sequence were also unsuccessful. Either the assays were not 
sensitive enough to detect the low levels of RNA present in the semm (as assessed by the 
standard PCR) or the genome is so different or deleted (perhaps due to the presence of 
defective-interfering particles) that amplification was not possible. Indeed, the discovery 
that 85% of enteroviral RNA samples lacked a poly-A tail may also point to there being 
atypical sequence present. Limited sample volume prevented this from being pursued 
further.
Persistence was examined by analyzing the 5’ NTR sequence of two sequential samples 
obtained from sixteen patients. Many sequences, however, were more similar to those 
isolated in the same year than to their respective pair. Additionally, correlation with 
clinical data did not suggest a role for enteroviral persistence in the maintenance of the 
syndrome, although a positive correlation between severity of symptoms (based on ability 
to work and time spent walking for example) and the presence of enteroviral sequence was 
noted on analysis of first questionnaires from a cohort of 130 patients. This was not 
present on analysis of the second questionnaire from each patient. The average duration of 
fatigue for this group of patients was 3.9 years and thus questionnaire analysis proved 
difficult in terms of patients recalling features prior to their fatigue.
In a preliminary study, a group of patients who had a history of fatigue of approximately
I
six months was described. Enteroviral sequences were detected in the serum of 42% of 
CFS patients compared to 27% of acutely-ill patients and 2% of healthy control 
individuals. Additionally, a number of positives in the CFS patient group were detected 
after one round of PCR only, perhaps indicating a higher titre of enterovirus in these 
samples. While this study was being carried out there was an outbreak of echovirus 4 and 
this suggested therefore that the virus played a direct role in triggering the syndrome. 
Sequence analysis of PCR positives was not performed at this time to confirm this theory. 
Thus it may be useful to test patients shortly after the onset of fatigue where there is a 
history of a flu-like illness, when there is a greater chance of recovering a possible 
triggering agent, even though a formal diagnosis has not been made.
Consistently, a higher proportion of CFS patients than comparison individuals were 
positive for enteroviral sequences throughout this study (except in 1997) and thus this work 
does not rule out the enteroviruses as being involved in CFS. However, the methods 
employed did not elucidate any further sequence information nor provide a definitive 
answer regarding the role of these viruses in individuals with a long history of illness.
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Introduction
1. In troduction
1.1. Towards the concept of  ^ viruses'
By the end of the nineteenth century the existence of microorganisms such as bacteria, 
fungi and protozoa was well established. However, there were many infectious diseases at 
the time, such as measles and rubella, that could not be attributed to these agents and the 
search for alternative causes began.
In the late 1870s, Adolf Mayer discovered that tobacco mosaic disease could be transmitted 
to healthy tobacco plants by inoculating them with an extract of the diseased plant. He 
was unable to demonstrate the presence of any kind of disease agent, but continued to 
search for a bacterium as the cause. Dimitri Ivanofsky (1864-1920) also working on this 
disease confirmed some of the findings of Mayer, passing the infected plant material 
through a Chamberland filter (designed to retain most bacteria) and showing that it still 
retained infectivity. He suggested that the infective material might be a toxin produced by 
bacteria, but he did not pursue this idea. Also at this time, Martinus Beijerinck (1851- 
1931) demonstrated that the filtered plant material could be diluted and that it could regain 
its ‘strength’ after replicating in the living tissue of a plant. He showed that only living 
cells could be infected and postulated that the agent responsible must be incorporated into 
the living protoplasm of the cell and could not multiply outside the cell. He subsequently 
called the agent ‘Contagium vivum fluidum’, meaning contagious living liquid (Levine, 
1996; Collier, 1998).
Together, Mayer, Ivanofsky and Beijerinck developed the idea of the existence of a 
filterable agent that was too small to observe in the light microscope, but was able to cause 
disease by multiplying in living cells. This agent was subsequently called a ‘virus’, from 
the Latin for slimy liquid or poison.
This idea of a filterable agent was accepted by many individuals who began to look in 
diseased tissues for these agents and in 1898 to 1899, Loeffler and Frosch described and 
isolated foot and mouth disease virus (FMDV), the first filterable agent from animals.
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Work by Frederick Twort in 1915 and that of Felix d’Herelle at the Pasteur Institute on 
Shigella led to the discovery of viruses that killed bacteria. D ’Herelle named these 
bacteriophages, and developed the plaque assay in 1917 for determining vims titre. From 
this date, bacteriophage studies were pivotal in the development of molecular biology, 
being used as models for the study of replication of other viruses.
Tobacco Mosaic Virus (T.M.V.) continued to be studied with a view to purifying the virus 
and identifying the biochemical nature of the particle. Crystallization of the vims was 
achieved in 1935 by Wendell Stanley, followed a few years later by X-ray crystallography 
of the T.M.V. crystals. The stmcture was confirmed in 1939 when the first electron 
micrographs of any vims were taken. Brenner and Horne described negative staining of 
viruses for electron microscopy in 1959 and this led to a great increase in knowledge 
regarding virus structure and it is still an important technique today.
7It was however, the development of cell culture techniques (from culturing single cells by 
Sanford in 1948 to developing the HeLa cell line by Gey in 1952) that was crucial to the 
advancement of virology as a science. Discovering that poliovirus could replicate in non- 
neuronal human tissue (Enders et a l, 1949) led to the development of the poliovims
■".1vaccine since the virus could be grown in cell culture whereas previously, viruses such as %
smallpox, rabies and influenza which were used for vaccines had been grown in animals or 
embryonated hen eggs. Poliovims was the first animal virus to be subject to the plaque 
assay and this led the way for detailed study of this virus. Today many hundreds of vimses 7 |
have been described (Levine, 1996).
1.2. Classification of Viruses
Early virus classification systems were based on what were regarded as common 
pathogenic properties (for example viruses causing hepatitis i.e. hepatitis A, hepatitis B and 
yellow fever were grouped together as ‘hepatitis viruses’), common organ tropisms (for 
example respiratory vimses would have included those now known as influenza viruses, 
rhinoviruses and adenoviruses) and common ecological characteristics (for example, the 
arboviruses would have included agents now known as togaviruses, bunyavimses and 
rhabdo viruses).
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In the 1950’s there was sufficient biochemical and moiphological data on the nature of the 
virus particles to influence the classification of viruses. This eventually led to the first 
groupings based on shared virion properties. From this basis, taxonomic groups were 
constructed and included the herpesvirus group, myxovims group and poxvirus group. 
There were also an increasing number of new human and animal viruses discovered at this 
time. This led to the establishment in 1966 of the I.C.N.V. (The International Committee 
on Nomenclature of Viruses) at the International Congress of Microbiology in Moscow. 
The function of the ICNV was to classify hundreds of viruses isolated from humans, 
animals, plants, invertebrates and bacteria (The ICNV changed to the International 
Committee for the Taxonomy of viruses (ICTV) in 1974). In its report of 1995, a 
universal taxonomy scheme for viruses was described. It comprised one order (suffix - 
virales), 71 families (suffix -viridae), 11 subfamilies (suffix -virinae) and 164 genera 
(suffix -virus), including many floating genera and more than 4000 member viruses 
(Murphy etal., 1995).
Classification of viruses into families is mainly based on virion morphology (size, shape, 
symmetry, presence of envelope), and the nature of the genome (DNA or RNA, single or 
double stranded, linear or circular, positive-sense or anti-sense). Lwoff, Horne and 
Tournier laid down the basis for this scheme in 1962. Other factors such as biological 
properties (host range and mode of transmission), physicochemical properties such as pH 
stability, and antigenic properties are also important in identifying types and strains within 
the families. The relationship between viral mRNA and the virus genome forms the basis 
of the Baltimore scheme for the grouping of viruses (Baltimore, 1971). Groupings include 
the positive-sense single stranded RNA viruses typified by the Picornaviridae; double 
stranded RNA vimses such as the Reoviridae and double-stranded DNA viruses which 
replicate in the cytoplasm i.e. Poxviruses, as opposed to the nucleus i.e. Herpesviruses.
Today the techniques of molecular biology are widely available and sequencing of the 
nucleic acid of a new vims is often carried out before other data are available. Hepatitis C 
vims (HCV) for example, shows high levels of sequence variability, and cannot be 
classified into serotypes using neutralization assays because of the absence of simple virus 
culture methods. Instead, comparison of nucleotide sequence data has led to classification 
into genotypes that differ from each other by approximately 30% over the entire genome 
(Mellor e ta l ,  1995; Simmonds et a l,  1993).
3
----------------------:----- :------------------ :_________ :_:_______L._________  .
iï;
Introduction 7#
1.3. Picornaviridae
1.3.1. Members of the Picornaviridae family
The Picornaviridae are examples of the single-strand positive sense RNA viruses, 
officially classified in 1963. They are among the smallest (pico) RNA viruses known,
comprising a diverse group of human and animal pathogens. The picornavirus genera are |%distinguished by a number of criteria including buoyant density in caesium chloride, acid 
stability and size of capsid proteins.
Within the genera, species are distinguished immunologically by the ability of specific 
antisera to neutralize only homotypic virus. Table 1 shows the six genera of the family f  
and the type species for each genus. The genus name parechovirus was recently approved 
by the ICTV (Pringle, 1997; Mayo & Pringle, 1998) to include human echovirus types 22 
and 23.
Rhinoviruses inhabit the upper respiratory tract and are one of the causative agents of the 
acute afebrile upper respiratory diseases, which group clinically as the common cold. |
They are acid labile and have a low optimal temperature of replication which reflects their 
adaptation to the nasopharyngeal region. There are now over 100 recognized human 
serotypes and they have a buoyant density of 1.4g/ml.
The cardioviruses are rarely associated with human disease having been recovered mainly 
from rodents, but their true natural host is unknown. They are acid stable, have a buoyant ft
density of 1.34g/ml and are represented by two serotypes: the encephalomyocarditis (EMC) 
viruses (EMC virus, Columbia SK virus, ME virus, MM virus and mengovirus) and 
Theiler’s Murine Encephalomyelitis Viruses (TMEV).
Aphthoviruses rarely infect humans and are named for the vesicular lesions they produce in 
cloven-footed animals especially cattle, goats, pigs and sheep. They have a buoyant 
density between that of the enteroviruses and the rhinoviruses. They are highly labile 
being rapidly inactivated at pH 7 or less.
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The hepatovimses have also only recently been considered to be a distinct genus within the 
picornavirus family. Previously, human hepatitis A vims was classified as enterovirus 72 
because it shared similar physical properties with the enterovimses, such as acid stability, a 
buoyant density of 1.34g/ml and a similar genome and particle size. However, when the 
complete sequence of the hepatitis A genome was determined, it was found to share little 
homology with the enteroviruses at the molecular level and was thus reclassified (Melnick, 
1990; Rueckert, 1996).
I
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GENUS TYPE SPECIES
Enterovirus poliovirus 1
Rhinovirus human rhinovirus (HRV)-IA
Cardio virus encephalomyocarditis virus (EMC)
Aphthovirus foot and mouth disease vims (FMDV) 0
Hepatovims human hepatitis A virus (HAV)
Parechovirus echovirus 22
Table 1: The 6 genera within the Picornaviridae family and the type species for each 
genus.
I
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1.3.2. Virus Structure
Virus structures have been determined by X-ray crystallography and at least one member 
from each picornavims genus has been examined, Poliovirus is one of the most 
extensively characterized viruses but all the picornaviruses share similar features. They 
are non-enveloped, icosahedral particles of approximately 24-30nm in diameter. The 
protein capsid protects the RNA from nucleases, recognizes particular target cell receptors, 
determines the antigenicity of the virus particle and is involved in delivering the RNA 
through the cell membrane. The mature capsid is approximately 5nm thick and is 
composed of 4 types of protein- VPl, VP2, VP3 and VP4, one copy of each making up a 
sub-unit or protomer, the nomenclature following that of Rueckert and Wimmer (1984). 
These protomers are organized into pentameric units held together by a urea-sensitive 
binding domain. Twelve pentamers, held together by an acid-sensitive binding domain, 
associate to form the complete protein capsid (Figure lA).
Proteins VPl, VP2 and VP3 are exposed at the viral surface and are composed of 
approximately 250 amino acids. They are relatively compact, each consisting of an eight 
stranded anti-parallel beta-barrel with two flanking helices, the wedge-shaped folding 
pattern of which is conserved in the capsid proteins of icosahedral eukaryotic RNA vimses. 
One anti-parallel sheet is made up of strands B, I, D and G and the other is made of strands 
C, H, E and F (Figure IB), the two sheets forming the front and back of the barrel. The P 
sheets are joined at one end by 4 loops, the differences in size and conformation of which 
make the capsid proteins different. These loops cover the surface of the virion and mostly 
determine the antigenic sites of the virus. Five copies of VPl surround each five-fold axis 
of the icosahedral particle, while VP2 and VP3 alternate around the three-fold axis. The 
beta barrels of VPl are arranged in such a way that 3 loops are exposed and form a peak at 
the 5-fold axis of the pentamer. In the case of poliovims and human rhinovirus, the major 
neutralizing antigenic sites reside in the exposed BC loop of VPl, whereas in aphthovims 
the major sites reside in the GH loop (Rueckert, 1996).
 : 1    ^ -
Introduction
Figure 1: Picornavirus capsid structure showing V Pl, VP2 and VP3 icosahedral 
arrangement (A). P-barrel structure of capsid protein (B) (Hellen & Wimmer, 1995).
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The peak at the 5-fold axis is surrounded by a deep canyon in the human enteroviruses and 
rhino viruses, but not in the cardioviruses and aphtho viruses. This canyon is inaccessible 
to antibodies because of steric hindrance but is thought to be the acceptor site for receptor 
binding. Indeed, poliovirus mutants which are resistant to soluble receptor (srr) have been îj
identified. Mutations at the canyon surface at the interface between protomers, probably 
reduce binding affinity by interfering with receptor contact. A hydrophobic pocket of VP 1 
has also been identified, accessible through a pore in the canyon floor. In poliovirus types 
1 and 3 this pocket is occupied by a sphingosine-like molecule (pocket factor) which is 
thought to stabilize the virus during transit from one host cell to the next. Mutations near 
the pocket may affect the positioning of this molecule and thus modulate the receptor 
contact region on the surface. This pocket factor can be displaced by anti-viral WIN 
compounds (from Sterling-Winthrop) which bind in the hydrophobic pocket and result in 
conformational changes in the canyon floor, also affecting the receptor binding process 
(Racaniello, 1995).
Of the four proteins, VPl shows the greatest sequence variability probably because of its 
involvement in receptor interactions. VP4, containing 70 amino acids, is not exposed at 
the viral surface but is confined to the interior in close association with the RNA and thus 
shows the least variability (Rueckert, 1990). The N’ terminus of each VP4 is covalently 
bound to a myristic acid residue (Chow et a/., 1987). The myristate sequences penetrate 
the pentameric apex, possibly forming a framework for assembly of the capsid.
1.3.3. Genome Organization
The first picornaviral RNA to be completely sequenced was poliovirus type 1 (Kitamura et 
aL, 1981; Racaniello & Baltimore, 1981) and subsequent sequencing of other members has 
shown a common genome organization (Figure 2). The length of the genome varies 
between 7209 bases (HRV14) and 8450 bases (FMDV). At the 5’ end, there is a 
covalently attached protein of approximately 22 amino acids known as the VPg (virion 
protein, genome linked) which may play a role in the packaging of viral RNA or in the 
initiation of viral RNA synthesis (Grandien et a l, 1989). The next stretch, the 5’ non­
translated region (NTR), of between 600 and 1200 bases in length is highly conserved and
      . ,  , ,  ^ ^
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than 20% (Oberste et aL, 1998).
capable of forming secondary and tertiary interactions. It also contains the internal 
ribosomal entry site (1RES) the importance of which is discussed in section 1.3.4. The 5’
NTR is followed by a long open reading frame (ORE), which is translated into a single 
large protein (polyprotein) that codes for the structural capsid proteins (PI region), and the §
non-structural proteins (P2-P3 regions). Sequence variation is highest in VPl, which 
codes for the major antigenic sites, whilst variation in the non-structural proteins is 
considerably less. This is because many of the non-structural proteins are enzymes and %
thus extreme variation may be deleterious. In contrast, variation in the capsid proteins |
may be advantageous, enabling the virus to evade the immune responses of the host. At 
the 3’ end, a second NTR ends with a variable length polyadenosine (poly-A) tract. 
Cardioviruses and aphthoviruses differ slightly from this organization encoding a leader 
(L) protein before the coding region that contains a polycytidylate (poly-C) tract. 
Additionally, the 2A protein of FMDV is very small (16 amino acid residues compared to 
approximately 140) and the genome has three individual copies of the VPg protein in 
tandem (Rueckert, 1996).
Phylogenetic analysis of the nucleotide sequences (partial and complete) of the picornaviral 
genomes can be used to present the genetic relationships of the family. Figure 3, based on 
nucleotide sequence comparisons of the PI capsid region, shows the genera clustering 
according to their original classification, with the enteroviruses most closely related to the 
rhinoviruses and more distantly related to the aphthoviruses, cardioviruses and ÿhepato viruses.
The recently described parechoviruses, would cluster apart from the rhinovirus.
enterovirus, aptho virus and cardiovirus group, much like the hepato viruses, based on 
amino acid sequence identity of the VPl capsid region (Ghazi et aL, 1998). Compared to I;
the enteroviruses, the average amino-acid sequence identity of the parecho viruses was less iI
ICÎ
I
Introduction
PI P2 P3
Structural region Non-Structural regions 
,3B
5’ NTR
VPg lA IB 1C ID 2A 2B 2C
&
3A 3C 3D
3’ NTR 
_ AAAA,,
VP4 VP2 VP3 VP4
Protease VPg RNA polymerase
Protease
Figure 2: Diagrammatic representation of the genome organization of the 
Picornaviridae. The products of specific regions are indicated where known. 
Adapted from Field’s “Virology” (Rueckert, 1996).
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Figure 3: Phylogenetic clustering of members of the Picornaviridae based on sequence 
of the PI capsid region (Rueckert, 1996).
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1.3.4. Features of the 5’ NTR
The 5’ NTRs of the picomavimses have highly conserved primary and secondary 
structures, and play a vital role in RNA replication and translation of viral proteins. 
Manual and computer assisted folding procedures have been used to predict the secondary 
structure for the 5’ NTR of poliovirus RNA (Rivera et al., 1988; Filipenko et a i, 1989; 
Skinner et aL, 1989). Sub-optimal folding algorithms also showed conservation of 
secondary structure among the other enterovimses and rhinoviruses which was supported 
by phylogenetic data (Le & Zuker, 1990; Foyry et aL, 1992). The nucleotide sequence 
variation observed in this region of all sequenced enteroviruses shows compensatory base 
changes, in general, that support the stem-loop structures (Foyry et aL, 1992, Foyry et aL, 
1996). The aphthoviruses, cardioviruses and hepatoviruses have a different folding 
arrangement (Figures 4A and 4B). At the 5’ end, approximately 90 nucleotides form a 
cloverleaf-like structure that is essential for replication and which also functions as a 
binding site for the viral polymerase (3CD) and a host protein with a relative molecular 
weight of 36,000 (Andino et a l, 1990, 1993).
The next section of the 5’ NTR, a highly folded region of approximately 450 nucleotides 
long is known as the internal ribosome-binding site (1RES). Deletion experiments have 
been used to define the 1RES borders at 130 and 600 nucleotides encompassing domains II 
to V and part of VI. Deletion experiments and mutation analysis have also been used to 
identify regions of importance in the 1RES. For example, if position 200 in domain HI is 
affected, the recombinant virus has a temperature sensitive phenotype and protein synthesis 
is affected detrimentally. Domain IV is a highly complex multiple stem-loop structure the 
details of which differ in several of the proposed models. Internal deletions and insertions 
can result in viruses with defective translation activity. In domain V, nearly all mutations 
that disrupt base pairing are lethal to vims replication and translation in vitro. A mutation 
(C to U) at position 472 has been identified as a major attenuating mutation of Sabin type 3 
vaccine strain (Evans et aL, 1985). Similarly at position 480 in sabin type 1, an A to G 
mutation has been shown to contribute to attenuation (Kawamura et at., 1989).
The downstream 5’ NTRs of seven echoviruses with different neurovirulent phenotypes 
have been amplified and sequenced (Romero & Rotbart, 1995). The polypyrimidine tract 
of echovimses 2, 4, 6 , 9 ,  11 and 12 was shown to be twenty nucleotides in length, 
supporting the idea of a critical distance for efficient translation initiation. The
13
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echovimses with neurovimient phenotypes, that is, those frequently causing infection of 
the central nervous system (CNS), possessed the same sequence as each other, also seen in 
highly neurovimient poliovirus. The less neurovimient types (echoviruses 2 and 12) were 
slightly different in this sequence which may decrease their ability to initiate translation, 
enabling the host to limit their spread to the CNS.
Picornavims replication occurs in the cell cytoplasm, beginning with the attachment of the 
vims to its cellular receptor on the surface of the target cell. The details of the replication 
cycle, uncovered using poliovirus type 1/Mahoney as the model vims, have been described 
extensively elsewhere (Rueckert, 1996) and will not be expanded upon in this thesis. One 
important aspect of the replication cycle worth mentioning further is the mechanism of 
translation initiation. Picomavimses lack the 7-methyl-guanosine cap structure found at 
the 5’ end of eukaryotic cellular mRNA. In addition to the extensive secondary structure 
they have an unusually long 5’ NTR and they contain multiple AUG codons all of which 
can be inhibitory to the initiation process. The 5’ NTR is therefore not an easy target for 
the conventional initiation process and inefficient translation would be expected (Belsham 
& Sonenberg, 1996). In an in vitro cell-free translation system such as the rabbit 
reticulocyte lysate, enteroviral RNAs are very inefficient and additional aberrant internal 
translation products are generated. However, if cytoplasmic extracts from HeLa cells are 
added, the aberrant translation initiation is suppressed and viral protein synthesis is 
stimulated. Conversely, RNA from EMCV and FMDV is extremely efficient when 
translated in rabbit reticulocyte lysate systems and replicates efficiently and therefore must 
require different trans-eictmg factors from the enterovimses.
Picornavims translation initiation must therefore occur in a cap-independent manner and 
this involves the binding of ribosomes to the 1RES. Both 1RES types contain a highly 
conserved polypyrimidine tract located 20 to 25 nucleotides upstream of a conserved AUG 
triplet at the 3’ end of the 1RES. If this spacing is altered in any way then translation 
initiation is affected in a negative manner (Filipenko et aL, 1992). Translation initiation of 
enterovirus and rhinovirus genomes does not usually occur at this AUG. It is likely that 
the ribosomes are transferred probably by a scanning mechanism to the correct AUG 
initiation codon, approximately 150 nucleotides downstream. With FMDV, 
approximately 30% of ribosomes initiate translation at the AUG at the 3’ end of the 1RES 
while the rest initiate at the next AUG downstream and almost all the cardiovims 
ribosomes initiate translation at the AUG at the 3’ end of the 1RES.
14
Introduction
IV
siem-loop \
loop
Yj spacer 
region
•AUG
1RES
loops
ccocc AUG
1RES
Figure 4: Secondary structure prediction for the enterovirus and rhinovirus 5' NTR 
elements (A) and the cardiovirus and aphthovirus S' NTR elements (B) (Belsham & 
Sonenberg, 1996). Numbering of regions in A is according to the convention of 
Harber & Wimmer (1993). The polypyrimidine tract is indicated by *.
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1.4. Enterovirus Genus
1.4.1. Background and properties of the enteroviruses
In 1908, Landsteiner and Popper described the transmission of poliomyelitis to monkeys by 
inoculation of a faecal extract from a patient with paralytic disease. Forty years later, 
Dalldorf and Sickles inoculated suckling mice with faecal samples from suspected 
poliomyelitis patients from the town of Coxsackie, New York. The mice became 
paralysed, buFnot from poliovirus infection. Polio viruses are now known to have a 
restricted host range in laboratory animals with most types infecting and causing flaccid 
paralysis in monkeys and chimpanzees only.
This new virus induced flaccid paralysis and widespread myositis of skeletal muscle in 
suckling mice and the isolates became the first prototypes of the group A coxsackieviruses. 
Other strains were identified that produced a different pathology causing spastic paralysis 
in suckling mice with some types producing pancreatitis, necrosis of brown fat pads, 
myocarditis, endocarditis and hepatitis in both suckling and adult mice. These became the 
prototypes of the group B coxsackieviruses (Godman et aL, 1952).
Virus types that were not pathogenic for new-born mice or neutralized by poliovirus 
antisera were also identified (Robbins et aL, 1951). These were named echoviruses 
(Enteric Cytopathogenic Human Orphan viruses) because at the time they could not be 
associated with any disease, but they now form the largest enterovirus subgroup. Some of 
the isolates initially reported as being ‘novel’ echoviruses had not been identified correctly. 
Echovirus 10 was actually a reovirus, echovims 28 was found to be rhinovims type A1 and 
echovirus 34 was shown to be a variant of coxsackievirus A24. Echovirus 22 although 
identified as a picomavirus in terms of genome organization, has little sequence identity 
with the other enteroviruses. The cytopathic effect observed is incomplete, compared to 
other enteroviruses, as is that of echovirus 23 which shares identity with echovims 22 in 
certain parts of the genome. In addition analysis of the protein composition of echovirus 
22 showed that VPO does not undergo processing to VP2 and VP4 and that VP3 contains 
an apparent insertion of approximately 25 amino acids at its amino terminus. This has led 
to their recognition as an independent group of picomavimses and to their reclassification 
(Auvinen & Hyypia, 1990; Hyypia et a l, 1992; Stanway et a l, 1994; Pringle; 1997; Mayo
16
  : :______
Introduction
& Pringle, 1998).
Classification of new enterovirus types as echoviruses was based on their failure to produce 
any disease in suckling mice or monkeys, but there are some variants that exhibit animal 
pathogenicity. A number of echoviruses produce asymptomatic infections in monkeys, 
and some echovirus 9 strains can cause paralysis in new-born mice leading to their early 
classification as coxsackievirus A23. Conversely, some strains such as coxsackie A9 lack 
pathogenicity and therefore resemble the echovimses.
Thus with 67 types recognized all subsequently identified enteroviruses were designated 
‘enterovirus’ and given a consecutive number starting with 68.
The human enteroviruses are distinguished from each other by neutralization of infectivity 
by specific antibodies (Table 2). Simian, porcine, bovine and insect enteroviruses have 
also been identified, but it is unusual for humans to have recognizable infections with the 
animal enterovimses. Enteroviruses are stable over a pH range of 3-10 and are insensitive 
to ether, chloroform and deoxycholate. They have a buoyant density in caesium chloride 
of 1.32-1.35g/ml and a sedimentation co-efficient of 150s-165s. Treatment with 0.3% 
formaldehyde, O.IN hydrochloric acid or free residual chlorine at a level of 0.3-0.5 ppm 
(parts per million) causes rapid inactivation that can be prevented in the presence of 
extraneous organic material (Melnick, 1990). Enteroviruses are also thermolabile and can 
be destroyed rapidly at 50^C unless magnesium chloride is present to inhibit the 
inactivation. This has led to the use of magnesium chloride as a stabilizer in poliovims 
vaccines (Melnick a/., 1961).
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Human Enterovirus species Types
poliovirus types 1, 2 & 3
coxsackievirus group A types A1-A22 & A24
coxsackievirus group B types B1-B6
echovirus types 1-9, 11-27,29-33
enterovirus types 68-71
Table 2: Human enteroviruses and types in each species.
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1.4.2. Transmission and clinical features
Enterovimses are transmitted mainly via the faecal-oral route, but infection can also be 
passed by droplets and aerosols from coughs and sneezes. Virus is generally shed for long 
periods in stools (up to a month or more) thus contaminating the sewage system where the 
virus can survive the chlorination process. In the United States the average concentration 
of enteroviruses in sewage is approximately 100 plaque forming units (pfu)/litre, a figure 
which may be 100 times higher in less developed countries. Enterovirus survival in the 
marine environment is aided by adsoiption to sediment material, which can ultimately lead 
to the contamination of domestic water and of molluscs and crustaceans (Melnick, 1990).
The portal of entry for enteroviruses in humans is thought to be the alimentary tract via the 
mouth. Once acquired, the virus multiplies in the lymphoid tissue of the pharynx and gut 
and reaches the lymph nodes within a day. A minor viraemia occurs by the third day 
(primary viraemia) and then the virus can spread to several secondary sites and replicate 
there. This leads to a major viraemia occurring usually between the 3rd and 7th day that 
generally coincides with the appearance of clinical symptoms. Secondary spread of the 
virus thus occurs via the bloodstream to other susceptible sites including the spinal cord, 
meninges, myocardium and skin, depending on the infecting enterovirus. If a high level of 
multiplication of virus occurs as it spreads through the CNS, motor neurons are destroyed 
and paralysis occurs. Vims is usually excreted in the stools for several weeks and is 
present in the pharynx one to two weeks after infection in an individual with a clinical or 
sub-clinical infection. Enteroviruses can also be recovered from pharyngeal washings, 
spinal cord and cerebrospinal fluid (CSF), brain, heart, blood, urine, conjunctivae and 
lesions of the skin and mucous membranes.
Multiplication of one type of enterovims in the alimentary tract may interfere with the 
replication of another which may explain why live poliovaccine can fail in patients with 
concunent enteroviral infections (Parks etal., 1967).
Enterovirus type 70, in contrast to the other enteroviruses, is spread by fomites and by 
direct inoculation of the conjunctiva from contaminated fingers. Incubation times are 
relatively short (12 to 72 hours) and replication occurs preferentially at 33-35®C, due to 
their adaptation to conjunctiva temperatures (Jin-Murphy, 1973; Melnick, 1990).
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Enterovimses are not predominantly associated with enteric disease but they are so named 
because the human alimentary tract is the main site of replication. Single types can cause 
a number of distinct clinical syndromes while a given clinical syndrome can be associated 
with many different enterovims types, as outlined in Table 5. For an enterovirus to be 
associated with a particular disease, homotypic antibodies must be present; evidence for 
infection by other likely candidates must be negative; the vims must be recoverable from 
body fluids or target organs and the recovery rate from patients with the illness must be 
significantly higher than from healthy persons of similar age and socio-economic setting in 
the same area at the same time. Infections with the enterovimses however, are 
characterized by a high proportion of sub-clinical manifestations. In the case of poliovirus 
for example, recognized clinical illness occurs in approximately 1 % of infections (Melnick, 
1990). The outcome of enteroviral infection is dependent on a number of factors including 
the age of the individual and the serotype as will be discussed later.
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1.4.3. Epidemiology of the enteroviruses
Poliovirus infections were established throughout most of the world’s populations up to the 
late nineteenth century, surviving in endemic form because of a continuous supply of 
susceptible infants. Antibodies to all three types were present almost universally in r | 
women of childbearing age producing high levels of passive immunity in babies at birth. | |
Consequently, most infants were protected by maternal antibody at the time of their first 
poliovirus infection. However, subsequent improvement in hygiene and sanitation in
industrialized countries in the late nineteenth and early twentieth centuries led to a delay in
1the exposure of infants to poliovirus. This meant that the virus was encountered later in 
life when the disease was more likely to be paralytic in nature and the pattern of disease is
changed. Instead of being relatively uncommon and endemic, large epidemics of 
poliomyelitis began to occur (Minor & Bell, 1990). Poliomyelitis is no longer a major 
problem in developed countries due to the widespread vaccination programmes using the 
live attenuated oral poliovirus vaccine (OPV) developed by Albert Sabin in 1961 and the 
inactivated vaccine (IPV) developed by Salk (Salk, 1953; Sabin, 1957; Sabin & Boulger 
1973). Due to the efforts of the World Health Organization (WHO) global eradication 
programme, established in 1988, the number of reported cases of poliomyelitis has been 
reduced by 89%. As of mid-May 1998, 4116 cases with onset during 1997 were reported 
worldwide (WHO, 1998).
National immunization days (NID) have been carried out in all but 4 poliomyelitis endemic 
countries. In 1997, approximately 450 million children under 5 years of age in 80 
countries were immunized. Reported cases in China dropped from 5000 in 1990 to zero in 
1995 following an immunization day. Surveillance systems for acute flaccid paralysis 
(AFP) have also been established in many countries and have shown that transmission of 1wild poliovirus has been interrupted in a number of areas throughout the world. 
Poliovirus transmission now occurs primarily in South Asia and Sub-Saharan Africa and is 
most intense in highly populated countries like India. The eradication programme has led 
to the certification of the Americas (in 1994) as poliomyelitis-free, the probable ■ 
inteiTuption of poliovirus transmission in the Western Pacific region and the restriction of 
poliovirus transmission to a single area in Europe (Bland & Clements, 1998; WHO, 1998). 
Vaccine associated paralytic poliomyelitis can occur, albeit at a very low rate, following
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reversion of the oral poliovirus vaccine (OPV) to virulence within the individual. The risk 
in the USA was estimated to be one case of paralytic poliomyelitis per 2.5 million doses 
administered. In England and Wales an average of three cases of paralytic poliomyelitis 
per year occurred between 1985 and 1991 (Joce et a l, 1992) and Sabin vaccine was 'Iassociated with 13 out of 21 cases in both recipients and contacts. Of the remaining cases, ;| 
5 were imported and in 3 the source was not discovered.
Infection with the non-polio enteroviruses (NPBV), that is the coxsackieviruses, 
echoviruses and higher enteroviruses, still occurs frequently in different areas of the world, I
in different climates and at different time intervals. Information regarding cases and youtbreaks of infection is extensive with literature from the general medical and scientific 
press along with reports from the WHO, the CDC and the CDR (Communicable Disease 
Report) in the United Kingdom. The global surveillance data reported a total of 59,776 §
non-polio enterovirus infections from 1975 to 1983, 64% of which were due to the 
echovirus group. In tropical climates enteroviruses are isolated throughout the year :i
whereas in temperate climates they are most common in the summer and autumn when |
warm weather favours their spread, although they can be present at low levels in the winter A
and spring. In the United States from June to October, the average number of enterovirus 
isolations was 6.6 times higher than the monthly average for the other seven months of the I
year, with 82% of the total isolates recovered during these peak months (Moore, 1982).
A number of factors influence the frequency and type of symptomatic infection in the 
population including age, sex, serotype, virulence, portal of entry, immunocompetence and 
previous exposure.
Age is one of the most important determinants of the course of enteroviral infection.
...Infection with coxsackie B viruses for example, is generally more severe in new-borns than 
in older children and adults, whereas poliovirus infection is more likely to lead to paralysis 
in adults. A difference in the rate of occurrence of enteroviral disease between males and 
females has also been noted (1.5:1 to 2.5:1 ratio) generally for the more severe disease with |
cardiac or CNS involvement.
Low socio-economic status is also a factor in the early acquisition of infection. Active 
surveillance of infection in young children in West Virginia in 1951 to 1953 showed the 
isolation rate in the lower socio-economic setting to be 2 to 7 times higher than in the
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higher socio-economic setting. These figures may be influenced by the greater number of 
individuals per household and per room in the former group. Overcrowding, poor 
sanitation and hygiene combine to maximize the spread of enteroviral infection (Minor &
Physical exertion is another important risk factor. In the 1940s it was observed that
physical exertion while incubating poliovirus was associated with higher incidence and 
greater extent of paralysis (Russell, 1947).
Ï
Beil, 1990).
There tends to be a particular serotype of NPEV that is endemic circulating among a small 
number of non-immune individuals many of whom are young children. In some isolated 
communities such as the Eskimos the whole population may lack antibody to particular 
serotypes. When a serotype is absent from an aiua for a number of years a population of 
susceptible individuals builds up. If that virus is then introduced into the population, a 
wave of infection occurs in all age groups. Data from the UK and Ireland in the 1960’s 
and early 1970’s shows evidence of these waves of infection. In 1969 an epidemic of
echovirus 9 accounted for 40% of the isolates reported that year, with 25% to 33% of the 
cases occurring in Scotland. From isolation data collected in the Regional Virus 
Laboratory in Glasgow over 20 years (1957 to 1976), echovims 9 was shown to be the 
predominant virus at 3-4 yearly intervals (Grist et a i, 1978). In the UK in 1971, 60% of 
echoviruses were type 4, previously responsible for approximately 5% of cases. The 
Glasgow data show similar figures with a higher number of echovims 4 isolates in 1971- 
1972 compared to the previous years where there had been none. In 1990, in the largest 
outbreak to be reported in this country and to have been confirmed by vims isolation, 
echovims 4 was isolated from over 400 individuals, with 80% of these cases presenting 
with meningism (Gallacher et aL, 1993). This vims accounted for 80% of the isolates that 
year compared to only 10 isolates in the previous 17 years.
In 1970 a large epidemic of acute conjunctivitis was observed in Singapore with over 
60,000 cases reported. The agent responsible was identified as a variant of coxsackievirus 
A24. At approximately the same time, a pandemic of acute haemonhagic conjunctivitis 
(AHC) occurred in Africa, South East Asia, Japan and India caused by an unidentified 
enterovims, subsequently named enterovims 70. AHC almost always occurs as epidemics 
and these two vims types are responsible for the majority of outbreaks. In 1981, a
24
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pandemic of AHC occurred with over 30 million cases worldwide. Oligonucleotide 
fingeiprint analysis showed that isolates obtained from different areas of the world were 
closely related, whereas isolates from the epidemic of 1969, though related to each other, 
differed from the pandemic strains by many nucleotides. This data suggested that one 
basic genotype is in circulation worldwide at any one time (Kew et aL, 1983).
1.4.4. Traditional methods of enterovirus detection
Traditionally, enteroviral diagnosis relies on isolation in cell culture and subsequent 
serotyping by neutralization with intersecting pools of antisera (LBM pools) (Lim & 
Benyesh-Melnick, 1960). However, no single cell line is optimal for all of the enterovirus 
serotypes and laboratories generally use a combination of a simian cell line (such as Rhesus 
Monkey Kidney, RMK) and a human diploid cell line (such as MRC-5). Successful virus 
isolation is however difficult. Certain serotypes, especially within the coxsackievirus A 
group, grow poorly or not at all in cell culture; some samples may contain substances 
which are toxic to the cells; the virus itself may be antibody-neutralized or replication 
defective; virus titres may be too low for detection; the vims may not be viable due to 
delays in transit and specimen handling or virus shedding may have ceased (Nicholson et 
aL, 1994; Rotbart & Romero, 1995). A high level of expertise is required to recognize 
cytopathic effect (c.p.e.) and the process is time consuming: mean times for the isolation of 
enterovims from CSF samples have been reported as ranging from 3.7 to 8.2 days 
(Chonmaitree et aL, 1982; Jarvis & Tucker, 1981).
The difficulties of virus isolation have highlighted the need for alternative diagnostic 
strategies. The large number of serotypes means that serological methods are limited to 
individual cases where a particular virus is suspected. Ideally, paired sera are used to test 
for rising titres of enterovims specific antibody, but the tests can be of low sensitivity and 
specificity due to poor recognition by reference antisera. Extensive cross-reactivity can 
also occur between the many serotypes such as echovims types 1 and 8, which have 
recently been reclassified as a single serotype (Hyypia et aL, 1997).
Antigenic relationships also exist between coxsackievims types A3 and A8; A ll  and A15; 
A13 and A18; echovims types 6 and 30 and types 12 and 29 (Morens et aL, 1991). 
Antigenic variants have also been identified which may have arisen from mutation or
25
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antigenic drift. This can lead to the appearance of prime strains, which are neutralized 
poorly or not at all by antibody to the prototype strains.
present in stool specimens.
A number of alternative techniques to neutralization have been described including an 
ELISA for the detection of coxsackievims A antigens (Yolken & Torsch, 1981), a 
micrometabolic inhibition test for estimating levels of coxsackie B1 to B6 neutralizing 
antibodies (Bell & McCartney, 1984) and a p,-antibody capture ELISA for detecting 
coxsackievirus B specific IgM (King et a l, 1983). There are disadvantages with these 
approaches including the high cost of antisera and monoclonal antibodies due to the testing 
of each sample with all serotypes and controls, and the difficulties in interpreting high 
static antibody titres.
1.4.5. Molecular methods of detection
4‘i
The most direct method of detection is to look for the virus itself or a sub-component of it 
and advances in molecular biological techniques have now made this possible.
1,4.5.1. Hybridization studies. The initial cloning and sequencing of the genome of 
poliovirus type 1 led to the development of nucleic acid hybridization assays using 
molecular probes to detect a wide range of enterovims serotypes (Kitamura et aL, 1981).
:
A cDNA probe of the 3’ end of coxsackievims B3 RNA (Nancy strain) was used to detect 
enterovimses in infected cells (Hyypia et aL, 1984). The test was specific (Herpes simplex 
virus (HSV) type 1, Adenovims type 2 and measles vims were negative) and could detect 
nucleic acids from approximately 5000 infected cells. This sensitivity was adequate for 
samples that had undergone cell culture procedures but not for samples tested directly 
probably because of low levels of vims in the sample or RNase activity which can be
A . #■ 4Cova et al. (1988) described the use of RNA probes corresponding to the VPl capsid 
region and 5’ NTR of poliovims type 1 to detect enteroviral RNA in stool specimens or 
infected cell lysates. The 5’ NTR riboprobe was much more efficient than the 
corresponding cDNA probe, detecting 10^  ^to 10^  TCIDso of poliovims compared to not less 9
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than 10“^  TCIDso. The VPl riboprobe detected all three poliovims serotypes and 
coxsackievims A21 indicating a close relationship between these serotypes, whereas the 5’
NTR probe also detected coxsackieviruses B l, B3, B4, A7, A9, A21, echoviruses 9, 11, 33 
and HRV-2 due to the conserved nature of this region. Of a panel of positive specimens, 
the VPl probe detected 50% of poliovims infected stools, all the poliovirus infected cell 
lysates but did not react with the other enteroviruses. The 5’ NTR probe picked up 16/18 
positive enterovirus samples including poliovirus types 1, 2 and 3 from cmde cell extracts.
One advantage of using riboprobes was that a large amount of probe could be synthesized 
with a high specific activity, compared to the cDNA probes
4:
Rotbart and co-workers (1988) prepared synthetic probes for the 5’ NTR of coxsackievims 
B3 or the protease gene of echovirus 9 labelled with either or alkaline phosphatase for 
use in blot assays. They were able to detect a wide range of human enteroviruses but with f  
a sensitivity of only 10^  to 10^  TCIDso of target virus.
The limiting factor in hybridization assays is that clinical specimens may contain low 
levels of enterovirus (as low as 1-10 titratable vims per ml in CSF from cases of aseptic 
meningitis (Wilfert & Zeller, 1985). Consequently, many assays are not sensitive enough 
to be of use in the diagnostic laboratory.
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1.4.5.2. Detection of VPl antigen. Another potential diagnostic tool described by Yousef 
and colleagues (1987a), used a monoclonal antibody (5-D8/1) which reacted with a single 
peptide (VPl) common to all the enterovimses tested. The antibody was used in both 
immunofluorescence (IF) and enzyme immunoassay (EIA) tests, with no non-specific 
reactions, but the latter was more sensitive. Antibody 5-D8/1 was unable to neutralize 
coxsackievirus types B l, B3 and B5, since neutralizing antibodies tend to be serotype 
specific, but it did have complement fixation activity. Clinically, the antibody was used in |  
dot-blot enzyme immunoassays to identify 122/130 field isolates (Yousef et ah, 1987b). 
Unidentified isolates were subsequently shown to have low viral titres and could be picked 
up by an indirect IF assay. Evaluation of the commercial antibody for the identification of 
enterovirus in primary culture cell lysates by indirect IF, compared to seroneutralization
"4:and the polymerase chain reaction (PCR) was carried out (Trabelsi et aL, 1995). All 39 
serotypes tested were reactive with the antibody. Cell lysates from primary culture of 61 
clinical isolates were also tested by indirect IF which detected all strains that could be
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typed and those that could not. PCR of the 5’ NTR produced the same results. The
,advantage of the antibody is that it can also detect echovirus types 22 and 23, which most 
PCR tests cannot. I
1.4.5.3. Polymerase Chain Reaction (PCR). The problem of sensitivity encountered with 
hybridization reactions has been overcome to a large extent by the development of the
■'4Polymerase Chain Reaction (PCR). This is a relatively new technique, (original protocols 
by Saiki et a l, 1985; Mullis et a l,  1986; Mullis & Faloona 1987), which allows the 
amplification of a segment of DNA that lies between two regions of known sequence.
Two synthetic oligonucleotides are used as primers in a series of reactions catalysed by a 
thermostable DNA polymerase enzyme, enabling very small quantities (from as low as aj
Ing) of mRNA to be amplified and detected (Gilliland et aL, 1990). A second set of 
primers that lie within the amplified region can be used to amplify the first round product, 
increasing the sensitivity, a process known as ‘nested’ PCR. Enteroviruses have an RNA 
genome, which has to be reverse-transcribed to complementary DNA (cDNA), to act as the 
template for PCR. RT-PCR has become the tool favoured by investigators looking for 
enteroviruses in various clinical syndromes and it has been refined into a rapid and 
sensitive technique. The conserved 5’ NTR is an ideal target for the use of a single group- 
specific PCR. Primers can also be designed to be serotype-specific depending on the 
requirements of the investigator, for example, a coxsackievirus A specific PCR has been i
described (Gjoen & Bruu, 1997).
a. PCR and Hybridization. Zoll and colleagues (1992) described one of the first 
protocols for the detection of almost all the human enteroviruses. Using one primer set 
based on the 5’ NTR, 60/66 serotypes were amplified, the exceptions being echovirus types I
16, 22 and 23 and coxsackievims types A l l ,  A17, A24. A second primer set which 
amplified a larger fragment of the 5’ NTR confirmed these results. Hybridization of the 
amplified products with an internal probe resulted in 55/60 positive results.
Coxsackievirus types A l, A 12, A20, A21 and A22 were not detected. A coxsackie B3
cDNA clone was used to estimate the detection limit of the PCR and a product was 
observed from 0.1 fg of the clone that corresponded to approximately 10 genome 
equivalents. Other viruses including 10 different rhinovims types, human 
cytomegalovirus (CMV) and herpes simplex 1 and 2 were not detected by these primers. 
Twelve enterovirus positive stools were positive by PCR as were the corresponding throat
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swabs from 6 of these patients, thus proving the applicability of group-specific PCR for 
diagnostic use.
b. Semi-Nested and Nested PCR. A  semi-nested PCR of the 5 ’ NTR, with a 
sensitivity of Ifg of R N A , was used to investigate a number of clinical syndromes 
including suspected meningitis and encephalitis (Leparc et a l, 1994). The results showed f  
that the enteroviral PCR was positive in 35% of CSF samples and 30% of throat swabs 
compared to 15% positives by culture of both sample types. Testing of faecal samples 
resulted in 50% positives by enteroviral PCR versus 43% by culture, which reflects the 
high level of enterovirus shedding in faeces, compared to other biological samples. 
Thoren and Widell (1994) also using a semi-nested PCR, with a sensitivity of 0.01 TCIDso 
showed that PCR of serum could be used to detect enterovirus in patients with suspected 
enteroviral meningitis. They suggested that it should be used in conjunction with PCR of 
CSF, as it was less sensitive when used on its own (52% sensitivity for serum alone 
compared to 71% for CSF alone and 86% for PCR of serum and CSF samples combined).
Compared to the traditional isolation and typing of viral agents, PCR only produces a 
positive or negative result for the virus of interest, with no information regarding the 
serotype. This is generally acceptable since knowing the serotype is not important in the 
clinical management of the patient and it is useful for epidemiological purposes. 
Kammerer et al. (1994) used a nested PCR with a sensitivity of 5x10^ pfu/ml to ^
successfully amplify the 33 prototypes tested, except echovirus 22 which produced smaller 
sized bands. The PCR product was then subjected to digestion with restriction 
endonucleases designed to identify different serotypes. PCR was carried out on 37 
specimens from patients with neurological disease, 43% of which were positive and 117 
heart tissue specimens, 10% of which were positive. Restriction enzyme analysis provided 
conclusive information on the typing of 14/28 of the positives, and for those that could not ■/ 
be typed, subsequent sequencing showed that mutations had occurred at the restriction site, 
resulting in the altered cleavage pattern seen.
c. Commercial PCR Kits. Rotbart et al. (1994) developed a PCR assay that uses a 
single enzyme for both the RT and PCR stages, and detects the amplified product in a 
simple microwell plate format with colour detection. Uracil A-glycosylase (UNO) is also 
incorporated to prevent amplification of carry-over product. Twenty-seven isolates
29
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(including coxsackievirus A and B types, echovirus types and enterovirus type 70 and 71 ) 4
■■'Iwere detected at a sensitivity of <1 TCIDso and there was no cross-reactivity with other «
non-enterovirus or bacterial agents. With archival CSF specimens, the sensitivity and
rspecificity of PCR versus culture plus clinical diagnosis was 97.4% and 100% respectively.
■!
The PCR can also be performed in 5 hours and thus has the potential to be a good 
diagnostic aid. The system is now available commercially as the Roche Amplicor 
Enterovirus Kit. Yerly et a l (1996) compared this kit with standard cell culture 
techniques for CSF samples from aseptic meningitis cases. After 2-6 days of cell culture, f
only 34% of CSF specimens were positive for enterovirus compared to 66% positives with 
the kit. The PCR positive results were independent of the time delay between the onset of 
symptoms and the collection of the sample which is an advantage as delays will inevitably i
occur in the clinical situation. In this case, samples collected more than 24 hours after I
onset were culture negative. An in-house single round PCR was also used (specificity 
confirmed by southern blotting) and was found to be more sensitive than the kit (it was 
positive for 3 additional samples). In-house PCR systems also generally include an 
additional PCR to control for the extraction procedure by amplifying for example, a 
‘housekeeping’ gene. This PCR control has to be positive for the ‘test’ PCR to be valid.
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In the case of the commercial kit an extraction control is not included, therefore it is 
difficult to assess whether negative samples are genuinely negative. ,4
Even with these latest developments virus isolation is still performed in the routine 
virology laboratory with confirmatory neutralization and IF tests. PCR is slowly emerging '
as a useful addition to these tests and is being integrated into the modern diagnostic
4:laboratory. This has resulted in the increased detection of enteroviruses in clinical 7
jsyndromes such as aseptic meningitis, where currently, non-polio enteroviruses account for
~V'.80-92% of all cases from which an aetiological agent is identified. In general, of the 25- 
33% of CSF specimens negative for virus in tissue culture, two thirds will be positive for €
enterovirus by PCR (Chonmaitree et a l, 1982).
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1.4.6. Molecular relationships among the human enteroviruses
Molecular techniques have allowed a number of the enteroviruses to be sequenced and 
although not used in the routine identification of the enteroviruses, genome sequencing can 
be useful for epidemiological purposes.
Analysis of the sequence of the capsid region as a whole (Hyypia et a l, 1997) and of the 
individual proteins (Poyry et a l, 1996; Huttunen et a l, 1996; Pulli et a l, 1995; Dahllund et 
a l, 1995; Poyry et a l, 1994), has led to the identification of 5 clusters of enteroviruses 
(Table 5). Analysis of the 3D RNA polymerase region of a number of enteroviruses 
produces the same clustering (Poyry et a l, 1996; Dahllund et a l, 1995).
In the capsid coding region, the amino acid similarity is at least 71% within a cluster and 
ranges from 53% to 68% between clusters, whereas amino acid similarity in the 3D protein 
can be up to 90% within a cluster.
In contrast, phylogenetic analysis of the highly conserved 5’ NTR reveals the presence of 
only two genetic clusters, one containing the polioviruses, coxsackievirus A21, 
coxsackievirus A24 and enterovirus 70, and the other containing enteroviruses from 
clusters A and B with a minimum nucleotide identity of 77% within each cluster (Hyypia et 
a l, 1997).
I :
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Interestingly, one enterovirus of lower animals, Swine Vesicular Disease Virus (SVDV) is 
shown to group in cluster B alongside the coxsackie B-like enteroviruses. SVDV has been 
shown to be closely related antigenically to coxsackie B5. SVDV can be neutralized by 
coxsackie B5 antisera and vice versa and it has been suggested that coxsackie B5 gave rise 
to SVDV through transmission and adaptation to swine (Brown et a l, 1973; Graves, 1973). 
However, sequence analysis by Zhang and colleagues (1993) showed that SVDV was not 
any more closely related to coxsackievirus B5 than to the other coxsackie types, except in 
the capsid region.
I
I
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Cluster Enterovirus types
A
Coxsackie A 16-like
Coxsackie types A2, A3, A5, A7, A8, A 10, A 12, 
A14, A16, enterovims type 71
B
Coxsackie B-like
Coxsackie types B l, B3, B4, B5, coxsackie A9, 
enterovims 69, echovirus types 1 to 9, 11 to 17, 19- 
21, 24, 26, 27, 29, 30, 31, 32, 33, SVDV
C
Poliovims -like
Poliovirus types 1, 2, 3, coxsackie types A l, Al l ,  
A13, A15, A17, A18, A19, A20, A21, A22, A24
D
Enterovirus 70-like
Enterovims types 68, 70
E
BEV- like
Bovine enterovims types 1, 2a, 2b
Table 4: Genetic clusters of the enteroviruses based on the amino acid sequence of the 
capsid protein region and the 3D RNA polymerase region
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The molecular relationships observed suggest that the present subgroup classification for 
enteroviruses should be revised. This is especially true when considering the coxsackie A 
viruses which occur in several of the clusters rather than as a particular subgroup. Revised 
subgroup classification is also indicated when the receptor specificity of the enteroviruses 
is considered (Table 5). A number of receptors belong to the immunoglobulin (Ig) 
superfamily, members of which are involved in cell-cell recognition and adhesion. Others 
are integrins, a family of adhesion receptors comprised of at least 7 different |3 sub-units 
and 14 different a  sub-units, that associate to form at least 16 heterodimers (Bergelson et 
al., 1992). The three poliovirus types use a common specific receptor (PVR), whereas the 
coxsackie A types use a variety of molecules for cell entry, some of which are also 
receptors for other enterovirus types, for example ICAM-1 is also used by the major 
rhinovirus group.
Molecular techniques such as nucleic acid hybridization and PCR have also been useful in 
investigating the role of enteroviruses in heart muscle disease (myocarditis and dilated 
cardiomyopathy) (Bowles et a l, 1986) and have confirmed the association originally 
established by retrospective serology (Grist et a l, 1974). Similarly, enteroviruses have 
been implicated in the initiation of juvenile-onset type-1 diabetes mellitus and Chronic 
Fatigue Syndrome (CFS) by epidemiological and serological data. However, in many 
studies the associations have not been independently confirmed. The conflicting evidence 
for the involvement of enteroviruses in CFS will be discussed in the following section.
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Table 5: Enteroviruses and their receptor molecules.
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1.5. Enteroviruses and Chronic Fatigue Syndrome
1.5.1. Chronic Fatigue Syndrome (CFS)
CFS is a chronic illness characterized by severe disabling fatigue of greater than six months 
duration with a combination of symptoms that features self (patient)-reported impairments 
in concentration and short-term memory, sleep disturbance and musculoskeletal pain. 
(Sharpe et al., 1991). Diagnosis is confirmed only after alternative medical and 
psychiatric causes of chronic fatiguing illness have been excluded. This is not a new 
illness. Reviews of the medical literature have uncovered reports of syndromes 
resembling CFS described as febricula, neurasthenia and DaCosta’s syndrome in the 18th, 
19th and early 20th centuries respectively (Straus, 1991). Chronic bmcellosis, 
hypoglycemia and candidiasis have been blamed for many cases over the years as 
investigators sought a name for this illness (Evans, 1947; Straus, 1991; Anderson et a l, 
1986).
In the summer of 1934 an epidemic of poliomyelitis struck Los Angeles with many of the 
patients treated in the County Hospital (Gilliam, 1938). Within a few weeks, a large 
number of cases of similar illness began appearing among the staff, particularly the nurses, 
suggesting the presence of a transmissible agent, but examination of the CSF showed 
nothing abnormal in 53 out of 59 cases. Approximately 200 cases were reported, an attack 
rate of 4.4%, with no deaths and most of the patients fully recovered.
Fourteen years later (1948-1949) a similar epidemic occurred in Iceland with over 1000 
cases, nearly half of them in children (Sigurdsson et al., 1950) leading to the term ‘Iceland 
disease’ or ‘Akureyri disease’ to describe the outbreak. The label of benign myalgic 
encephalomyelitis (M.E.) was introduced in 1956 in an article in the Lancet (Ramsay & 
O’Sullivan, 1956) describing an outbreak at the Royal Free Hospital in London. Between 
July 13th and November 24th 1955, 292 hospital staff were affected by an illness which 
amongst other things, included CNS involvement. Eighty-seven percent of those affected 
were admitted to hospital. At approximately the same time, medical staff saw similar 
cases occurring sporadically in North-West London. The majority of cases recovered, but 
severe disability persisted in at least four patients. The epidemiology of the outbreak 
suggested that the disease was spread by case to case contact and had an incubation period
of 5 to 6 days. Symptoms of malaise, headache and sore throat are common to the
:
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prodromal phase of many infections but laboratory investigations proved negative for 
isolation and for antibodies to the agents tested. Other investigations were unremarkable
(Medical Staff of the Royal Free, 1957). In these three outbreaks, the attack rate per 100 
cases was higher in women than men (6.4 against 1.6 in Los Angeles; 8.3 against 5.1 in 
Iceland and 10.4 against 2.8 at the Royal Free). Subsequent outbreaks of similar infection 
were thus labeled as M.E., Royal Free or Iceland Disease: an outbreak of ‘Iceland disease’ 
was reported in children in New York in 1953 (White & Burtch, 1954) and more recently 
Fegan et al. (1983) reported on an epidemic of M.E, in a mral practice in Ayrshire, 
Scotland. The term M.E. however literally means a distinct pathological process of 
inflammation of the brain and spinal cord with concomitant muscle pain. There is no 
evidence for this in these patients and the use of this term should therefore be avoided.
I
In the 1950’s, sporadic cases of the illness were also described and because of the frequent 
reporting of flu-like symptoms at onset these were labeled as post viral fatigue syndrome 
(PVFS) (Newham & Edwards, 1979). Several studies in the 1980’s of such sporadic cases 
revealed that in some, chronic fatigue began during a bout of infectious mononucleosis. 
Additionally, some patients had abnormal levels of antibody to Epstein Barr Virus (EBV)
(Tobi et a l, 1982; Dubois et a l,  1984; Jones et a l, 1985; Straus et a l,  1985). The 
syndrome was therefore given yet another name- chronic EBV syndrome or chronic
■ ; ,
mononucleosis syndrome. A workshop organized by the Centres for Disease Control 
(CDC) was held in 1987 to develop a consensus on the features of this syndrome and this 
revealed doubt about there generally being a causal relationship with EBV. The meeting 
led to the renaming of the illness as chronic fatigue syndrome (CFS), to describe a 
syndrome characterized by chronic fatigue but making no assumptions regarding the 
aetiology or pathology of the disease. A case definition was also developed for research 
purposes to enable associated risk factors and laboratory abnormalities to be recognized 
(Holmes et a l, 1988). The CDC definition states that for diagnosis, two major criteria 
must be present, i.e., new onset persistent or relapsing fatigue that does not resolve with 
bed-rest, reduces the average daily activity by 50% of premorbid levels and has been 
present for at least 6 months, together with the exclusion of other disorders that would 
cause similar symptoms such as malignancy or auto immune disease. At least six 
symptoms are required from a list including headache, sore throat and myalgia together 
with two physical criteria such as low-grade fever and non-exudative pharyngitis, or
Nf'alternatively eight or more symptoms. This definition is often modified in practice by '
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researchers because some of the criteria are difficult to comply with, resulting in 
inconsistencies between studies. In an attempt to address this problem, the definition was 
revised in 1994 (Fukuda et a l, 1994). Cases including untreated hypothyroidism, 
malignancies, major depressive disorder, eating disorders, alcohol and substance abuse are 
excluded at the outset. Distinctions are then made between CFS and idiopathic chronic 
fatigue. For classification as CFS, patients must have unexplained persistent or relapsing 
chronic fatigue of new or definite onset that is not alleviated by rest, is not the result of 
ongoing exertion and results in substantial reduction in previous levels of occupational, 
educational and social activities. In addition, there must be the concurrent occurrence of 
four or more symptoms which have persisted or recurred during six months of illness from 
a list which includes memory impairment, difficulty in concentration, sore throat, muscle 
pain, joint pain, headache and non-refreshing sleep. Idiopathic chronic fatigue is described 
as unexplained chronic fatigue that fails to meet CFS criteria. Other disorders that do not 
necessarily exclude patients from a CFS diagnosis include fibromyalgia, somatoform 
disorders, anxiety disorders and neurasthenia, but it is important that such conditions are 
noted.
Other countries use slightly different criteria for diagnosis. In the United Kingdom, the 
Oxford Criteria (Sharpe et a l, 1991) state that fatigue must be the principal symptom, 
being severe, disabling, affecting physical and mental functioning and being present for at 
least six months for at least 50% of the time. The syndrome should also be of definite 
onset and symptoms such as myalgia, mood and sleep disturbance may be present. 
Patients with established medical conditions that produce chronic fatigue should be 
excluded along with those with diagnoses of schizophrenia, manic depressive illness, 
substance abuse, eating disorders and proven organic brain disease. The Oxford criteria 
also include a subtype of CFS called post-infectious fatigue syndrome (PIFS) where there 
is also definite evidence of infection at onset or presentation corroborated by a laboratory, 
and the syndrome is present for at least six months after the onset of infection.
Fatigue, as a symptom is extremely common in the community. Buchwald et n/.(1987) 
and Kroenke et a l  (1988) reported that between 21% and 24% of patients seeking medical 
care through a hospital based out-patient clinic had fatigue as their chief complaint. Only 
a fraction of these (2-5%) fulfil the criteria for CFS, with depression and anxiety the 
underlying causes of most of the cases of chronic fatigue (Komaroff & Buchwald, 1998),
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It is difficult to obtain prevalence figures for CFS because of the effects of selection bias 
for example. According to the Royal College Report (1996), the population point 
prevalence of CFS is 0.1%-0.9% using the CDC criteria that excludes patients with 
psychiatric disorder, and 2.6% in primary care according to the Oxford criteria.
The problems surrounding CFS are numerous including the difficulty of diagnosis; the 
different names used to describe it; the lack of objective biological markers; the debate 
about an organic or psychiatric cause and the fact that some medical professionals still do 
not believe in its existence. The illness has often been dismissed as hysteria by sceptics 
but was fully investigated in 1978 by a symposium at the Royal Society of Medicine. 
Their findings indicated that there was little evidence in favour of a hysterical phenomenon 
with the majority supporting an organic basis for the illness (Ramsay, 1978).
In 1996, a joint working group of the Royal colleges of physicians, psychiatrists and 
general practitioners published a report on CFS in response to a request from the Chief 
Medical Officer. This report highlighted the problems encountered in the study of the 
illness and provided a summary of a number of research topics including studies on 
virology, muscle function and immunology, psychiatry and neuropsychiatry, prognosis and 
management. A number of these will be expanded on below.
1. Virological Studies. The reason that many investigators began to look towards 
viruses as potential triggers of CFS was that many patients reported that the onset of 
fatigue had followed symptoms of a flu-like illness. Early studies linked EBV with CFS 
(Tobi et al., 1982; DuBois et al., 1984; Jones et al., 1985; Straus et a l, 1985) due to the 
presence of elevated levels of antibody to viral capsid antigen (VCA) and early antigen 
(EA). A fatigue state has been shown to exist after infection with EBV: a prospective 
study of 250 patients with either glandular fever or ordinary upper respiratory tract 
infection, showed that glandular fever was a significant risk for both acute and chronic 
fatigue syndromes (White et al., 1995; 1998). However, other studies of patients and 
evidence from seroepidemiologic surveys showed that many patients with clinical evidence 
of CFS had no serological evidence of prior EBV infection and that EBV titres in patient 
and control groups often overlapped, or were present alongside elevated titres of antibody 
to other viruses such as herpes simplex and measles (Holmes et a l, 1987; Sumaya, 1991). 
EBV is therefore not thought to be the aetiologic agent in most CFS cases (Horwitz et a l, 
1985; Hellinger et al., 1988; Sumaya, 1991). The other most common agents studied in
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association with CFS, especially in the U.K. are the enteroviruses and these will be 
discussed in the following section (1.5.2.).
Human Herpes vims-6 (HHV-6) infects B- and T-lymphocytes and most adults have been 
infected with the virus (over 85% prevalence rate in the U.S.). Evidence linking HHV-6 
with CFS has been reported by a number of individuals looking at elevated antibody titres 
and the detection of HHV-6 antigen and DNA in peripheral blood mononuclear cells 
(PBMC).
Buchwald and co-workers (1992) detected replicating HHV-6 in peripheral blood
lymphocytes of 70% of patients compared to 20% of controls, and this was confirmed by
the detection of the virus by specific monoclonal antibodies to HHV-6 proteins and by
PCR assays for HHV-6 DNA, Elevated levels of HHV-6 early antigen-specific IgM were
found in more patients than controls by Patnaik et al. (1995) perhaps indicating active
replication of the virus in CFS. In an Italian study, fresh PBMCs from heparinized blood
.samples were used for virus isolation studies. Typical HHV-6 cytopathic effect was found 
in 73.1% of CFS patients but not in controls and DNA was detected by PCR in 61.5% of 
patients versus 11.7% of controls (Zorzenon et al., 1996).
However, in four clusters of CFS in the U.S. there was no difference in the number of 
positives for HHV-6 antibody between patients and controls. The mean titre of antibody 
was higher for patients than controls but was not statistically significant (Levine et a l, 
1992). Both HHV-6 and EBV are capable of establishing latency after primary infection 
and it has been suggested that they are merely reactivated in CFS patients possibly because 
of immune dysfunction, rather than being the causative agent.
The detection of HTLV H (human T-lymphotropic vims) like viral sequences in the 
peripheral blood lymphocytes of patients with CFS suggested the possibility of retroviral 
involvement (DeFreitas et a l,  1991). Such sequences were not detected in the 
lymphocytes of healthy individuals. Other groups failed to confirm these findings (Levine 
et a l,  1992; Landay et a l, 1991; Gow et a l, 1992). Gow and colleagues found no 
difference between the patient and control populations by PCR of the gag, pol, env and tax 
regions of HTLV-I and HTLV-II. However, an endogenous gag band was observed in
both the patient and control groups, using the same primers as the DeFreitas group. The
authors suggested that this sequence represented an endogenous sequence rather than 
exogenous virus in their own and DeFreitas findings.
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Borna disease virus (BDV) is a neurotropic RNA vims and the prototype for a newly 
described group of animal vimses. Nakaya et a l  (1996) used nested PCR followed by 
hybridization to demonstrate the presence of BDV RNA in 3 out of 25 CFS patients. 
Together with the detection of antibodies to BDVp24 protein in 6 patients, the overall 
prevalence was 32% in Japanese CFS patients.
Kitani and colleagues (1996) looked at the seroprevalence of BDV in a larger patient group 
with 89 cases compared to 100 healthy control individuals. Antibody to BDV p24 protein 
was found in 30/89 patients (33.7%). BDV RNA was present in 12.3% of CFS patients 
compared to 4.7% of controls using nested PCR. Additionally, in one Japanese family, 3 
out of 5 developed CFS almost simultaneously. BDV RNA was detected in the peripheral 
blood lymphocytes from all 3, suggesting a close association of BDV infection with 
Japanese CFS patients.
In the U.K., Gow and colleagues (1997a) reported on the testing of brain samples, PBMCs, 
serum and CSF samples for BDV from CFS patients, matched controls and individuals 
with depressive disorder (not all samples were obtained from all patients). All samples 
were tested by nested PCR followed by hybridization and produced only one positive result 
from the CSF of a patient with CFS. Western blotting and IF were also carried out on the 
serum from 21 CFS patients and 13 controls. Two patients were positive by both tests. 
From this data there did not appear to be a significant association between BDV and CFS 
in these patients but it is possible that BDV is more prevalent in Japan, thus accounting for 
the results observed there.
Establishing a link with a particular virus is difficult because viral infections are common 
throughout the year and chance associations are difficult to exclude. Thus reliable markers 
of recent infection must be used to test patients and appropriately matched controls.
2. Immunological Studies. CFS has been referred to as Chronic Fatigue and 
Immune Dysfunction Syndrome (CFIDS) by some individuals (DeFreitas et a l, 1991; Ojo- 
Amaize et a l, 1994) suggesting involvement of the immune system. Numerous studies 
have reported various immunological abnormalities but interpretation is complicated by the 
lack of standardization of methods among laboratories, the heterogeneity of patient groups 
and by the lack of concurrent testing of patients and controls (Klonoff, 1992).
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Evidence for abnormal humoral immunity was reported by Lloyd et a l  (1989) who 
compared 100 CFS patients and 100 healthy age and sex matched controls. Reduced 
immunoglobulin levels were observed in 56% of patients, with levels of IgGs and IgGi 
subclasses particularly affected. IgGs is thought to play a major role in virus 
neutralization. Additional studies have also shown IgGi (Read et a l,  1988) and IgGj 
(Linde e ta l ,  1988) subclass deficiencies.
T-cell proliferation after exposure to phytohaemagglutinin (PHA) is a common marker for 
T-cell function. In general, CFS patients’ lymphocyte response in vitro to PHA is 
significantly lower than that of controls and the production of y-interferon (IFN) following 
mitogen stimulation is also decreased in most patients compared with controls. Klimas et 
a l  (1990) also observed a significant reduction in lymphoproliferative responses after PHA 
and PWM (pokeweed mitogen) stimulation. Over 80% of the study population had values 
of > ISD (standard deviation) below the normal mean. Impaired T-cell function was also 
observed in vivo, with reduced delayed type hypersensitivity skin responses in 88% of 
patients (Lloyd et a l, 1989). Klimas et a l  (1990) also noted a 67% elevation of CD8 cells 
co-expressing HLA-DR markers. Interferon or other cytokines may have induced these 
cell surface antigens. Once activated, these cells can continue to produce cytokines. 
Cytokines such as interleukin (IL)-6 are pro-inflammatory and may be responsible for 
changes in mood and cognitive function, appetite disturbance, myalgia and fatigue, 
symptoms observed frequently in patients with CFS (Landay et a l, 1991; Straus et a l,
1988). Recently, Gupta et a l  (1997) studied the response of adherent (monocytes) and 
non-adherent (lymphocytes) mononuclear cells to PHA or lipopolysaccharide (LPS) in CFS 
patients and matched controls. Spontaneous production of IL-6 was significantly higher
■. ■
from both cells in CFS patients than controls, while spontaneous production of DL-10 was 
lower than that of controls. Production of TNF (tumour necrosis factor)-a from non­
stimulated adherent monocytes was also higher in patients than controls.
Another immunological abnormality frequently reported has been low NK (natural killer) 
cell cytotoxicity. NK cells form part of the innate immune system that acts against tumour 
cells and virus-infected cells. Klimas reported that the number of NK cells was elevated, 
but killing of tumour cells was diminished. The NK cell defect may be due to the 
impaired ability of mononuclear cells to produce y-IFN, which enhances NK cell 
cytotoxicity and cellular antigen presentation to lymphocytes. The function of NK cells 
has been found to be increased (Gold et a l, 1990), decreased (Kibler et a l, 1985; Caligiuri
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et al., 1987) and normal (Borysiewicz et a l, 1986), as measured by cytolytic activity 
against a number of different target cell lines.
The Royal College report draws attention to the difficulties in interpreting these 
abnormalities, many of which can be non-specific in nature. Additionally the illness is
often not of comparable severity or duration in different patients and comparison may be 
difficult. Other variables such as age, sex and co-existent stress or infection could also 
affect immune status. Where there are no signs of a specific illness or laboratory findings, 
the immunological abnormalities observed may also be attributed to neuro-immunological 
influences. Immune function has been shown to change in association with mental states 
ranging from life stress to psychotic illness. For example, exam stress can alter salivaiy 
IgA concentrations and depression has been associated with altered T-cell function (Cohen 
& Williamson, 1991). Attention should therefore not be focused solely towards an organic 
cause for the illness.
Though there is evidence of a disturbed immune system in many cases, whether this is
primary or secondary to the development of CFS is unknown. Certain individuals may be 
»at risk of developing CFS because of an inherently hyper-responsive immune system,
responding to certain infections (e.g. viral) with sustained and inappropriate cytokine 
.release (interferons and interleukins). This release may disrupt neurotransmitter function 
and result in the symptoms of CFS (Straus et a l, 1988). Anxiety or depression (either 
present before the CFS or as a result of the illness) may magnify the response or cause a 
prolonged cycle of disturbed immune function, inappropriate cytokine release, further 
symptoms, depression and continued disturbed immune function. Latent viruses, of the 
hei-pes group for example, may also be reactivated in such circumstances.
The immune dysfunction could also be the result of a primary cause such as a viral trigger 
via a ‘hit and run’ mechanism, where the virus is cleared after infection but the immune 
system does not recover as normal. Alternatively, the vims or infecting agent may be 
defective resulting in abnormal persistence within the host. A low grade infection may 
result and this in turn could cause chronic low level activation of the immune system.
3. Other Studies. Patients consistently report muscle pain and muscle weakness on 
exercise. However, there is no consistent evidence of a primary disorder of muscle and no
i 'convincing evidence of any changes in muscle structure or function other than those that 
have resulted from inactivity in CFS patients. Behan et al (1991) reported mitochondrial
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abnormalities in the muscle of CFS patients, with diffuse or focal atrophy of type II fibres 
and mitochondrial degeneration in 80% of cases. These results were disputed in a blinded 
study where there was no difference between CFS patients and normal controls (Plioplys & ï
Plioplys, 1995).
Magnetic resonance imaging (MRI) and single-photon emission computed tomography 
(SPECT) have been used to study the involvement of the CNS in CFS patients with both 
techniques highlighting abnormalities. MRI has shown spotted areas of high signal in the 
cerebral white matter more often in CFS patients than in control subjects (Buchwald et a l,
1992). SPECT abnormalities have also been reported to occur more often in CFS than in 
control subjects and it has been postulated that they represent reduced blood flow and/or 
dysfunction of neuronal cells (Komaroff & Buchwald, 1998). However, other groups did :|
not find the same abnormalities and the Royal College report suggests that normal 
variations should be more clearly established to provide a background level against which 
the abnormalities can be compared (Royal College report, 1996).
The role of neuro-endocrine dysfunction has also been investigated in CFS. Subtle |
i.'abnormalities of the HP A (hypothalamic-pituitary-adrenal) axis have been reported and it 
is possible that previous depressive illness may alter the reactivity of the HP A axis to 
subsequent infection or psychosocial stress (Demitrack et al., 1991). Psychiatric disorders 
and especially depression have been shown to predispose patients to CFS: depression is 
diagnosed in CFS patients 2 to 3.3 times more frequently than those with other chronic !.. 
illnesses; a higher lifetime prevalence (24-50%) of prior psychiatric disorder is reported in 
CFS patients and depression and stress have also been suggested as being able to influence 
infection (Klonoff, 1992). A number of investigators have suggested that CFS does not 
have any organic basis and is purely psychiatric in origin. However, while some of the 
symptoms of CFS could reflect a primary psychiatric disorder many are not characteristic 
of psychiatric illness such as sore throat, arthralgias or post-exercise malaise. In addition 
individuals with CFS tend not to suffer from guilt or lack of motivation which are 
indicators of major depression and trials of Fluoxetine (Prozac) have been unsuccessful 
(Komaroff & Buchwald, 1998). These findings suggest that the symptoms of CFS are not 
an atypical manifestation of major depression and that psychiatric disease cannot fully |
explain CFS.
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CFS has also been shown to be associated with allergies: a premorbid history of inhalant, 
food or drug allergies has been reported by approximately 65% of CFS patients. 
Additionally, cutaneous reactivity to inhalants or foods occurs in 50% of CFS patients 
compared to 20-30% of the general population. There is also a positive correlation 
between allergy severity and the magnitude of the EBV serological response. Whether 
allergy predisposes to EBV infection and then CFS or whether EBV predisposes to 
allergies is unknown (Klonoff, 1992).
There is a plethora of research on CFS which cannot be fully described in this manuscript 
and as such only the main areas have been discussed. A general consensus on CFS is that 
it is multifactorial in origin involving the complex interaction of predisposing factors (past 
psychological illness, somatic attribution style, history of fatigue, disturbed immune 
function), triggering factors (viral illness, life events, stress, depression/anxiety) and 
maintenance factors, that is those factors which could maintain and prolong the illness such 
as the patients response to fatigue (time off work, bed rest), effects of inactivity (fatigue) 
and the response of the doctor (raising sick notes) for example. It is the role of the 
enteroviruses in CFS which will be explored in this thesis.
 - .....................
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1.5.2. Enteroviruses and CFS - evidence for an association
The evidence for an association between enterovirus infection (particularly the coxsackie B 
group) and CFS has accumulated over a number of years from serological assays, nucleic 
acid hybridization analysis and more recently PCR studies. Serological analysis has i; 
focused on the detection of elevated neutralizing antibody titres to coxsackievims types B1 
to B5. Elevated titres were observed in 82% of M.E. cases (Fegan et a l 1983), 76% of 
suspected M.E. cases (Keighley & Bell, 1983), 47% of cases in a retrospective survey
Yousef and colleagues (1988) attempted virus isolation from concentrated faecal samples 
by direct culture and after acid dissociation, to investigate 76 patients with PVFS and 30
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(Calder & Warnock, 1984), 70% of PVFS cases (Behan et a l, 1985) and 46% of patients in 
a subsequent study by Calder et a l  (1987). In this latter study, 65 patients who were 
initially positive were re-tested at 6 months and one year later. Of these, 55% were still 
unwell and high antibody titres persisted in all but two of the patients. These figures were 
significant when compared to a group of control individuals. Testing of 950 normal adults 
in the West of Scotland for coxsackie B virus neutralizing antibody showed only 4% of 
samples to have titres of >512 and 10% to be 256 (Fegan et a l,  1983).
Neutralization titres are not a reliable means of determining recent enteroviral infection 
since antibody levels can remain elevated in an individual for months to years. A more 
relevant assay would be to test for specific IgM, which is indicative of recent infection. A 
|l-antibody capture ELISA was used to show that 31% of 118 patients and 37% of 290 
patients respectively, were positive for IgM compared to 9% of controls (McCartney et a l, 
1986; Bell et a l, 1988). Additionally, IgM was detected more than one year later in a 
number of patients (McCartney e ta l ,  1986).
However, Miller et a l  (1991) also tested sera from 53 patients and 49 controls for IgM 
using the capture ELISA method and 122 patients and 120 controls for IgG neutralizing 
antibody using the micrometabolic inhibition method at entry into the study. The results 
showed no significant difference between patients and controls for either measurement 
(24.4 % versus 22.6% positive respectively for IgM; 56.2% versus 55.3% positive 
respectively for IgG). After six months the figures for IgG were relatively unchanged, 
whereas the percentage of IgM positives had decreased in both patient and control groups 
but were still not significantly different from each other.
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matched neighbourhood controls. Enterovirus was detected in 17 (22%) patients and 2 
(7%) controls. One year later the 17 isolation positives were re-tested and the same vims 
type was isolated from 5 (29%) patients. In addition, 13 (76%) had detectable IgM and 9 
(53%) were positive for VPl antigen in semm using the monoclonal antibody 5-D8/1 
(Yousef et al., 1987a). These results were suggestive of a chronic infection with 
enteroviruses in PVFS patients. In addition, there was a correlation between clinical 
improvement and disappearance of VPl antigen and IgM complexes. In an additional 
group of 87 PVFS patients, enteroviral antigen was detected in the serum of 51% of 
patients and IgM circulating immune complexes were found in 74% of samples. All the 
patients were re-tested after 4 months and 89% were still positive, while no controls were 
positive for enteroviral antigen. This difference in frequency of detection of VPl antigen 
between patients and controls was deemed significant (Yousef et al., 1988).
Halpin and Wessely (1989) confirmed this association, albeit at a lower frequency. Thirty 
percent (9/30) of patients with chronic unexplained fatigue were positive for VPl antigen 
compared with 12% (4/43) of neurological case controls, a result which was just 
significant. However, Lynch and Seth (1989) comparing 20 patients with PVFS and 20 
controls with depression could not distinguish the groups on the basis of VPl antigen 
detection, questioning the specificity and sensitivity of the test.
More recently, molecular techniques have been used to study enteroviruses. Archard et al. 
(1988) used an enterovirus specific probe prepared from coxsackievirus B2 RNA in 
quantitative slot-blots to test for RNA in skeletal muscle biopsy specimens. Ninety-six 
patients with a history of PVFS of up to 20 years were tested. Twenty were positive for 
enterovirus with hybridization signals more than 3 standard deviations greater than the 
mean of normal muscle controls. The remaining 76 gave low, background values which 
were statistically indistinguishable from the normal muscle controls. Increased semm 
creatine kinase levels, used as a marker of muscle damage, were present in 11 out of 96 
patient cases, 9 of whom were positive for enteroviral RNA.
Gow and colleagues (1991) also tested muscle biopsies of 60 patients with PVFS and 41 
controls undergoing routine surgery from the same catchment area. Routine investigations 
did not reveal any significant abnormalities and muscle samples showed no evidence of 
inflammation or necrosis. Mild to moderate, non-specific atrophy of type 2 fibres was 
present in the biopsy samples, which is consistent with a chronic illness. Of the 60
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patients and 41 controls, 12 and 6 respectively had neutralizing antibody titres of > 256 to 
one of the coxsackie B viruses (types B1 to B5). A single round PCR of the 5’ NTR 
followed by hybridization produced 32/60 (53%) positive results in the patient group, 
compared to 6/41 (15%) control group positives, results which were statistically 
significant. Based on the PCR results, the authors suggested that there was a persistent 
enterovirus infection in the muscle of some patients with PVFS and that this interfered 
with cell metabolism, causing the chronic fatigue.
In some patients, a continuing humoral immune response against viral antigens is not 
detected, even when enteroviral RNA is present in the affected tissue (Archard et a l, 1988; 
Bowles et al., 1989). Together with the failure to isolate infectious virus or detect virus 
specific antigen, this suggests that progression to disease is associated with some kind of 
selection of defective virus. Cunningham et al (1990) used single-stranded virus specific 
RNA hybridization probes to compare the relative amounts of viral RNA species in a 
possible persistent infection in vivo, to those in a cytolytic infection in vitro. In the 
coxsackie B2 productive infection, positive strand RNA was synthesized in approximately ; |
100-fold excess over the negative strand. However, where enteroviral RNA was detected 
in the skeletal muscle of CFS cases, production of equal amounts of positive and negative 
strands of enteroviral RNA was noted. This suggested that enteroviral persistence in 
muscle was due to a defect in the control of viral RNA synthesis.
It is not easy or practicable to obtain muscle biopsies from large groups of individuals and Kthe possibility of using alternative samples was explored. With access to a well-defined |
group of individuals with CFS, through the Department of Infectious Diseases at Ruchill 
Hospital, a study using blood and stool samples to test for enteroviral sequences was 
undertaken. j
The initial findings of this study are described by Clements et al. (1995), in which a group 
of 118 chronic fatigue syndrome (CFS) patients (181 samples of serum and/or buffy coat 
and/or stool) was tested for the presence of enteroviral sequences by nested PCR. The 
patient group comprising 77 females and 41 males, was matched as closely as possible to 
two comparison groups. The first comparison group (A) was composed of 101 patients 
(114 samples of semm and/or stools) with symptoms suggestive of an acute enteroviral 
disease such as headache, rash and/or pyrexia but no fatigue. This group was matched by T
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age, sex and date of specimen receipt. The second comparison group (B) comprised 126 
individuals from whom serum had been obtained for occupational health or ante-natal 
screening purposes. This group was assumed to be healthy and was age matched but not 
sex matched because the group was predominantly female.
Enteroviral sequences were detected in 41% of serum samples, 27% of buffy-coat samples 
and 48% of stool samples of CFS patients. Where patients provided both serum and buffy 
coat specimens, 53% of the PCR results were in concordance. In the comparison groups, 
27% of the serum samples from acutely ill patients and 2% of the healthy patients were 
positive for enteroviral specific sequences.
Analysis of the data revealed a significant difference at the 95% level between the findings 
on CFS serum samples and either comparison group. There was, however no significant 
difference between the CF stool results and group A stool results (28%). In the CFS group 
the results using serum and buffy coat were pooled and patients categorized as positive or 
negative, and on this basis 50/118 (42%) were enteroviral PCR positive. When the 
patients in the study were examined by sex and the duration of symptoms, it became 
appai'ent that the excess of females observed in the group overall was only seen in patients 
with a history of less than 2 years of fatigue. The majority of patients described symptoms 
commencing after an acute infection which is suggestive of a post-infectious fatigue 
syndrome. The presence of enteroviral specific sequences in a significant number of 
patients with chronic fatigue syndrome points to some role for the virus in this syndrome 
and provides additional evidence to confirm and extend the studies on muscle biopsies. 
The study also demonstrated that serum samples could be used as an alternative to muscle 
biopsies for the detection of enteroviral sequences in patients with CFS.
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1.6. Summary and aims of the study
Enteroviruses are established aetiological agents of a wide variety of clinical syndromes, 
many of which involve the musculo-skeletal system. They have also been implicated in a 
number of chronic diseases, enteroviral RNA being detected in affected tissues in some 
cases of chronic heart disease for example. For a number of years there has also been 
accumulating evidence of an association between enteroviruses and Chronic Fatigue 
Syndrome (CFS) although much of this evidence has come from the United Kingdom only 
and has not been confirmed in studies from other countries. In the U.K., initial serological 
data has been supported recently by molecular detection of enteroviral RNA in muscle 
biopsies and serum samples. Although enteroviruses do not persist normally in the course 
of infection, defective replication of enterovimses in some CFS patients has been suggested 
as a mechanism of persistence, thus contributing to the chronic nature of the syndrome. 
This evidence has also been disputed by other groups. Most studies have been based on 
the detection of enteroviral RNA by PCR, with sampling at one time point only which 
cannot provide direct evidence for persistence. No long-term follow-up studies have been 
carried out to look at enteroviral PCR status over time in relation to the clinical illness or to 
examine the type of enterovirus present in these patients.
The main aims of this study were therefore as follows:
1. To evaluate PCR-based technologies for the detection of enteroviral genomes in samples 
from CFS patients. This would be achieved initially using nested PCR to detect the 5’ 
non-translated region of the entero vims genome in semm samples obtained from CFS 
patients and comparison patients.
2. To determine the genetic sequence of the enterovims(es) associated with CFS. This 
would be achieved by sequencing the PCR products and carrying out phylogenetic analysis 
of the sequences in the context of the enterovirus group as a whole.
3. To detemnine whether enteroviruses are associated with the syndrome by following a 
cohort of individuals with CFS from a well-defined population of patients over time.
4. To correlate the clinical status of the CFS patient, by means of a questionnaire, with the 
presence or absence of enteroviral sequences over time.
------------------------------------------------ .........
■ .........
Materials and Methods
2. M aterials and M eth od s
2.1. M aterials
2.1.1. Cell Lines
MRC-5 (human embryonic lung fibroblasts) and RMK (Rhesus monkey kidney) cell lines 
(both obtained from Bio-Whittaker at a concentration of 2.5 x lOMn Earles Minimum 
Essential Medium (EMEM) with 10% foetal bovine serum (FBS) were propagated in
■75cm^ flasks in Medium 199 (with GlutaMAX™) supplemented with 10% foetal calf 
serum (FCS), 1% penicillin/streptomycin solution (10,000 units penicillin/10,000jig 
streptomycin/ml), 1% fungizone (250 jig/ml), 1% MEM vitamin solution (all Gibco BRL).
Cells were incubated at 37“C in 5% CO2 and passaged once before use.
2,1.2. Clinical Specimens
Specimens included in the 'Study' group were obtained from patients who had been 
diagnosed with Chronic Fatigue Syndrome (CFS) according to the Oxford Criteria (Sharpe 
et a l,  1991). Patients attended the outpatient clinic of the Infectious Disease Unit, Ruchill 
Hospital, or their general practitioner where a specimen of heparinized venous blood and/or 
a throat swab was obtained. Throat swabs were maintained in viral transport medium 
(VTM) (Gibco BRL) supplemented with 1% penicillin/streptomycin solution (Gibco BRL). 
The serum fraction was removed from whole blood by centrifugation at 2500 rpm for 5
minutes. Both samples were stored at -20"C until required.
The 'Comparison' Group was composed of patients who did not have CFS, and whose 
blood samples had been received at the Regional Virus Laboratory, either for ante-natal or 
for occupational health reasons. Samples with sufficient volume for testing were chosen 
at random each month to provide a background level of enterovirus detection throughout 
the years of the study. Again, the serum fraction was removed and stored at -20“C until 
required.
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2.1.3. Oligonucleotide Primers
Oligonucleotides were supplied from three sources during the course of the study: Oswell 
DNA Services (UK), Cruachem (UK) and Gibco-BRL. The sequences of the primers 
(shown 5’ to 3’) are presented in Table 6. All primers were used at a working 
concentration of approximately 40 pmoles/pl.
I
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Primer
Name
Nucleotide Sequence (from 5’-3’) Position Length % G+C 
content
Tm
P1+ cggtacctttgtgcgcctgt 63-82 20 60 77.5
Pl- acaggcgcacaaaggtaccg 82-63 20 60 77.5
P4+ ctgaatgcggctaatcctaac 457-477 21 47.6 71.4
P4- ttaggattagccgcattcag 476-457 20 45 70.2
P6+ gcacttctgttacccG 168-183 16 50 58.6
P6- ggtaacagaagtgcttgatc 181-162 20 45 63.7
P9+ gtgcgaagagtctattgagc 416-435 20 50 66.7
P9- tcaatagactcttcgcac 433-416 18 44 59.5
A+ tggctgcttatggtgacaat 581-600 20 45 66.2
A- attgtcaccataagcagcca 600-581 20 45 66.2
B- tctgggaacttccaccacca 1199-1180 20 55 75.0
protl+ aactccaccctgcagattga 5173-5192 20 50 72.0
prot2- acggcccacctatcatagat 5468-5449 20 50 70.4
prot3- agcattctcttggtgggtgt 5768-5749 20 50 71.0
Y- cgcaccgaatgcggagaatttacc 7398-7375 24 54 84.5
ABL1+ cagcggccagtagcatctgactt n/a 23 56 79.7
ABL2- tgtgattatagcctaagacccggag n/a 25 48 77.2
poly -T ttcgcgaggttaacgtcgact(i4) 3’ poly (A) 34 32.4 74.9
.1
Table 6: Oligonucleotide sequences and positions relative to the coxsackievirus B3 
genome (5* to 3’) (GenBank accession number M33854). Forward and reverse 
primers are denoted as and respectively. %G+C relates to the number of 
guanidine and cytosine residues. The Tm recorded is that according to the 
manufacturer.
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2.1.4. Extraction and PCR reagents
All reagents for the extraction and PCR procedures were stored as small volume aliquots 
(where appropriate) and either used as supplied or diluted in DEPC (diethyl pyrocarbonate) 
(Sigma) treated water (Baxter Healthcare Limited). DEPC (0.01%) was added to the water 
which was left to stand overnight before autoclaving. Aerosol resistant tips (Alpha 
laboratories) were used at all times and micro-centrifuge tubes (0.5ml thin-walled from 
Advanced Biotechnologies and 1.5ml from Sarstedt) were autoclaved before use.
2.1.5. Patient Questionnaire
In conjunction with the infectious disease consultants at Ruchill Hospital, a self­
administered patient questionnaire was developed (see Appendix). Patient details 
including previous medical history, present symptoms and PCR status were stored using 
the data manager software package DataBase version 4.5 (1992) supplied by DataBase
I
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U.K. Limited.
2.2. Coxsackievirus B neutralization assay
Study and comparison sera were diluted 1/16 in phosphate buffered saline (PBS) (Sigma)
and heat inactivated at 56®C for 30 minutes. Aliquots (25p,l) of each sample were
'I;transferred to 5 microtitre plates (one for each of coxsackievirus B types 1 to 5) and 
double-diluted 8 times in medium 199 (Gibco BRL). Aliquots (25|ri) of the |
coxsackievirus stock suspensions (types B1 to B5) at 100 TCID50 were added to the diluted 
sera and the plates incubated at room temperature to allow neutralization of the virus to 
occur. After the incubation, lOOp.1 aliquots of Vero cell suspension (at 1.5 x 10^  cells per 
ml) were added to each of the wells and incubated with carbon dioxide (CO2) at 37"C for 3 
days. Control wells were included to test that the semm alone was not toxic to the cells.
The end point was taken as the dilution below that which shows cytopathic effect (i.e. the :/lowest dilution of serum that just neutralizes the vims). In accordance with the routine
laboratory method of reporting, titres less than 256 were interpreted as not significant, titres 
of 256 were suggestive of infection and those of 512 and above were indicative of recent 
infection (Grist et al., 1974).
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2.3. Preparation of Control RNA
2.3.1. Preparation of negative control RNA
MRC-5 cells (Biowhittaker) were cultured as monolayers in 75cm^ flasks and maintained 
in Medium 199 (with GlutaMAX™) with 0.5% FBS, 1% penicillin/streptomycin and 1% 
fungizone at 3TC  in 5% CO2. When the cells were confluent the medium was decanted, â
the cell layer washed twice with lOmls PBS, and 1ml of trypsin/EDTA (Gibco) was added.
After approximately 1 minute the trypsin was removed and the tubes maintained at room 
temperature until the cells began to detach. Fresh medium (approximately lOmls) was f
then added and the cells removed to a universal container for centrifugation at 3000ipm for ’
5 minutes. The medium was decanted and the cell pellet washed twice with PBS before 
being subjected to the RNA extraction procedure as described in 2.4.
i
2.3.2. Preparation of Positive Control RNA
Coxsackievirus type A9 was used as the positive control virus throughout this 
investigation. All other enterovirus types mentioned in the text were prepared following 
the same procedure. MRC-5 cells were seeded with an aliquot of coxsackievirus A9 
positive cell culture fluid (previously identified by the RVL by traditional typing methods || 
(Grist et a i,  1979; Minor & Bell, 1990)) and incubated until a cytopathic effect (c.p.e.) of 
approximately 75% was evident. The viral titre of the tissue culture fluid was determined 
according to the method of Grist et al. (1974). Dilutions of the cell culture fluid to IQ-’ 
were made in 0.5% medium 199. Four culture tubes of MRC-5 monolayers were seeded 
with 200|al of each dilution and incubated in the stationaiy sloped position at 37°C. After 
approximately 6 days, the tubes were examined for c.p.e and scored accordingly. The titre 
was determined according to the Karber formula (Karber, 1931). The titred cell culture 
fluid was maintained in 1ml aliquots at -70"C.
2.4. Extraction of RNA
Two commercial methods were used in this study, the Glassmax™ RNA Microisolation 
Spin Cartridge system and TRIzol™ (Total RNA Isolation) reagent, both supplied by Gibco 
BRL.
Materials and Methods
2.4.1. Glassmax™ System
RNA was extracted using a modified version of the manufacturer’s instructions. Serum or 
throat swab sample (in VTM) (200p,l) was added to 450|il of ice-cold denaturing solution 
[guanidinium isothiocyanate/2-mercaptoethanol (10%)], 25pi RNAguard ribonuclease 
inhibitor (1/20 dilution) (Pharmacia), and 25pl calf-liver ribosomal RNA (1/100 dilution) 
(Sigma) in a 1.5ml micro-centrifuge tube and vortexed. To this, ethanol (420pl; 100%) 
(BDH) was added, the mixture vortexed and then centrifuged at maximum speed for 5 
minutes in a micro-centrifuge. The nucleic acid pellet was retained and resuspended in 
450 pi binding solution (6M sodium iodide) and 40pl of 3M sodium acetate solution pH 
5.5 (supplied). The resultant solution was vortexed and transferred to a Glassmax 
cartridge which was centrifuged at maximum speed for 1 minute. The nucleic acid bound 
to the cartridge was then washed three times with RNA wash buffer and twice with 80% 
(v/v) ethanol. After a final centrifugation to remove the last traces of ethanol, the nucleic 
acid was eluted by centrifugation with 25pl DEPC-treated water heated to 65‘^ C.
2.4.2. TRIzol™ (Total RNA Isolation) Reagent
This reagent consists of a mono-phasic solution (pH 4-5) of phenol and guanidine
isothiocyanate. TRIzol (lOOOpl) and 200pl of sample (or virus infected cell culture fluid)
were combined in a 1.5ml micro-centrifuge tube and incubated at room temperature for 5
minutes. Chloroform (200pl) was added, the mixture vortexed and incubated for a further 
.2 minutes before centrifugation at 12,000g for 15 minutes. The upper aqueous phase 
containing the RNA was transferred to a fresh tube and mixed with an equal volume of 
isopropyl alcohol and 15pl calf-liver ribosomal RNA (1/40 dilution) for 10 minutes at - 
20“C. Following centrifugation at 12,000g for 15 minutes, the RNA precipitate formed a 
gel-like pellet on the sides and bottom of the tube. The supernatant was removed and the 
pellet washed with 75% ethanol, and then dried briefly under vacuum. The RNA was 
dissolved in 20pl DEPC-treated water and incubated for 10 minutes at approximately 55"C. 
The RNA from both methods was stored at -70°C until required. The integrity of the 
extracted RNA was determined by visualizing the 18s and 28s ribosomal bands following 
agarose gel electrophoresis.
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2.5. R T -P C R
For the ‘nested’ PCR using P6+ and P9- primers (Table 6: p52), 2pl of first round product 
was amplified for 25 cycles in a 50pl reaction volume as described above. Reaction
2.5.1. Reverse Transcription of RNA 'I
For each reaction, 4pl 5x first strand buffer (250mM Tris-HCl (pH 8.3), 375mM KCl,
15mM MgCh) (Gibco BRL), 2pl lOmM deoxynucleoside triphosphates (dNTPs) I
(Advanced Biotechnologies), Ipl RNAguard (1/20 dilution), Ipl pd(N)e random hexamers 
(1/100 dilution) (Pharmacia), Ipl Moloney Murine Leukaemia Virus Reverse Transcriptase 
(M-MLV RT) (Gibco BRL) and Ipl O.IM dithiothreitol (DTT) (Gibco BRL) were mixed 
with lOpl sample or control RNA and incubated at room temperature for 10 minutes. The 5
reaction mixture was then incubated at 37'^C for 45 minutes followed by 95°C for 5 
minutes, before being cooled on ice. The cDNA was either amplified immediately by 
PCR or stored at -20"C until required. The use of random hexamers enabled the same |
cDNA sample to be used as a template in a number of different PCR reactions using 
different primers.
2.5.2. Polymerase Chain Reaction (PCR)
With the introduction of new thermocyclers and the use of thin-walled tubes, the PCR 71 
protocols originally described in Clements et a l (1995) and Galbraith et a l (1995) were 
modified resulting in smaller reaction volumes and shorter cycling times.
For a standard PCR amplification using P1+ and P4- or ABLl and ABL2 control primer |
combinations (Table 6: p52) , a 50pl reaction mixture was prepared containing 5pi of lOx 
Reaction Buffer IV (200mM (NÏL)2S04, 750mM Tris-HCl (pH 9.0), 0.1% (w/v) Tween) 
and 3pi magnesium chloride (25mM) (both Advanced Biotechnologies), Ipl dNTPs 
(lOmM), 40 pmoles each primer, 0.25pl Thermoprime plus DNA polymerase (5 units/pl) 
(Advanced Biotechnologies) and lOpl cDNA (prepared as described in 2.4.1,). The 
mixture was overlaid with a drop of mineral oil (Sigma) to prevent evaporation and 
subjected to the following conditions on an Omnigene Thermocycler (Hybaid): 1 minute at 
94"C, followed by thirty-five cycles of 50 seconds at 94"C, 50 seconds at 55"C and 1 
minute, 10 seconds at 72"C, followed by a final extension step of 72‘^ C for 10 minutes.
" ' i
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conditions for other primer combinations will be described in the text where appropriate.
2.6. M onitoring  fo r  contam ination  in the RT-PC R process
In this study all reasonable precautions were taken within the laboratory to minimize the 
risk of contamination. Separate rooms (and safety cabinets in some areas) were used for 
extraction of RNA, preparation of reagent mastermixes, cycling of RT and first round 
mixes, cycling of second round mixes and gel electrophoresis of PCR products. In each 
room, dedicated pipettes and specimen racks, aerosol resistant tips, protective clothing, 
gloves and storage facilities were available. Only six samples were processed together 
alongside one positive (coxsackievirus A9 infected MRC-5 cells) and one negative (MRC- 
5 cells) control. A ‘no template’ control was included at the RT and first round stage. A 
second PCR was run simultaneously using control primers ABL1/ABL2. These amplify 
ableson tyrosine kinase messenger (m)RNA and are used to ensure that RNA has been 
successfully extracted from the samples (Gow et a l, 1991). In approximately 99% of 
serum samples an amplification product was observed using the ABL primers. If all the 
controls were amplified as expected, then the sample results were accepted. Any positive 
results were repeated from the extraction stage.
Surfaces in each working area within the laboratory were swabbed with cotton-tipped 
swabs twice over the study period. These surfaces included: bench tops, pipettes,
specimen racks, fume cabinet surfaces, centrifuges, freezer handles and door handles. 
Two swabs were obtained from each surface: one was placed into water for direct PCR 
amplification to detect PCR product and one was placed into VTM for extraction and RT- 
PCR amplification to detect viral RNA.
For direct PCR amplification, lOfil of the swab solution was amplified using P6+ and P9- 
primers in a standard 50|il reaction as described in 2.5.2.
The VTM solution (200p.l) was extracted using TRIzoF*^ as described previously (2.4.2). 
The resulting RNA was subjected to RT-PCR as described in section 2.5.
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2.7. Agarose Gel Electrophoresis
PCR products (10|li1) were combined with 2.5|xl loading buffer (prepared using a 
concentrated solution of F icolf 500 (Pharmacia) and Orange G dye (Gurr Microscopy) in 
0.5x Tris/boric acid/EDTA (TBE) buffer). Products were mn alongside 350ng of 100 base 
pair ladder (Gibco BRL) on a 1.5% agarose (w/v) (SeaKem^, Flowgen) horizontal gel 
containing 10|lg ethidium bromide (Sigma) in 0.5x TBE running buffer for approximately 
2 hours at 80 volts. Bands were visualized under U.V. light and images recorded with a 
gel documentation system (Sony).
Predicted PCR product sizes
P1+/P4- 414 base pairs P6+/P9-
P4+/B- 750 base pairs A+/B-
protl+/prot3- 595 base pairs protl+/prot2-
ABL1/ABL2 220 base pairs P4+/prot2-
264 base pairs 
600 base pairs 
295 base pairs 
5000 base pairs
2.8. 'Purification' of PCR Products
PCR products were separated from the unincorporated PCR components using the 
Geneclean kit (Stratech Scientific). A much simpler and more rapid method was later 
adopted using Microspin™ S-400 HR columns (Pharmacia).
2.8.1. Geneclean IP kit
In a micro centrifuge tube, 20|Ltl PCR product, 30p,l Tris-EDTA Buffer (pH 8.0) (Sigma) 
and 150]Lil Sodium Iodide (Nal) stock solution were combined before adding 6jal 
Glassmilk'^ silica matrix (Stratech Scientific) and mixing continuously for 10 minutes. 
The DNA/Glassmilk'^ complex was then pelleted and the supernatant removed. The pellet 
was washed three times with New Wash (made according to manufacturer’s instructions). 
Any remaining liquid was carefully removed and the pellet resuspended in 20|il sterile 
DEPC-treated water. After incubating at 50°C for 3 minutes the mixture was centrifuged 
and the supernatant (approximately 20|al) containing the eluted DNA was removed to a 
fresh tube.
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2.8.2. Microspin™ S-400 columns
The column resin was resuspended by vortexing, the cap was loosened and the bottom 
closure snapped off. The column was then placed in a 1.5ml micro-centrifuge tube and 
centrifuged at 3000 r.p.m. in a micro-centrifuge (MSB Micro Centaur) for 1 minute to 
remove the storage buffer. After placing in a clean 1.5ml microcentrifuge tube, 30pl of 
PCR product was then placed carefully on the top of the sephacryl resin which was 
centrifuged again for 2 minutes to elute the product.
2.9. Sequencing o f PCR products
A  number of enterovirus isolates in tissue culture fluid were available for sequencing. 
Isolates were either identified in the Regional Virus Laboratory or obtained from reference 
collections (Table 7). RNA extraction and RT-PCR procedures were as described 
previously.
Initially, manual chain termination sequencing of samples and a few echovims isolates 
(echo 3, 4 ,7 ,9 , 11, 20) was performed using the Sequenase*  ^version 2.0 DNA sequencing 
kit (United States Biochemical). This technique was later replaced by automated 
fluorescent sequencing.
All fragments were sequenced using both forward and reverse primers, using the same set 
that had generated the PCR product. For example, the 264 base pair product from the 
nested PCR was sequenced using P6+ and P9- primers.
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iIClinical Isolates Code Location/month/ye arCoxsackie A1 Reference strain Unknown
Coxsackie A5 Swartz strain USA/8/1964
Coxsackie A7 M708 USA/7/1964
Coxsackie A9 8558 Monklands/12/1994
Coxsackie A ll ET9I1 USA/10/1960
Coxsackie A15 ETL69 USA/5/1961
Coxsackie A20 M1165 USA/4/1966
Coxsackie A22 Reference strain Unknown
Coxsackie B2 4048 Glasgow/4/1994
Coxsackie B2 49 Edinburgh/7/1992
Coxsackie B2 50 Edinburgh/8/1992
Coxsackie B2 51 Edinburgh/9/1992
Coxsackie B2 53 Edinburgh/9/1992
Coxsackie B2 54 Edinburgh/11/1992
Coxsackie B2 55 Edinburgh/11/1992
Coxsackie B2 56 Edinburgh/12/1992
Coxsackie B3 3629 Dumfries/5/1997
Coxsackie B3 3748 Dumfries/5/1997
Coxsackie B3 4413 Dumfries/6/1997
Coxsackie B3 4541 Dumfries/6/1997
Coxsackie B3 4625 Dumfries/6/1997
Coxsackie B3 5027 Dumfries/6/1997
Coxsackie B3 6220 Dumfries/8/1997
Coxsackie B3 6687 Glasgow/8/1997
Coxsackie B3 8985 Stirling/10/1997
Coxsackie B3 1996QC CPHL/6/1996
Table 7: Clinical isolates typed and sequenced in the RVL. Sources of isolates are 
indicated where known.
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Clinical Isolates Code Location/month/year
Coxsackie B5 6237 Dundee/5/1961
Coxsackie B5 6242 Dundee/5/1961
Coxsackie B5 2868 Dumfries/4/1996
Coxsackie B5 2907 Dumfries/4/1996
Coxsackie B5 6093 Glasgow/8/1996
Coxsackie B6 Reference strain Unknown
Echovims 2 Reference Unknown
Echovims 3 6291 Dumfries/11/1993
Echovims 4 1990 Glasgow/3/1990
Echovims 5 E5 Glasgow/U/1994
Echovims 6 4283 Glasgow/6/1994
Echovims 6 4566 Glasgow/7/1994
Echovims 6 4730 Glasgow/7/1994
Echovims 6 4989 Glasgow/7/1994
Echovims 7 1788 Dumfries/3/1994
Echovims 9 6518 Glasgow/11/1993
Echovims 11 2350 Lanarkshire/2/1989
Echovims 19 E19 Glasgow/3/1980
Echovims 20 645 Glasgow/1/1994
Echovims 25 E25 Glasgow/3/1980
Echovims 30 6392 Ayrshire/7/1966
Echovims 30 6398 Ayrshire/7/1966
Echovims 30 6548 Ayrshire/11/1975
Echovims 30 8117 Monklands/10/1995
Echovims 30 8293 Monklands/11/1995
Echovims 30 3786 Dumfries/5/1996
Echovims 30 4313 Dumfries/6/1996
Echovims 30 4844 Glasgow/6/1997
I
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Table 7 (cont): Clinical isolates typed and sequenced in the RVL. Sources of isolates 
and year of isolation are indicated where known.
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2.9.1. Manual sequencing
2.9.1.1. Chain termination sequencing using the Sequenase version 2.0 DNA 
sequencing kit. In a 0.5ml microcentrifuge tube, 5pi of primer and lOpl 'genecleaned' 
PCR product (as described in 2.8.1.) were incubated at 95°C for 2 minutes. After a 10 
second spin the mix was incubated at 70"C for 3 minutes, 95"C for 45 seconds and 37"C for 
10 minutes before cooling on ice. An aliquot of this (8pl) was added to 2pl reaction buffer 
(5x), Ipl O.IM DTT, 2pl labelling mix (1/10 dilution with water) and Ipl Redivue [^ S^] 
dATP (Amersham International pic). Finally 2pl sequenase enzyme (1/8.5 dilution with 
enzyme dilution buffer) was added and the reaction mixed thoroughly. Four tubes were 
prepared containing 2.5pl of each termination mix (ddG, ddA, ddT, ddC) and pre-warmed 
to 37"C for 1 minute. Aliquots of the labelling reaction mixture (3.5pl) were then added to 
each of the four tubes, centrifuged for a few seconds and incubated at 37'^C for 5 minutes. 
Stop solution (4pl) was added and the tubes refrigerated until required for electrophoresis.
2.9.1.2. Denaturing Acrylamide Gel Electrophoresis. Two glass plates were 
thoroughly cleaned with ethanol and one treated with Repelcote water repellent (BDH) in a 
safety cabinet. The plates and 1mm spacers were placed together and bound with 
electrical tape. A 6% acrylamide gel was prepared by adding 24ml concentrate, 66ml 
diluent and 10ml buffer (Sequagel™ sequencing system. National Diagnostics) followed by 
300pl ammonium persulphate (25%) (w/v) (Sigma) and 40pl TEMED (Sigma). The 
solution was poured between the glass plates and a sharkstooth comb placed in upside 
down. Once the gel had set, the tape and the comb were removed and the plates loaded 
into the gel electrophoresis system (Gibco BRL) buffered by 0.5x TBE (Gibco BRL). The 
comb was repositioned with the teeth touching the top of the gel, and the gel was pre-mn 
for 30 minutes at approximately 1500 volts. The radioactive samples were denatured at 
95"C for 5 minutes and 3p,l of each mix loaded onto the gel in the order G, A, T, C. The 
gel was run for 2.5-3.0 hours at a constant 1500 volts and then soaked in acetic acid (5%) 
(BDH) /methanol (15%) (v/v) (BDH) for 15 minutes. After washing in water for 10 
minutes, the gel was transferred to 4mm chromatographic paper and dried under vacuum 
at 80°C for 1.0-1.5 hours. The dried gel was placed in a film cassette in contact with 
photographic film (Kodak) for 2-5 days, and the film developed in an automatic processor 
in the hospital X-Ray department. The nucleotide sequence was determined and 
transferred manually to the computer database (UNIX system) for analysis.
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accompanying software for base calling of sequences.
Template DNA (6p,l) (prepared as described in 2.8.2.) and 3.2 pmoles of primer were 
mixed and added to 8pl reaction premix (ABI PRISM™ Dye terminator Cycle Sequencing
2.9.2. Automated Sequencing
Initially, sequencing was carried out by Mr Robert McFarlane of the Beatson Institute for 
Cancer Research (results presented in Galbraith et a l, 1995, 1997). Subsequent 
sequencing reactions were performed by the author and run on gels by staff of the 
Molecular Biology Support Unit (M.B.S.U.) of Glasgow University.
4Both laboratories used the ABI 373 DNA sequencer (Applied Biosystems) and
i)
7Ready Reaction Kit, Perkin Elmer) in a 20 p.1 volume. The reaction was overlaid with a
wax pellet (PCR Gem 50, Perkin Elmer) and incubated through 25 cycles of 96"C for 30 
seconds, 50°C for 20 seconds and 60“C for 4 minutes. After cycling the product was 
removed from under the wax layer to a fresh tube. To this, 50pl ethanol (100%) and 2pl 
sodium acetate (3M: pH 4.5) (Sigma) was added and the reaction incubated at -70°C for 15 
minutes. After centrifugation at maximum speed in a microcentrifuge for 15 minutes, the 
pellet was washed with 70% ethanol (v/v) and then air-dried. Samples were then sent to |  
the M.B.S.U. for electrophoresis. Raw data was returned on disc and transferred to the 
database (UNIX system) for analysis. The forward and reverse sequences were aligned 
and any ambiguities corrected manually.
2.10. Inverse PCR
This is a method for obtaining the sequence of flanking regions of a known sequence, by 
using primers in the reverse orientation to those that will amplify the known sequence (see f
Figure 22: p i23). The first stage involves the production of double-stranded cDNA from |
the RNA template. A specific primer in the RT reaction will produce a cDNA fragment of 
a specific size whereas a poly-T primer will attach to the poly-A tail and produce full- 
length cDNA. In the latter case, a restriction enzyme can then be used to cut the DNA into 
fragments of appropriate size for ligation. A low DNA concentration favours 
circularization of product rather than concatemerization, and fragments between 300 base ;
pairs and 3 kilobases can be ligated. The circular DNA can then act as a template for 
PCR, or can be linearized with a second restriction enzyme prior to PCR.
Protocols for inverse PCR were based on the methods described by Ochman and colleagues jf
s. -L'-, . L. -v' r.
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(1990) and Zeiner and Gehring (1994).
2.10.1. Preparation of double stranded cDNA using specific internal primer
Coxsackievirus A9 was used as the control in the development of this technique. RNA 
extracted as described in 2.4.2, was used as a template for double stranded cDNA synthesis 
using a kit provided by Boehringer Mannheim. Essentially, 9p.l sample RNA was copied 
into cDNA according to the manufacturer’s instructions except for the omission of the 
radioactive tracer. The final reaction mix was extracted with an equal volume of 
phenol/chloroform/isoamylalcohol (25:24:1) before precipitating with 2 volumes of 100% 
ethanol. After washing with 70% (v/v) ethanol, the pellet was resuspended in lOpl sterile 
water.
A short double stranded cDNA fragment (approximately 600 base pairs) was produced by 
using primer A- (Table 6: p52) in the initial first strand synthesis reaction. The resulting 
blunt ended fragment was then self-ligated in a lOOpl reaction containing 10 units T4 DNA 
ligase. The ligation reaction was divided into two aliquots, one which was heat 
inactivated at 65‘’C for 20 minutes and one which was extracted with an equal volume of 
phenol/ chloroform/isoamylalcohol followed by precipitation with 2 volumes of 100% 
ethanol. The resulting pellet was washed with 70% (v/v) ethanol, air-dried and 
resuspended in 20p.l sterile water.
2.10.2. Preparation of full length double-stranded cDNA using a poly-T primer
Full-length double stranded DNA was obtained using the poly-T primer (Table 6: p52) to 
initiate first strand synthesis following the protocol outlined above. Hae H (Gibco BRL) 
was used to digest the double stranded cDNA in a 15pl reaction containing 10 units of 
enzyme and 5pi cDNA in 2x One Phor All buffer (OPA buffer, Pharmacia: lOx buffer 
contains lOOmM Tris Acetate pH7.5, lOOmM magnesium acetate and 500mM potassium 
acetate) for 2 hours at 37"C. Hae H cuts at positions 39, 1207 and 2294 of the coxsackie 
A9 genome, producing fragments of 38, 1168, 1087 and 5206 base pairs. Following 
inactivation of the enzyme at 65‘’C for 20 minutes, lOpl of the reaction was included in a 
lOOpl reaction containing 10 units of T4 DNA ligase (Boehringer) and ImM ATP 
(Pharmacia) in Ix OPA buffer. This was incubated overnight at 15°C and then inactivated
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at 65“C for 20 minutes. Linearization of the 1168 base pair cDNA fragment was 
accomplished using 10 units of Xmn I (Promega), which cuts at position 229 of 
coxsackievirus A9, in a 50pl reaction in Ix OPA buffer at 37°C overnight.
2.10.3. Inverse PCR
Aliquots (lOpl) of double stranded cDNA template (either in circle or linear' form), 
prepared as described above were amplified in 50pl reactions using P6- and P9+ primers 
(Table 6: p52) under the following conditions: 94"C for 2 minutes followed by 35 cycles of 
94"C for 50 seconds, 55“C for 50 seconds, 72“C for 2 minutes, with a final extension at 
72"C for 5 minutes. A second ‘nested’ PCR was also carried out under the same 
conditions (for 25 cycles) using primers P4+ and PI- (Table 6: p52).
Aliquots of the template were also amplified using the standard P1+/P4- and P6+/P9- 
primer combinations (Table 6: p52) as described in section 2.5.2 as a control to ensure that 
the template was present and intact.
All PCR products were visualized by gel electrophoresis on 1% agarose gels.
2.11. Poly A polymerase reaction
I.
■4
Adenosine residues were added to the 3’ end of RNA in a 20pl reaction containing 6.5pl 
sample RNA; 4pl of buffer (250pl R E a c t  1 buffer (50mM Tris-HCl, lOmM magnesium 
chloride pH 8.0)) (Gibco BRL), 125pl sodium chloride (5M), 125pl acetylated BSA 
(lOmg/ml) (Promega)); Ipl RNAguard; 2.5pl ATP (lOmM) (Pharmacia); 5p.l manganese 
chloride (lOmM) (Sigma) and Ipl poly A polymerase enzyme (Gibco BRL) (method kindly 
provided by Daniel Bailey, Reading University). The reaction was centrifuged for a few 
seconds in a microcentrifuge and incubated at 37®C for 15 minutes. The final reaction
■iproducts were extracted with phenol/chloroform /isoamylalcohol (25:24:1), followed by 
precipitation with 2 volumes of 100% ethanol and 1/10 volume of sodium acetate (3M, pH
■:5.2). After washing with 70% ethanol (v/v) the pellet was dried and resuspended in l lp l  
DEPC-treated water. Samples treated in this way were subjected to RT-PCR using 
primers P1+/P4- and P6+/P9- following the standard protocol of 2.5 except that poly-T 
primer was used in place of the random hexamers in the RT reaction.
PCR products were then visualised by agarose gel electrophoresis according to method 2.7.
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2 .12 . Long distance PCR
As an alternative to designing internal primers capable of amplifying fragments of the 
genome of different enterovirus types, it is possible to take advantage of the conserved 
sequence at the 5’ end and the poly-A tail at the 3’ end of the viral genome. A primer 
designed to bind to the poly-A tail can be used to prime the RT reaction and produce full- 
length cDNA. A combination of a 5’ primer and a primer at the extreme 3’ end (Y-) could 
then be used to amplify the cDNA. Primers protl+, prot2- and prot3- were also designed 
at this stage to bind to a relatively conserved region of the 2C protease among the 
coxsackie and echo viruses, with a view to amplifying longer regions of the genome.
Long distance PCR was carried out following the methods of Gow et a l, (1996) and
Lindberg et al (1997). Positive control coxsackievirus A9 (dilutions 10 ' to 10^) was
reverse transcribed using a 3’ end primer (i.e. poly-T) and SUPERSCRIPT™ II (Gibco
BRL) reverse transcriptase. The sample RNA (lOpl) was heated to 70"C for 10 minutes
with Ipl RNAguard (1/20 dilution) and Ipl of the chosen primer, before quick chilling on 
.ice. The contents were collected by centrifugation before adding 4p.l of 5x first strand 
buffer, 2|al DTT (O.IM) and Ipl dNTPs (lOmM) and incubating at 42''C for 2 minutes. To 
this, Ipl of the reverse transcriptase was added, mixed and incubated at 42°C for 50 
minutes, before inactivating at 70“C for 15 minutes. The RNA component in the RNA- 
cDNA hybrid was then removed by incubating with 2 units of RNase H (Gibco BRL) at 
37^C for 20 minutes.
/:Different combinations of forward and reverse primers (eg. P1+ and prot3-) were then used 
.in a first round reaction of 50p.l containing Ix reaction buffer IV, 2.5 units Thermoprime 
plus DNA polymerase (both Advanced Biotechnologies), and 0.06 units Deep Vent DNA
polymerase (New England Biolabs). The reaction was incubated for 2 minutes at 94‘’C, 
followed by 15 cycles of 50 seconds at 94°C, 50 seconds at 55°C and 68"C for 5 minutes, 
and then 15 cycles as above with an additional 15 seconds on each successive extension 
cycle. The amplification was terminated by a final extension at 72°C for 10 minutes. A 
second PCR was performed on these products using nested (eg. P4+ and prot2-) or semi­
nested primers (eg. P1+ and prot2-), under the same conditions as above except that 25 
cycles (10 of these with the additional extension time) were performed. Gel 
electrophoresis was performed on 0.7% (w/v) agarose gels as described in section 2.7.
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2.13. Cloning P rotocol
This protocol was performed at the Beatson Institute for Cancer Research using the ZAP- 
cDNA® synthesis kit and the ZAP-cDNA® Gigapack® m  gold cloning kit (Stratagene®) 
according to the manufacturers instructions except where indicated. Ingredients of 
solutions and agar used are described fully in the manufacturer’s protocol.
2.13.1. Preparation of cDNA
cDNA was prepared using 20pl sample RNA (poly-(A)+) according to the manufacturer’s 
instructions using [a-^^P]dGTP at the second strand synthesis stage. After size 
fractionation through sepharose CL-2B gel filtration medium, cDNA fractions were 
extracted with phenol/chloroform [1:1 (v/v)] and then precipitated with ethanol. The 
cDNA pellets were resuspended in sterile water, the volume dependent on the amount of 
radioactivity detected (3.5pl if less than 30 counts per second/ 5p.l if greater than 30 counts 
per second). Quantitation of the cDNA was carried out by the ethidium bromide plate 
assay described in 2.15.
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2.13.2. Ligation into vector and packaging into host bacteria
Ligation of the sample cDNA (2.5pl) into the Uni-ZAP XR vector (Lambda/pBluescript 
phagemid) was carried out as described in the manufacturer’s protocol. Ligated DNA 
(3pl) was then packaged as described and the phage supernatant stored at 4"C until 
required.
%■îf
2.13.3. Plating, titering and ampliBcation of the library
The packaged reaction was titered with XLl-Blue MRP’ host bacteria on NZY agar 
(Gibco) plates using IPTG (isopropyl-1-thio-P-D-galactopyranoside) and X-gal (5-bromo- 
4-chloro-3-indolyl-p-D“galactopyranoside) for blue/white selection. Aliquots of each 
library containing ~5 x 10'' pfu of bacteriophage were then amplified according to the 
manufacturer’s protocol, and the titre checked using host cells and serial dilutions of the 
amplified library.
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2.13.4. Performing plaque lifts
Approximately 250,000 pfu (previously incubated with 4ml host cells) was plated onto 
240mm^ NZY agar plates and incubated at 37“C for approximately 8 hours. Hybond-N 
(22x22cm, Amersham) membranes were used to perform the lifts in duplicate according to 
the protocol. Dénaturation, neutralization and rinsing of the membranes were carried out
as follows. Whatman® paper was placed in three trays and soaked in 1.5 M sodium i
:chloride/0.5M sodium hydroxide solution, 1.5 M sodium chloride/0.5 M Tris-HCl (pH 8.0)
solution and 2x SSC buffer respectively. Membranes were placed on the paper (lift side 
up) for the recommended time and then blotted briefly before undergoing cross-linking 
using the autocrosslink setting on a Stratalinker® UV crosslinker.
2.13.5. Hybridizing and screening
Prehybridization of the membranes was carried out in prehybridization buffer (see 
appendix 2) for at least 2 hours in a shaking water bath at 65"C. Radioactive probe was 
prepared using High Prime solution (Boehringer Mannheim), [a^^P] dCTP (Redivue, 
Amersham International, pic) and l lp l  template DNA according to the manufacturer’s 
instructions. The reaction was stopped by incubating with an equal volume of 0.4M 
sodium hydroxide (NaOH) for 5 minutes. The probe was then added to approximately
50mls prehybridization solution and incubated with the filters overnight at 65^0. The 
membranes were washed (for 20 minutes) in decreasing concentrations of SSC (containing
0.1% SDS), from 2x SSC to 0.2 SSC and then exposed to film (Kodak) at -70°C, the % 
exposure time depending on the level of radioactivity observed. The film was developed 
in an automatic processor.
The duplicate developed films were then matched to the original plate and areas of positive 
hybridization on both were noted. Any positive plaques were picked into SM buffer for 
further screening.
A number of probes were available for screening the membranes; one of approximately 
5kB was obtained from the long PCR of coxsackievirus A9 (primers P4+/prot2-); one |
encompassed approximately 300 base pairs of the protease region and was produced by 
semi-nested PCR using primers protl+, prot2- and prot3- and the specific 264 base f
fragment generated by the standard PCR (primers P6+/P9-) from the sample being 
screened. In addition, the control probe consisted of the PCR product from the 
ABH/ABL2 PCR.
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2.14. Ethidium Bromide Plate A ssay  - Quantitation of cDNA
2.15. Molecular Computing
Agarose (100ml of 0.8% (w/v)) in TAB buffer (Ix) was prepared and cooled before adding 
lOp.1 of ethidium bromide stock solution (lOmg/ml) and mixing. This was poured into 
100mm petri dishes using approximately 10ml per plate and allowed to harden. Hind IE ||
digested Lambda DNA (Gibco BRL) (500ng/pl) was used as the standard and diluted in 
lOOmM EDTA to cover the range from 200 to lOng/pl. Duplicates of the standard (0.5pl) 
were each spotted onto the surface of the plates by capillary action, immediately before |
spotting the cDNA samples adjacent to the standards. After 10 to 15 minutes at room
temperature the plate was inverted and photographed using a UV lightbox. Estimations of 4
-■the concentration of the samples were made by comparing the intensities of the spots to the 4; 
standards. 4
Sequence information was stored in the UNIX database maintained by the University of 
Glasgow. Sequence data was analysed using the University of Wisconsin Genetics 
Computer Group (UW/GCG) package, version 7.0 (Devereux et a l, 1984) accessed via 
UNIX.
2.15.1. Phylogenetic trees
Alignment of sequences was carried out using PILEUP (GCG). Programs COMPACT and 
TOPHYLIP (A.Wright, University of Glasgow) were then used to truncate the sequences. 
Trees were generated using parsimony analysis (PHYLIP/DNAPARS).
2.15.2. Dendrograms
Alignment of sequences was carried out using PILEUP. A distance analysis method 
(DISTANCES) using one of six distance correction methods (uncorrected, Jukes-Cantor, 
Kimura 2-parameter, Jin-Nei gamma, Tajima-Nei and Tamura) was used to compare the 
aligned sequences. GROWTREE using either the neighbour joining or UPGMA methods 
was then used to generate the dendrogram plot (UW/GCG).
»  i
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The programs to create the phylogenetic trees were not available after 1995 and therefore 
method 2.15.2 was used after this date for all sequence comparisons.
The program FASTA was used to compare newly generated sequence data to sequences in 
the GenBank database to identify that with most sequence identity.
The program GAP was used to obtain the percentage identity between two nucleotide 
sequences based on the whole sequence available. For amino-acid comparisons, 
percentage identity (at the level of the nucleotide sequence) and percentage similarity (at 
the level of the amino acid) can be calculated.
2.16. Statistical methods
2.16.1. Chi-square analysis
1. Data in the form of a 2x2 contingency table (Table 8).
Test statistic = n(ad-bc)V(a+c)(b+d)(a+b)(c+d)
2. Data with more than two categories of classification (Table 9).
The expected frequency for each cell in the table is calculated as follows:
Expected ~ total of row x total of column/total
Test statistic = X (observed value-expected value)Vexpected value
In both cases the degrees of freedom = (r-l)(c-l) where r = rows and c = columns
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2.16.2. Comparing two population means
Comparison of two means from populations A and B that aie not normally distributed 
requires the following test statistic;-
z  =  (xi-X î) -  (fii -fia)/ V(0",Vni + G 2Vn2)
-where x is equal to the mean and a  is equal to the standard deviation.
The mean of population A is larger than the mean of B if the null hypothesis (Ho) that pi is 
less than or equal to p,2 can be rejected, where p,i and |i2 are parameters for the data sets A 
and B respectively.
Statistical methods taken from Daniel (1983).
Table 8: 2x2 contingency table.
Table X y Total a•a
X a b a+b . ■"! V:V
y c d c+d
Total a+c b+d n gv;
Second
Category
First Category
Ic 2c 3c (n)c
Ir Total Ir
2r Total 2r
(n)r Total (n)r
Total Ic Total 2c Total3c Total (n)c TOTAL
Table 9: Two-way classification of data values
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3. R esu lts
3.1. Standardization o f PCR methods
3.1.1. Titration of coxsackievirus A9
Coxsackievirus type A9 (8558) was chosen as the positive control for this study. The viral 
titre was determined as described in 2.3.2., the results presented in Table 10. The titre of 
the virus was determined to be 10® TCID50 per inoculum volume (200pl). RNA extracted 
from this stock was used as the positive control in the standardization of all PCR assays.
3.1.2. Sensitivity and specificity of the ‘standard’ enterovirus PCR
The standard enterovirus RT-PCR described in 2.5 was already established in the laboratory 
and conditions optimized before this project was undertaken. The sensitivity was measured 
using a ten-fold dilution series (in sterile DEPC-treated water) of titred coxsackievirus A9 
RNA to a final dilution of 10 '“. This series was amplified using primers P1+/P4- and 
P6+/P9- (Table 6: p52) according to method 2.5. Both first and second round products 
were visualized by gel electrophoresis as described in 2.7. Figure 5A shows that the 
‘nested’ PCR was 100-fold more sensitive than one round of PCR detecting the 
coxsackievirus A9 control to a dilution of 10 “ (equivalent to 0.01 TCIDjo) compared to 10® 
(1 TCID50) for the first round. The diffuse banding observed in lanes 1 to 6 is a result of an 
overload of virus at these high dilutions, which gradually reduces as the dilutions decrease. 
The nested PCR primers were shown to amplify all the enterovirus types (59 types: viral 
titres unknown) available for testing in the laboratory with the exception of echovims 22. 
Coxsackievims types A6, A24, and echovims types 23, 29 and 32 were not available for 
testing.
Rhinovimses (untyped) and unrelated vimses such as cytomegalovims (CMV) and herpes- 
simplex vims (HSV) were not amplified (Figure 5B) and are shown alongside five examples 
of enterovims amplification products, confirming that the primers are enterovims-group 
specific.
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Dilution of 
Coxsackievirus A9
Proportion of 
infected cultures
10' 4/4 =1
10' 4/4=1
10“ 4/4 =1
10^ 4/4 =1
10® 4/4=1
10® 2/4 =0.5
10' 0/4=0
Note: Calculation of the 50% tissue culture infective dose (TCID50). This was determined 
using the Karber formula (Karber, 1931), where L= the negative log of the lowest dilution, 
d= the difference between the log dilution steps and S = the sum of the proportions of 
‘positive ‘ tests.
log TCID50 = L-d (S-0.5)
-l-l(5.5-0.5)
-1-5 =-6
Table 10: Results of titration of coxsackievirus A9 showing dilution of virus and 
number of tubes with cytopatbic effect (c.p.e.).
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#  #  & #  m m
M 1 2 3 4 5 6 7 8 9  1 0 M
P1/P4 - 
414 bp
P6/P9 - 
264 bp
B.
600
P1/P4 -
414 bp
100
M l  2 3 4  5 6  7 8 9  10 M
Figure 5: A. Agarose gel showing PCR products from first (top) and nested (bottom) rounds of the 
standard EV-PCR on a dilution series of coxsackievirus A9. Lane M-lOObp DNA ladder, Lanes 1 to 10 
- dilutions ID'* to 10 '^ '^ of coxsackievirus A9. B. Agarose gel showing PCR products from a first round 
standard EV-PCR on a series of viruses. Lane M- lOObp DNA ladder. Lanes 1- MRC-5 control, 2- 
Rhinovirus untyped, 3- Rhinovirus untyped, 4- CMV, 5- HSV, 6- coxsackievirus A9 8558,7- 
coxsackievirus B3 3629, 8- coxsackievirus B5 2907,9- echovims 4 1990,10- echovims 6 4566.
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Of the 100 study group samples, 42 were positive for enteroviral sequences after two
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3.1.3. Monitoring for contamination
3.1.3.1. Swabs in VTM. These swabs were used as a monitor of viral RNA 
contamination. Two out of 30 swabs were positive. These were from the outside door 
handles of two laboratories where RNA extraction and PCR cycling were carried out 
independently.
3.1.3.2. Swabs in water. These swabs were used as a monitor of PCR product 
contamination. Two out of 30 swabs were positive. These were from the pipette used for |  
loading agarose gels, and the surface of the centrifuge used in the gel electrophoresis room.
On a few occasions contamination was observed in the routine screening PCR where all or 
most of the samples were positive along with the negative controls. When this occurred, i
all reagents in use were discarded, laboratory equipment and surfaces were swabbed with 
hydrochloric acid (IM) and the RNA extraction and RT-PCR was repeated with fresh 
aliquots of reagent. Contamination occurred approximately 3 times over the study period.
3.2. Comparison of coxsackie B neutralization and PCR
■ pPA
Serum samples from 100 chronic fatigue patients and 100 healthy comparison individuals 
were tested for the presence of enteroviral RNA by PCR and the presence of 
coxsackievirus type B neutralizing antibodies (Nairn et al,, 1995). The coxsackie B 
neutralization assay (method 2.2) results are shown in table 11 A. Titres equal to or above 
256 were regarded as evidence of recent infection and were scored as positive. Following 
these criteria, 34% of the study group and 41% of the comparison group were positive for 
antibody to one or more of the coxsackie B viruses, a result which was not significant 
(computed value= 1.045, 95% value with 1 degree of freedom =3.84). In addition, 
statistical analysis showed that the presence or absence of any particular coxsackie virus 
was not associated with either study or comparison group. In 12 individuals, there was 
evidence of more than one serotype of coxsackie B antibody in the serum sample. This 8
could be a result of cross-reactivity of the neutralizing antibodies or of infection by several 
serotypes.
Results
rounds of PCR, compared to only 9 from the comparison group. Statistical analysis 
showed a significant difference at the 95% level between the groups with respect to 
positive enterovirus PCR (computed value=28.60, 95% value with 1 degree of 
freedom =3.84).
Table IIB  shows a comparison between the neutralization results and the PCR results. In 
the study group, 66% of results were concordant and in the comparison group, 58 results 
correlated. Of the samples that did not correlate, the majority in the study group were 
PCR positive/coxsackie B antibody negative (21/34). This was probably a result of the 
PCR detecting enterovirus types other than coxsackie B. In the comparison group the 
majority were PCR negative/antibody positive (37/42).
The neutralization assay therefore did not differentiate the CFS study group from the 
healthy comparison group whereas the PCR results did differentiate the two groups. PCR 
was thus chosen as the method for screening a prospective group of patients with CFS for 
the presence of enteroviral RNA.
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Coxsackie B 
antibody titre
Coxsackie B 
antibody type
Study group Comparison
group
>256 coxsackie B 1 1 2
>256 coxsackie B2 6 16
>256 coxsackie B3 2 1
>256 coxsackie B4 16 10
>256 coxsackie B5 2 7
>256 coxsackie B2+B4 3 3
>256 coxsackie B3+B4 1 0
>256 coxsackie other* 3 2
<128 negative 66 59
Total 100 100
* Other refers to either coxsackie antibody types B2+B4+B5 (2) or B1+B4 (1) in the study group and either 
coxsackie antibody types B4+B5 (1) or B1+B2 (1) in the comparison group.
B.
Enteroviral PCR 
positive
Enteroviral PCR 
negative
Total
Study group
Coxsackie B antibody positive 21 13 34
Coxsackie B antibody negative 21 45 66
Total 42 58 100
Comparison group
Coxsackie B antibody positive 4 37 41
Coxsackie B antibody negative 5 54 59
Total 9 91 100
I
Table 11: (A) Results of coxsackievirus type B neutralization test comparing tbe study 
and comparison patients. (B) Comparison of coxsackie B neutralization test witb 
enteroviral PCR analysis for tbe study and comparison groups.
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3.3. Sequence analysis o f the 5' non-translated region
In this initial analysis, semm and or throat swab samples were obtained from individuals 
with a diagnosis of CFS that fulfilled the Oxford Criteria (Sharpe et al., 1991). Patients 
attended the outpatient clinic of the Infectious Disease unit at Ruchill Hospital, between 
January 1992 and January 1994. Serum samples from a group of comparison individuals 
were tested simultaneously as were echovirus isolates (types 3, 4, 7, 9, 11 and 20) 
identified in the R.V.L.
RNA was extracted from the samples using the ‘Glassmax’ extraction kit as described in
2.4.1 and reverse transcribed following the method outlined in 2.5.1. Nested PCR 
amplification using primers P1+ /P4- followed by P6+/P9- and a separate control PCR 
using primers ABL1/ABL2 were carried out in lOOpl volumes as described in 2.5.2. 
Nested products and ‘ABL’ products were run out on a 1.5% agarose gel as described in 
2.7.
Within this study group, 44/238 serum samples and 29/175 throat swab samples from 
patients with CFS were enteroviral PCR positive. In the comparison group, 3/130 serum 
samples were positive. PCR products of the correct size were also observed in all cases 
for the ABL control PCR. The echoviruses were also successfully amplified.
The following PCR products were purified using the Gene-clean kit according to method
2.8.1 and sequenced in both directions using primers P6+ and P9- as described in 2.9.1.
1. Twenty products derived from samples obtained from CFS cases (CFS 1-20).
2. Three products derived from samples obtained from non-CFS comparison cases 
(Non-CFS 1 ,2&7) .
3. Four products derived from samples obtained from patients complaining of 
anterior chest pain with a presumptive diagnosis of myocarditis (Non-CFS 3-6).
4. Six echovirus isolates (types 3, 4 ,1,9, 11 and 20) (Table 7).
Additionally, two other samples obtained from CFS patient 7 were positive for enteroviral 
sequences, a throat swab obtained at the same time as the serum sample together with a 
second serum sample obtained eight months later. A sequence comparison of these three
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sequences, a throat swab obtained at the same time as the serum sample together with a
second serum sample obtained eight months later. A sequence comparison of these three
sequences with coxsackievirus B3 (Klump et a l, 1990) is shown in Figure 6. The overall
comparison shows a 99.05% identity between the two serum samples taken 10 months
apart, 98.10% identity between the throat swab and the semm samples taken at the same
time and 87.68% identity between the first serum sample and the published coxsackievims
B3 sequence.
The sequences obtained were closely related to each other and were similar to the |
coxsackievims B3, being derived from the highly conserved 5’ NTR. Further 
phylogenetic comparisons were thus made with other members of the enterovims genus 
(Galbraith et a l,  1995). Figure 7 shows the phylogenetic tree produced by parsimony 
analysis of the CFS patient sequences in relation to the non-CFS and published sequences i
available in the GenBank database and the echoviruses from the R.V.L. The analysis
v>showed three groupings of vimses. Group I comprised poliovirus types 1, 2 and 3, I?
enterovirus type 70 and coxsackievimses A21 and A24. Group II contained the coxsackie 
B vims types 1, 3, 4 and 5, coxsackievirus A9 and echoviruses 3, 4, 7, 9, 11 and 20, 6/7 
non-CFS patients and one CFS patient. The third group (HI) comprised 19/20 sequences 
obtained from the CFS patients and one non-CFS patient. "Î
if
Another method of illustrating the relationships between sequences uses a dendrogram 
format which produces a numerical measure of relationships. Figure 8 shows a 
dendrogram of nine representative sequences, three from each of groups I, II and m. The 
dendrogram shows that the sequences from each group map together, as predicted from the i
phylogenetic tree.
Analysis of the 264 base pair fragment demonstrated that the CFS patient sequences were 
similar to the known published enteroviral sequences (see Table 12 for comparison with |  
coxsackievirus B3) and unrelated to all other available sequences in the GenBank database 
(sequence homology less than 50%) at this time. Although the primers used in this study 
were designed to amplify the enterovirus genus only, it was possible that other members of 
the Picornaviridae may have been amplified due to the conserved nature of the genome at 
the 5’ NTR.
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193 238
S a m p le  t a k e n  3 0 / 0 8 / 9 3  ATCAATAAACTGCTCACGCGGTCGAAGGAGAAAACGTCCGTTACCC
S a m p le  t a k e n  0 2 / 0 6 / 9 4  -----------------------------------------------------------------------------------------------
T h r o a t  sw a b  3 0 / 0 8 / 9 3   TT------------------------------ ---------------------------------------------
C o x s a c k i e v i r u s  B3----------------- G---------------------------- T -------------------- G------T ----------T - -
309
GACTGACTACTTCGAGAAACCCAGTAACACCATGGAGATTGCGAAGCGTTTCGCTCAGCACACCCCCAGTG
“  ( j  — — —- — — — _  _  _  — —^ —— — — — — — — — — — — —I —« *”  — — — — — — — — — — — — — — —
380
TAGATCAGTCCGATGAGTCACCGCATTCCCCACAGGCGACTGTGGCGGTGGCTGCGTTGGCGGCCTGCCCA
------------- G-------------------------------------------------------------------------------------------------------------
----------------GT----------------------------------------------- G------------C--------------------------------------------------------------
403
TGGGGCAACCCATGGGATGCTTC
 ^ -----------
:S
Figure 6: Partial 5’ NTR sequences derived from CFS patient 7. Differences between 
the patient sequences and a published coxsackievirus B3 sequence are shown. S 
refers to a mixed population of both G and C nucleotides at this position. The 
numbers refer to the nucleotide positions of the complete genome of coxsackievirus 
B3 (GenBank Accession Number M33854).
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Figure 7; Phylogenetic tree produced by parsimony analysis (PHYLIP/DNAPARS) 
based on tbe sequence of a short region of tbe 5* NTR. GenBank sequences and 
accession numbers are as follows: coxsackievirus A9 (D00627), coxsackievirus A21 
(D00538), coxsackievirus A24 (D90457), coxsackievirus B1 (M16560), coxsackievirus 
B3 (M33854), coxsackievirus B4 (X05690), coxsackievirus B5 (X67706), enterovirus 
70 (D00820), poliovirus 1 (J02281), poliovirus 2 (D00625, M12197), poliovirus 3 
(K01392), poliovirus 3a (X04468). Echoviruses were isolated and typed in tbe 
Regional Virus Laboratory, Glasgow. CFS and non-CFS patient sequences were 
derived as described in tbe methods.
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88%
86%
68%
M%
8?%
87%
85%
CFS patient 10 
CFS patient 12
■ CFS patient 11
■ Cpxjacktevinn B1 
• Cox»BckievinM B3 
' Coxsacldevirua B5
- Enterovirus 70
- Coxsaddevims A21
- PoUovims type 1
Figure 8: Dendrogram produced using the programs PILEUP and FIGURE from 
nine enteroviral sequences extracted from figure 7. The numbers indicate tbe degree 
of identity between tbe sequences at each branch of tbe dendrogram. GenBank 
sequences and accession numbers are as follows: coxsackievirus B1 (M16560), 
coxsackievirus B3 (M33854), coxsackievirus B5 (X67706), enterovirus 70 (D00820), 
coxsackievirus A21 (D00538), poliovirus 1 (J02281).
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CFS patient no. Identity (%) CFS patient no. Identity (%)
1 75.8 11 78.3
2 78.1 12 76.6
3 75.9 13 81.4
4 75.5 14 84.3
5 82.0 15 83.9
6 79.7 16 78.1
7 84.2 17 68.9
8 81.3 18 72.1
9 83.1 19 84.1
10 78.9 20 74.8
Table 12: Comparison of CFS patient nucleotide sequence witb coxsackievirus B3 
(GenBank Accession No. M33854). Figures were generated by FASTA analysis 
(refer to methods).
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A consensus sequence from the CFS patient sequences was obtained and compared with 
other Picornaviridae including swine vesicular disease virus (SVDV; accession no. 
D00435), Theiler’s murine encephalomyelitis virus (TMEV; accession no, X56019), foot 
and mouth disease virus (FMDV; accession no. M32257), mengovims (accession no. 
L22089), echovirus 22 (accession no. L02971), hepatitis A virus (accession no. K02990), 
encephalomyocarditis virus (EMC; accession no. M22457) and human rhinovirus IB 
(accession no. D00239). The CFS consensus sequence was found to be unrelated to any of 
these vimses (sequence identity less than 50%) other than SVDV (83.2% sequence 
identity). Phylogenetic analysis of the capsid region of a number of enteroviruses has 
shown that SVDV groups alongside the coxsackie-like viruses (Hyypia et at, 1997).
Reproducibility of sequence analysis in this series of samples was established by carrying 
out two independent RNA extractions on a single serum sample and amplifying by PCR in 
the same laboratory, followed by sequencing the amplicons in two different laboratories. 
One amplicon was sequenced at the R.V.L. where the study was carried out while the other 
was sequenced at a second laboratory using automated fluorescent sequencing (Beatson 
Institute of Cancer Research, Glasgow). The sequence from the two laboratories was 
identical with the exception of a single base change.
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3.4. Prospective F ollow -up s tu d y
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Patients who had previously presented to the out-patient clinic at Ruchill Hospital with a 
diagnosis of CFS and new patients who fulfilled the Oxford criteria (Sharpe et ah, 1991) 
were recruited to the follow-up study. A sample of clotted blood was obtained from the 
patient and a health questionnaire (see appendix) was completed at or as near as possible to 
the time of blood sampling. Patients were contacted (via their general practitioner) at 
twelve-month intervals and asked to complete another questionnaire and to provide an 
additional blood sample. All blood samples were tested for the presence of enteroviral 
sequences by the standard PCR methods described (designated EV-PCR). Information 
from the questionnaires was maintained on DataBase version 4.5.
3.4.1. Features of patient group
Over the study period, 585 questionnaires were completed. Within this group, 333 
individuals completed one questionnaire, 159 completed two, 68 completed three and 25 
completed four questionnaires. General information regarding age and sex distribution, 
occupations etc. was obtained from the first questionnaire. The age distribution of both 
male and female patients presented in Figure 9 shows an approximately normal 
distribution. The age and sex of the patients within each of the four questionnaire groups 
is presented in Table 13 and shows a female to male predominance throughout. The 
number of general practitioners involved was approximately 230.
A broad range of occupations was recorded (bus driver, civil servant, pharmacist for 
example) with no one occupation over-represented. Forty-eight per cent of patients were 
married, 37% were single and 47% had children.
In the 6 months prior to the onset of fatigue, 84 (25%) reported receiving prescribed 
medication (mainly antibiotics) from their general practitioner; 68 (20%) reported allergies 
(for example hay fever and penicillin); 20 (6%) had been immunized and 33 (10%) had 
experienced health problems while on holiday. One hundred and seventy patients (51 %) 
reported the occurrence of a major change in life, which included job-related and personal 
events. Eighty-one percent reported an acute illness prior to the onset of fatigue. 
Different combinations of symptom category were reported and as such patients could not 
be divided into distinct groups.
j
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Figure 9: Age distribution (from 0 to 80 years) of male (n=96) and female (n=237) 
patients with a diagnosis of CFS. Data obtained from the first questionnaire.
Questionnaires
completed
Total Female (%) Male (%) Age range in years 
(mean)
1 333 237 (71%) 96 (29%) 9-72 (36.6)
2 159 113(71%) 46 (29%) 14-73 (40.3)
3 68 49 (72%) 19 (28%) 16-74 (42.1)
4 25 18 (72%) 7 (28%) 18-70 (46.6)
Table 13: Total number and age range of patients completing 1, 2, 3 and 4 
questionnaires divided into female and male categories.
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Individuals were also asked about their stress levels prior to fatigue: high (30%), middling 
(44%) and low (25%) levels were reported. Similarly, mood prior to fatigue was assessed: 
good (47%), middling (36%) and poor (15%) responses were noted. Physical activities 
such as gardening, sports and socializing were given up by 78% of the study group.
The majority of individuals (90%) reported suffering from their condition for more than 
50% of the time. The month of onset of fatigue for the patients is shown in Figure 10, 
alongside the monthly distribution of enterovirus isolates reported in Glasgow, for the 
years 1994 to 1997. The figure clearly shows that the monthly distribution of the onset of 
fatigue does not coincide with the seasonal distribution of the enteroviruses, which shows 
the majority of isolates in the summer/autumn months. The distribution of onset of fatigue 
is more evenly spread throughout the year with small peaks in December and February. 
The average duration of fatigue was 3.9 years within a range of 6 months to 9 years or 
greater. The greatest proportion (63%) reported suffering from their illness for less than 3 
years, while 7.6% had suffered for greater than 9 years. The duration of fatigue for both 
male and female patients is shown in Figure 11, showing there is little difference between 
the sexes. The ten most common symptoms reported by patients are shown in Figure 12, 
with daytime drowsiness reported most frequently. Symptoms that were not reported 
frequently included being unable to recognize objects by sight (6%), difficulty swallowing 
foods (11%) and appearance of any recent allergies (11%).
Of these 333 individuals, 36% were positive for enteroviral sequences by PCR analysis. 
The patients were thus split into two groups (positive and negative) based on the PCR 
results and the questionnaire responses were compared between the groups. In all cases, 
there was no difference between the groups in terms of month of onset of fatigue, duration 
of fatigue, symptoms reported and so on.
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Figure 10: Monthly distribution of enterovirus isolates (coxsackievirus A types 
(n=37), coxsackievirus B types (n=117) and echovirus types (n=189)) reported in 
Glasgow for the years 1994 to 1997 compared to the distribution of the month of 
onset of fatigue for CFS patients (n=242).
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Figure 11: Distribution of the duration of fatigue (years) for both male (n=96) and 
female (n=237) CFS patients.
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Figure 12: The ten most common symptoms reported by CFS patients
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3.4.2. Analysis of patients over time
Following completion of the follow-up study, 130 patients were identified where a 
completed questionnaire and corresponding blood sample, obtained over two time points, 
were available for analysis. This cohort consisted of 95 females (age range 15-73 years; 
mean age 39.3 years) and 35 males (age range 14-67 years: mean age 43.1 years). The 
female to male ratio and the mean age in this group was similar to that observed for the 
patient group as a whole,
3.4.2.1. Analysis o f data derived from questionnaire 1 (Q 1). The overall EV-PCR 
results for this group were as follows: sixty-seven patients (51.5%) were EV-PCR positive 
and sixty-three (48.5%) were EV-PCR negative. To test the hypothesis that the presence 
of enterovirus is related to CFS, a number of features were identified which might reflect 
the severity of illness in a patient, for example, ability to work. The EV-PCR positive and 
negative groups were then compared with respect to these features.
Feature 1 - Employment. Individuals were asked about their current employment status, 
ticking one of seven choices including at work/school or retired on health grounds for 
example. The employment status of individuals in both EV-PCR groups is shown in 
Table 14. From Q l, of those EV-PCR positive, 25% were at work or school whereas 42% 
were on sick leave. Conversely, 43% of the EV-PCR negative group were at work or 
school whereas 28% were on sick leave. To examine whether PCR positivity has an effect 
on work status the results in each group were divided into two categories, those able to 
work and those not able to work (discounting the three ‘unknowns’) (Table 15).
A value for this 2x2 contingency table could then be calculated, according to method
2.16.1. The computed value for was 7,4. The 95% value with one degree of 
freedom equalled 3.84. The computed value was therefore significant at the 95% level 
indicating a relationship between enteroviral PCR status and ability to work from Q l, that 
is, those individuals who were EV-PCR positive were less likely to be working than those 
who were EV-PCR negative.
____________________________________ :___:_____:____   _ _ "I
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Ql: feature 1 -  
employment
EV-PCR + EV-PCR - Total
At work/school 17 (25.4%) 27 (43%) 44
Housewife/unemployed 5 (7.5%) 8 (12.7%) 13
Retired 2 (2.9%) 1 (1.6%) 3
Retired on health grounds 15 (22.4) 6 (9.5%) 21
Sick leave 28 (42%) 18 (28.6%) 46
Unknown 0 3 (4.7%) 3
Total 67 63 130
Table 14; Feature 1 - employment status from questionnaire 1 of EV-PCR positive 
and EV-PCR negative CFS patients.
Q l -  ability to 
work
EV-PCR + EV-PCR - Total
Able to work 24 36 60
Not able to work 43 24 67
Total 67 60 127
Table 15: 2x2 contingency table comparing ability to work and EV-PCR status for 
CFS patients from questionnaire 1.
92
Results
Feature 2 - Domestic Work. For those individuals not in employment, the severity of 
illness was measured by the ability to carry out normal domestic work in the home, 
answering either yes or no. The results are shown in Table 16. Only 28% of those who 
were EV-PCR positive were able to carry out their normal domestic duties, whereas 44% 
of those who were EV-PCR negative were able to carry out their domestic work. These 
percentages are very similar to those observed for the two groups regarding employment 
status. The value for this data was 3.37 which was not significant at the 95% level 
value of 3.8), but was significant at the 90% level value of 2.7).
Taking these two features together for the first questionnaire, the results would suggest that 
EV-PCR positivity was related to the severity of illness as measured by the ability to work, 
attend school or carry out domestic work.
Feature 3 - Physical activity. The physical activity of each patient was measured by the 
amount of time they spent outside during the day, how much of this time they spent 
walking and how far they could walk (questions 3, 4 and 5 of the questionnaire). For the 
latter question, if the response was “a few yards”, this was scored as 0 miles. If the 
response was “unlimited”, this was scored as an arbitrary 10 miles. The scores for the 
patients in each group were totaled and a mean value calculated, shown in Table 17. The 
mean time spent outside and the mean time spent walking was no different between the 
groups, but the distance walked by those in the EV-PCR negative group was almost double 
that of the positive group, although the distances are small. The distribution of the 
distance walked for the positive and negative groups is shown in Figure 13. The 
maximum distance walked by individuals in the EV-PCR positive group was 4 miles 
compared to some individuals in the EV-PCR negative group who could walk an unlimited 
distance.
The mean distance walked was compared between the two groups using hypothesis testing: 
sampling from populations that are not normally distributed (2.16.2). The test statistic (z 
= 1.99) was greater than the critical value of 1.645 (where cx=0.05 in a one-tailed test) and 
thus the null hypothesis (that the EV-PCR negative group mean is less than or equal to the 
EV-PCR positive group mean) was rejected. The mean distance walked was therefore 
significantly different between the two groups.
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Ql: feature 2 -  
domestic work
EV-PCR + EV-PCR - Total
Yes 19 (28%) 26 (44%) 45
No 48 (72%) 33 (56%) 81
Total 67 59 126
Table 16: Feature 2 - ability to carry out domestic work from questionnaire 1 of EV- 
PCR positive and EV-PCR negative CFS patients.
Ql: feature 3 -  physical activity EV-PCR + EV-PCR-
Mean time spent outside (hours) 3.0 3.0
Mean time spent walking (hours) 0.8 1.0
Mean distance walked (miles) 1.0 1.8
Table 17: Feature 3 - physical activity from questionnaire 1 of EV-PCR positive and 
EV-PCR negative CFS patients.
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Figure 13: Distribution of distance walked (miles) comparing EV-PCR positive and 
EV-PCR negative CFS patients. 1
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Feature 4 -  Time off work. Individuals in employment were asked to say how much -g 
time (greater than two weeks) they had taken off work in the previous year.
Those individuals EV-PCR positive at the time of their first questionnaire had taken an 
average of 5.4 months off during the previous year. Those individuals EV-PCR negative 
had taken an average of 3.7 months off during the previous year.
The distribution of time off work, comparing EV-PCR positive and EV-PCR negative 
individuals is shown in Figure 14. Only 11% of individuals who were EV-PCR positive 
had taken no time off work in the previous year compared to 27% of the EV-PCR negative
'7
group. Conversely, 27% of the EV-PCR positive group had taken more than 10 months Jÿ
'off work, compared to 14% of the negative group. The same test statistic used for the
distance walked was calculated to compare the means of the two groups. The test statistic 
(z =1.85) was greater than the critical value of 1.645 (where a=0.05 in a one tailed test) 
and thus the null hypothesis was rejected. The means of the two groups were therefore 
significantly different.
I
In summary, from the data derived from the first questionnaire there was a significant
y#difference between those individuals who were EV-PCR positive and those EV-PCR y.;negative with respect to the features examined. Those individuals with an EV-PCR +
result were less likely to be at work/school, less likely to be able to carry out domestic ■■work, less able to walk distances and more likely to have taken time off work. I
yy
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Figure 14; Distribution of time off work (months) comparing EV-PCR positive and 
EV-PCR negative CFS patients.
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3.4.2.2. Analysis o f data derived from second questionnaire (Q 2). After 12 
months the EV-PCR results for the patient cohort were as follows: 21 (16%) patients were 
positive and 109 were negative. The patients were sub-divided into 4 groups based on the 
PCR results at the two time points: - EV-PCR +/+, EV-PCR +/-, EV-PCR -/- and EV-PCR 
-/+ for Q1/Q2. Table 18 shows the numbers of patients in each group. Only 9.2% of 
patients were positive over the two time points. A comparison of sequence data obtained 
from ten of these patients is presented in section 3.4.3. The four groups identified here can 
be compared where possible for the features analysed previously. In some instances, the 
small sample numbers made it impossible to apply any statistical analysis to the findings.
Feature 1 -  Employment. The employment status of individuals EV-PCR positive 
initially, then positive or negative twelve months later is shown in Table 19. After the 
twelve months, a greater proportion of the group were at work/school than previously (37% 
compared to 25%), fewer individuals were on sick leave (10% compared to 42%) and there 
was an increase in the number who had retired on health grounds (22% to 34%). 
Comparing between the EV-PCR +/+ and +/- groups, 25% of the former were at 
work/school compared to 40% of the latter. There was no significant difference between 
the groups reporting sick leave and retired on health grounds.
Table 20 shows the employment status of those individuals EV-PCR negative initially then 
positive or negative after 12 months. Over the twelve months, there was no change in the 
number of individuals at work/school, the percentage of individuals on sick leave had 
reduced from 28.6% to 15.8% and the percentage retired on health grounds had increased 
from 9.5% to 20.6%.
Comparing between the EV-PCR -/- and -/+ groups, a greater proportion of individuals in 
the former was at work or school (46%) compared to the latter (22%). The percentage 
retired on health grounds was no different between the two groups and the percentage on 
sick leave was greater in the -/- group.
The ability to work was compared among these four groups (EV-PCR +/+, +/-, -/+ and -/-) 
according to method 2.16.1 producing a value of 1.41. This value was not significant at 
the 95% level with three degrees of freedom (%^ value of 7.815) or the 90% level with three 
degrees of freedom (%^ value of 6.261).
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PCR positive Q2 PCR negative Q2 Total
PCR positive 12 (9.2%) 55 (42.3%) 67
Ql +/+ +/“
PCR negative 9 (6.9%) 54 (41.5%) 63
Ql -/+
Total 21 109 130
Table 18: EV-PCR results over 12 months for 130 CFS patients.
Q2: feature 1 -  
employment status
EV-PCR +/+ EV-PCR +/- Total
At work/school 3 (25%) 22 (40%) 25 (37%)
Housewife/unemployed 4 (33%) 4 (7.2%) 8 (12%)
Retired 0 2 (3.6%) 2(3%)
Retired on health grounds 4 (33%) 19 (34.5%) 23 (34%)
Sick leave 1 (8%) 6 (10.9%) 7 (10%)
Unknown 0 2 (3.6%) 2(3%)
Total 12 55 67
Table 19: Feature 1 - employment status from questionnaire 2 comparing individuals 
EV-PCR positive initially then positive or negative after 12 months (+/+ or +/-).
___________________
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Q2: feature 1 ~ 
employment status
EV-PCR -/- EV-PCR -/+ Total
At work/school 25 (46%) 2 (22.2%) 27 (43%)
Housewife/unemployed 8 (14.8%) 4 (44.4%) 12(19%)
Retired 1 (1.8%) 0 1 (1.6%)
Retired on health grounds 11 (20.4%) 2 (22.2%) 13 (20.6%)
Sick leave 9 (16.7%) 1 (11.1%) 10(15.8%)
Total 54 9 63
Table 20: Feature 1 - employment status from questionnaire 2 comparing individuals 
negative initially, then negative or positive after 12 months (-/- or -/+).
  _   _ .
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ÎFeature 2- Domestic work. The ability of the individual to carry out domestic work was 
also assessed after twelve months. Firstly, 33% of those individuals in the EV-PCR +/+ f
group were able to carry out their normal domestic work compared to 42% in the EV-PCR 
+/- group. Of those individuals with two negative results (-/-), 56% were able to carry out 
their domestic work, compared to 67% of those in the -/+ group.
■ v :î
These four groups were compared for their ability to carry out domestic duties, resulting in 
a value of 3.84. This value was not significant at either the 90% value of 6.251) or 
the 95% level value of 7.815).
Taking these two features into account, severity of illness as measured by employment 
status and ability to carry out domestic work, was not related to EV-PCR positivity after 12
months. a
3aaFeature 3 - Physical Activity. The physical activity of the patients in each of the four 
groups is shown in Tables 21 and 22. Within the groups, those who remained positive 
(+/+) spent 1 hour less outside than they did twelve months previously, but could on 
average walk further (2.3 miles compared to 1.0 mile). Those in the +/- group, spent one 
hour more outside and could also walk further than before (1.8 miles compared with 1.0 
mile).
Those individuals in the -/+ group spent an average of one hour longer out of the home 
than they did twelve months previously. They spent slightly less time walking, but could 
walk further (2.2 miles compared to 1.8 miles). Those individuals with two negative 
results also spent an average of one hour longer outside the home, but the time spent 
walking and the distance walked remained the same.
Feature 4 - Time off ’work. The time taken off work in the year prior to the second 
sample being taken is shown in Table 23. The group with most time off (9.3 months) was 
EV-PCR positive at the two time points (EV-PCR +/-h) while the group with least time off 
(4.1 months) had two negative results (EV-PCR -/-) over the time period. Only 4 people 
in the EV-PCR +/+ group answered this in questionnaire 2 compared to 35 of the EV-PCR 
-/- group and therefore it is difficult to assess the significance of the result.
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Q2: feature 3 - physical 
activity
EV-PCR +/+ EV-PCR +/-
Time spent outside (hours) 2.0 4.0
Time spent walking (hours) 0.6 0.9
Distance walked (miles) 2.3 1.8
Table 21: Feature 3 - physical activity after 12 months comparing individuals in the 
+/+ and +/- groups.
Q2: feature 3 - physical 
activity
EV-PCR -/- EV-PCR -/+
Time spent outside (hours) 4.0 4.0
Time spent walking (hours) 1.0 0.8
Distance walked (miles) 1.8 2.2
Table 22: Feature 3 - physical activity after 12 months comparing individuals in the 
-/- and -/+ groups.
Q2: feature 4 - time (months) off 
work prior to second sample
Positive Q2 Negative Q2
Positive Ql 9.3 6.9
Negative Ql 7.0 4.1
Table 23: Feature 4 - Time taken off work by CFS patients in the year prior to 
obtaining the second sample.
102
Results
Of this cohort of 130 individuals, 65 completed a third questionnaire and provided a blood 
sample for analysis, 7 (11%) of which were EV-PCR positive. Only 19 completed a fourth 
questionnaire and supplied a blood sample, none of which was EV-PCR positive. These 
questionnaires were not subjected to further analysis since the numbers in the PCR groups 
were too small for statistical analysis.
The groups providing either 1, 2, 3 or 4 questionnaires were compared to identify any 
changes in the populations responding at each call-back. The age range of the patients 
narrowed slightly over the 4 questionnaires with the mean age increasing from 36.6 years 
for those providing one questionnaire to 46.6 years for those providing four (Table 13). 
The duration of fatigue was also examined (Table 24). The average duration of fatigue 
increased, in general, by one year, with each subsequent questionnaire submitted, as would 
be expected. There was however a shift in the distribution of the duration of fatigue. 
Only 7.6% who provided one questionnaire had suffered for greater than 9 years compared 
to 21.7% of those who had provided four questionnaires. These figures would suggest that 
those continuing to submit questionnaires had been ill for longer, thus enriching the study 
cohort.
___
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Questionnaire Duration of 
fatigue (years)
Mean duration 
of fatigue (years)
% suffering for 
<3 years
% suffering for 
>9 years
Q l 0.5 - >9 3.9 63 7.6
Q 2 1 ->9 5.2 35 15.6
Q 3 1.5->9 6.4 19.7 23
Q 4 3 -> 9 7.2 0 21.7
Table 24: Duration of fatigue (range and mean). The % of patients suffering for 
fewer than 3 years and greater than 9 years for patients providing 1, 2, 3 and 4 
questionnaires is shown.
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3.4.3. Analysis of PCR positives over time
As part of the prospective study, screening new CFS cases for enteroviral sequences and 
following up those already tested, patients who had two enterovirus PCR-positive samples f
at two different time points were identified. These products were sequenced as described Ain 2.8.2 and 2.9.2. Ten of these are from the 12 patient samples identified as EV-PCR+ at 
least twelve months apart (Table 18). The remaining 6 pairs of sequences identified were 9
not part of the clinical follow-up because the patients did not provide two completed 
questionnaires for analysis.
Table 25 shows the GAP comparison statistics for the maximum available sequence of the 
pairs obtained from individual patients. Five of the sixteen pairs of sequences [patients 
2(HA), 4(M 0), 5(PA), 6 (TI) and 10 (HV)] demonstrated a level of identity of 97.5% or
greater with samples taken up to 24 months apart. In the case of patient 6, the 0.4% 
difference equates to 1 base pair change within the region analysed.
Figure 15 presents the pairs of sequences from the sixteen patients compared to a 
consensus sequence of 250 bases. The sequence comparison of patients 1 to 8 has been 
described previously (Galbraith et al., 1997). The additional pairs were identified as the 
Study progressed. From the data derived from the original eight sequences it was 
concluded that there was evidence for enteroviral persistence in patients TI, PA, MO and 
HA, based on the presence of unique base pairs that were different from the consensus 
sequence. For example, pair TI at bases 174 and 241, pair HA at 318 and pair PA at 196 
(where there is an additional cytosine). A comparison using the pairs TI, PA, MO and HA 
was made with 34 sequences derived from additional CFS patients from whom a single 
sample was available (comparison not shown). Comparing these sequences with pair TI, 9 
one contained guanine at position 241, but did not have the feature at 174 and furthermore 
was dissimilar at seven other bases. None of the 34 sequences in the comparison 
contained the inserted cytosine present in pair PA. In the case of pair MO, the features 
were present in one of the comparison sequences, and in pair HA the thymine at position 
318 was present in two of the 34 sequences. However, the rest of these three individual 
sequences showed at least ten differences from the consensus sequence.
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Patient (code) Interval between 
samples (months)
Percentage identity
1(CR) 26 92.00
2 (HA)* 10 98.20
3 (HO) 40 70.60
4 (MO)* 5 97.50
5 (PA) 8 97.50
6 (TI) 24 99.60
7(M C) 12 90.00
8 (HMa) 41 89.50
9 (HMb)* 12 84.2
10 (HV)* 12 98.3
11 (MCK)* 12 88.4
12 (MCN)* 12 95.8
13 (WI)* 12 87.8
14 (SE)* 12 89.6
15 (MCG)* 12 85.9
16 (HP)* 12 88.7
■#
Table 25: GAP comparison statistics for pairs of enteroviral sequences obtained from 
individual CFS patients. * indicates the pairs included in the clinical follow-up as EV- 
PCR positive over time (Table 17).
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Figure 15: Nucleotide sequences of the partial 5* NTR of enterovirus isolates from 
CFS patients as described in Table 25. GenBank accession numbers for samples 1 to 
8 are X96897-X96912. Differences between the sequences and a consensus sequence 
(Con) are shown. Unique bases referred to in the text are highlighted in bold. The 
nucleotide positions are based on the complete genome of coxsackievirus B3 
(GenBank Accession no. M33854). N represents a mixture of bases at this position.
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The two sequences from H091 and H094 were only 70.6% identical. This strongly 
suggests that these sequences were derived from two different enteroviruses. The 
sequence derived from the serum of patient 3 (H091) was 99% identical to a 
coxsackievirus B3 sequence (accession no. M33854) and the other (H094) was most 
similar to echovirus 6 (accession no. U 16283).
When the sequences of a further eight pairs were included in the comparison, TI, PA, MO 
and HA still had unique differences but there were no such unique bases in the remaining 
pairs. Overall the CFS sequences were very similar, for example MC94, HM94 and HV94 
at positions 200/201, 214/215, 242 and 245, though none of the sequences were identical.
On further examination, it was discovered that sequences from samples isolated in the 
same year were often more alike each other than they were to their consecutive pair. For 
example, CR94 was compared with MCN94, MC94 and HM02, generating identities of 
greater than 94%. These figures were equal to (MCN) or greater than the identities with 
the respective pair. Similarly, HA93 was compared with other sequences from 1993 and 
MCG93 shared 99.2% identity, and comparing WI96 to other 1996 samples showed 
identities greater (91%) than with the paired sample.
The first samples of each of the four pairs of sequences that suggested persistence were 
compared with all the sequences in the database by FASTA analysis to determine the 
sequence closest in identity. Only two of them, TI93 and PA93 were most like their 
respective pair (TI95 and PA94). Additional evidence for a lack of persistence is observed 
with patient HM who provided 3 samples that were PCR positive over time. Comparison 
of the sequence shows no pattern of evolution of sequence over time with base changes 
from the consensus occurring at random, for example, the CT at position 214/215 is 
present in the two later sequences, and not in the first, the A at position 334 is present in 
the first and last sequences but not the second.
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3.4.4. Reliability of direct sequencing of RT-PCR products
Five sequences of coxsackievirus A9 control RNA were obtained by RT-PCR and direct 
sequencing using P1+ and P4- primers. Coxsackievirus A9 sequences 1 and 2 were 
derived from PCR products obtained from RNA extracted from one aliquot of control 
while samples 3 to 5 were derived from PCR products obtained from RNA extracted from 
separate aliquots of the control. Four consensus sequences of 350 base pairs and one of 
311 were obtained. The sequence was identical in all cases with the exception of one base 
pair at position 109 in sequence 4 (Figure 16). The coxsackievirus A9 control used in this 
study was 84% similar to the published sequence.
3.4.5. Analysis of enteroviral PCR results over time
A
This study was conducted over 8 years in total, with work in the last 6 years carried out by 
the author. A total of 1716 specimens from CFS patients was tested for the presence of 
enteroviral sequences by PCR during this period. In addition 441 specimens from a group 
of comparison individuals were tested. Overall, 22% of CFS patients were enteroviral 
PCR positive and 5.2% of comparison individuals were positive. The percentages within 
the years did not vary greatly for the comparison group, but did differ for the patient group 
(Figure 17). The difference between 1990 and 1997 was quite marked with 52.2% 
positives in 1990 compared to 0% in 1997. PCR of control specimens was not carried out 
in 1997.
ÏÏrî
As part of a study on enterovirus isolations in Glasgow over a 21-year period, the number 
and type of enteroviruses isolated by the routine laboratory for the study period described 
in this thesis was determined (Nairn & Clements, 1999). The number of isolates and the 
predominant enterovirus in each year are shown in Table 26.
■1:
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309 358
c o x  a 9 - l  g t a g a t c a g g  c c g a t g a g t c  a c c g c g t t c c  c c a c a g g t g a  c t g t g g c g g t
c o x  a 9 " 2  ...................................................................................................................................................
c o x  a 9 - 3  ...................................................................................................................................................
c o x  a 9 - 4  ....................................................................................................................................................
c o x  a 9 - 5       .
359 408
c o x  a 9 - l  g g c t g c g t t g  g c g g c c t g c c  c a t g g g g c a a  c c c a t g g g a c  g c t t c a a t a t
c o x  a 9 - 2  ....................................................................................................................................................
c o x  a 9 - 3  .............. .. ....................................... ................................................................... .. ................
c o x  a 9 - 4  ...................................................................................................................................................
c o x  a 9 - 5  ...................................................................................................................................................
409 458
C O X  a 9 - l  g g a c a t g g t g  c g a a g a g t c t  a t t g a g c t a g  t t a g t a g t c c  t c c g g c c c c t
c o x  a 9 - 2  ...................................................................................................................................................
c o x  a 9 - 3  ...............................
c o x  a 9 - 4  ....................................................................................................................................................
c o x  a 9 - 5  ....................................................................................................................................................
Figure 16; Alignment of sequences derived from 5 separate PCR products of 
coxsackievirus A9 control using the program PILEUP. The numbers refer to the 
nucleotide positions of coxsackievirus B3 (GenBank accession no. M33854).
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Figure 17: Percentage of enterovirus PCR positives from 1990 to 1997 for the patient 
and comparison groups.
Year Total enterovirus 
isolations (number)
Predominant enterovirus type(s) (% 
of total for year)
1990 525 echo 4 (86)
1991 186 echo 30 (34)
1992 110 echo 30 (13.6), echo 11 (14.5)
1993 89 coxsackie A9 (21)
1994 156 echo 6(19)
1995 118 coxsackie A9 (18.6)
1996 116 coxsackie B5 (25.8), echo 30 (23)
1997 79 coxsackie B3 (24)
Table 26: Number and predominant type of enteroviruses isolated during the years 
1990-1997.
I:
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The most striking feature in this period, in fact in the whole 21-year analysis was the 
outbreak of echovirus 4 in 1990 (Gallacher et ah, 1993) which contributed 86% of the 
enterovims isolates that year. This coincided with the highest proportion of enterovirus 
PCR positives (52%) over the study period. Fourteen out of 22 patients who were PCR 
positive in 1990 reported a date of onset of fatigue, following a flu-like illness, of the end 
of 1989 or beginning of 1990. All the positive PCR results came from samples obtained 
from August to December of that year. For one patient, an echovirus 4 was isolated 2 
months prior to an enterovirus positive PCR result. However, no other isolation data was 
available for this group of patients and no sequence studies were undertaken at this time to 
determine the relatedness of the PCR products to the echovirus 4 isolates.
3.4.6. Comparison of CFS sequences with clinical isolates
Representative clinical isolates identified in the laboratory in the years of the study (Table 
7) were sequenced as described in 2.9.2 and compared to the CFS sequences described 
previously. In addition, earlier isolates and multiple isolates suspected to have come from 
outbreaks were included to measure the amount of variation that would be expected for a 
particular serotype. Other sequences accessed from GenBank, which were not available at 
the time of the initial analysis, were also included.
Ten CFS patient sequences (from analyses 3.3 and 3.4.3.) were taken as representative of 
the group, and Figure 18 shows the dendrogram produced from the extended analysis. The 
enteroviruses grouped into two main clusters, one containing the poliovimses, some
coxsackie A viruses and EV70, and the other containing the remainder of the sequences f
'■i
including those derived from the patients with CFS and the enteroviruses isolated and 
typed in the RVL. This clustering of enteroviruses has been observed previously and has 
been reviewed by Hyypia et a l  (1997).
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Figure 18: Dendrogram showing the relationships between the CFS patients, clinical 
isolates and published enteroviruses based on the 5’ NTR sequence. GenBank 
accession numbers (from top to bottom of the dendrogram) are as follows: poliovirus 
lA  (J02281), poliovirus IB (U01150), poliovirus 2A (X00595), poliovirus 2B (D00625), 
poliovirus 2C(M12197), poliovirus 3A (X04468), poliovirus 3B (X01076), poliovirus 
3C (KO1392), coxsackievirus A24 (D90457), coxsackievirus A21 (D00538), enterovirus 
70 (D00820), echovirus 7A (L76400), echovirus 9A (X84981), coxsackievirus B5 
(X67706), echovirus 6A (U16238), echovirus 9B (X92886), coxsackievirus B2
(Y09512), echovirus 25A (X90724), echovirus 5 (X89535), echovirus 2 (X89532),
echovirus I2A (X79047), echovirus 7B (L76401), coxsackievirus B3A (M33854),
coxsackievirus B3B (M88483), coxsackievirus B3C (U57056), coxsackievirus B1 
(M l6560), echovirus 25B (X90722), coxsackievirus A16 (1105876), echovirus 6B 
(L76399), echovirus 8 (X89539), echovirus 3 (X89533), enterovirus 71 (U22521), 
coxsackievirus A9 (D00627), echovirus 4 (X89534), echovirus 1 (L76395), echovirus 11 
(X80059), coxsackievirus B4A (D00149), coxsackievirus B4B (X05690), echovirus 27 
(L76396), echovirus 30 (L76398), The remaining sequences represent the
enteroviruses isolated and typed in the RVL and those derived from patients with 
CFS (MCN94, TI93, HMOl, CR92, SE95, H091 highlighted in pink and CFS9, 13, 
15, 16 highlighted in green). The dendrogram was generated by the programs 
PILEUP, DISTANCES and GROWTREE. The numbers represent the percentage 
identity (calculated by the program GAP) of the sequences at that point of the 
branch.
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the coxsackie B3 isolates as suggested by the previous FASTA analysis.
The CFS patient sequences from Figure 7 (CFS patients 9, 13, 15, 16) still grouped ::
together, separately from the known enteroviral sequences, the closest match being 
echovirus 6B, with a percentage identity of 87.4%. The CFS patient sequences from the 
follow-up study grouped within the major enterovirus cluster, MCN94 grouping alongside 
echovirus 19 with an identity of 95.6% and SE95 grouping beside echovirus 7B also with ’an identity of 95%. HMOl, CR92 and TI93 clustered together, with identities of 88-90% 
to echovirus 6B which was the most similar enteroviral sequence. H091 clustered with
IClinical isolates of echovirus type 5 (echo 5 RVL) and coxsackievirus A9 (cox A9 RVL)
I;grouped alongside their respective serotype. Nine sequences derived from coxsackie B3 |
isolates obtained in 1997 (cox B3 3629, 3748, 4541, 4625, 5027, 6687, 4413, 6220, 8985) 
clustered together on the dendrogram with identities ranging from 97.2% and 100%. 
However, all the isolates differed from the published coxsackie B3 sequences (cox B3A
and cox B3B) by up to 15%. Similarly, four echovirus 6 sample sequences (echo 6 4566, I
j:
4730, 4283, 4989) isolated within one month of each other in 1994 clustered apart from the 
published sequences (echo 6A and echo 6B) with differences of up to 20%. ^
Other groups of multiple isolates of coxsackie B2, coxsackie B5 and echovirus 30 types did 
not cluster with their respective serotype obtained from GenBank apart from one 
coxsackievirus B2 isolate (4048) which was 98.6% identical to the published 
coxsackievirus B2. The remaining coxsackie B2 sequences were spread throughout the 
dendrogram with identities between isolates ranging from 76.9 to 93.5 %. The coxsackie 
B5 sequences formed two clusters, one containing the 1961 isolates (6237 and 6242) and 
the other containing the recent 1996 isolates (2868, 2907 and 6903). Similarly, the 
echovirus 30 isolates formed two clusters, one containing the early isolates of 1966 and 
1975 (6392, 6398 and 6548) and one containing the recent isolates from 1995 to 1997 f
(3786, 4313, 4844 and 8117). Only one echovirus type 4 isolate (echo 4 1990) from the 
meningitis outbreak in 1990 was available for sequencing and included in the comparison.
This sequence was only 82% identical to the published echovirus 4 sequence and did not f
group alongside it on the dendrogram. Three patients with a date of onset of symptoms in 
1990 or early 1991 (CR, SE and CFS 15) were identified and their sequences compared 
with the echovirus 4 isolate from 1990. Identities ranged from 78% to 88% only.
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3.5, Obtaining additional sequence information
3.5.1. Amplifying other regions of the genome
Sequence analysis of the 5’ NTR does not consistently group the enteroviruses according to 
their serotype and thus determining whether one sequence is like another is difficult. An 
alternative region was sought for amplification that would provide a more accurate 
indication of the genetic type of the virus. From the available sequence information in 
GenBank, enterovirus sequences were aligned by the program PILEUP, and regions of 
similarity were sought as targets for PCR amplification. One such region spanned bases 
580 to 1199 (numbering according to coxsackie B3: accession no. M33854), encompassing 
the end of the 5’ NTR, all of the VP4 capsid protein and part of the VP2 capsid protein. 
Phylogenetic analysis of sequences from the capsid region has been shown to group the 
enteroviruses according to their serotype (Hyypia et al., 1997).
Primers A and B (Table 6) were designed to amplify this region and in conjunction with 
primer 4+, a semi-nested PCR was developed. Primers 4+ and B- were used in a first 
round reaction (conditions as EV-PCR with primers P1+ and P4-) producing a band of 750 
base pairs. This was followed by a second round using primers A+ and B- (conditions as 
EV-PCR with primers P6+ and P9-, except that an annealing temperature of ÔO^ 'C was 
used) producing a fragment of approximately 620 base pairs. The sensitivity of this 
optimized reaction was measured using the titred coxsackie A9 stock as described in 3.1.2.
Gel electrophoresis of the PCR products was performed as described earlier (see Figure 
19A for results). The first round was sensitive to 100 TCIDso whereas the second round 
was sensitive to 1 TCIDso. This is 100 times less sensitive than the standard PCR. This 
lowering of sensitivity with larger products has been observed elsewhere (Arola et at, 
1996). However, it was necessary to design consensus primers which would amplify the 
majority of the enteroviruses, in order to screen the samples and these were the best that 
were available. These primers were tested against all the enteroviruses available in the 
laboratory. The majority of the enteroviruses were amplified with the exception of 
coxsackieviruses A2, A4, A8, A 12, A 14, A16 and echovirus 22. As described for the 
standard PCR, some types were not available for testing. Amplification of a small number
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capsid region was analysed.
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of untyped rhinovirus isolates using these primers produced a smaller product 
(approximately 500 bases) due to the presence of a short 5’ NTR (approximately 620 
bases) compared to the enteroviruses. Again unrelated virus types such as CMV and HSV 
did not amplify (Figure 19B).
A number of the amplicons from the standard enteroviruses (Table 7) were sequenced 
according to the methods outlined previously, to provide comparisons for the prototype
!■sequences in the database and the sequences derived from the patients. A dendrogram 
illustrating the relationships of these sequences in this region is shown in Figure 20. This 
figure shows that in general, multiple sequences of the same serotype cluster together. For
example, the coxsackie B2 and echovirus 30 sequences which were spread throughout the 
dendrogram based on the 5’ NTR, clustered with their respective serotype when part of the
Samples from CFS patients previously positive for enteroviral sequences using primers 
directed towards the 5’ NTR, were tested using the primers for the capsid region. Out of 
55 RNA samples tested, no specific amplicons of the desired size were observed and no 
consistent pattern was observed (Figure 21). Some samples produced a number of 
different sized bands. Increasing the annealing temperature to reduce the non-specificity 
did not alter the banding pattern observed. Altering other parameters such as starting 
template concentration and use of hot-start did not affect the results either. Other samples 
did not produce any bands at all, and altering the parameters to reduce the specificity did
' '■■not affect the results.
A third region of the genome was identified as a possible target for PCR spanning the 
region from 5173 to 5768 bases which encompasses all of the VPg region and part of the 
3C protease. Using a combination of primers protl+, prot2- and prot3- in a semi-nested 
PCR, a product of approximately 300 base pairs was generated using coxsackievirus A9 as 
a control. However, the RT reaction required priming with the poly-T primer rather than 
the random hexamers for this reaction to work efficiently and as will be discussed later this 
approach could not be used with the majority of clinical samples and was not pursued.
I
'Î
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Figure 19: A. Agarose gel showing PCR amplification products of part of the capsid region of a 
dilution series of coxsackievirus A9. Top- first round (primers 4+/B-), Bottom- semi-nested (primers 
A+/B-). M- lOObp DNA ladder. Lanes 1 to 10 -  coxsackievirus A9 dilution series 10'* to 10 B 
Agarose gel showing PCR amplification products of part of the capsid region for a series of virus types. 
Lane M - lOObp DNA ladder; lane 1- MRC-5 negative control; lanes 2 and 3 - rhinovirus (untyped); 
lane 4- CMV; lane 5- HSV; lane 6- coxsackievirus A9 8558; lane 7- coxsackievirus B3 3629; lane 8- 
coxsackievirus B5 2907; lane 9- echovirus 4 1990, lane 10- echovirus 6 4566.
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Figure 20: Dendrogram showing the relationships between the clinical isolates and 
published enteroviruses based on part of the capsid region. GenBank accession 
numbers (from top to bottom of the dendrogram) are as follows: coxsackievirus A21 
(D00538), coxsackievirus A24 (D90457), poliovirus 2B (D00625), poliovirus 2C 
(M12197), poliovirus 2A (X00595), poliovirus lA  (J02281), poliovirus IB (U01150), 
poliovirus 3B (X01076), poliovirus 3C (K01392), poliovirus 3A (X04468), enterovirus 
71 (U22521), coxsackievirus A16 (U05876), enterovirus 70 (D00820), echovirus 4 
(X89534), echovirus 11 (X80059), echovirus 12A (X79047), echovirus 12B (X77708), 
echovirus 6A (U16238), coxsackievirus B3B (M88483), coxsackievirus B3A (M33854), 
coxsackievirus B3C (Ü57056), coxsackievirus B5 (X67706), coxsackievirus B1 
(M16560), echovirus 9B (X92886), echovirus 9A (X84981), coxsackievirus B4B 
(X05690), coxsackievirus B4A (D00149), coxsackievirus A9 (D00627). The remaining 
sequences represent the enteroviruses isolated and typed in the R.V.L. (designated 
with the suffix -RVL). The dendrogram was generated with the programs PILEUP, 
DISTANCES and GROWTREE. The numbers represent the percentage identity 
(calculated by the program GAP) of the sequences at that point of the branch.
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Figure 21: Agarose gel showing amplification products of semi-nested PCR using 
primers 4+/B- then A+/B-. Lane M- lOObp DNA ladder; lanes 1 to 7 and 9 - CFS 
samples; lane 8- coxsackievirus A9 positive control; lane 10- 1®* round PCR no­
template control; lane 11- 2“** round no-template control. The expected 600 base pair 
product is indicated by an arrow.
121
Results
3.5.2. Alternative strategies
3.5.2.1. Inverse PCR. Coxsackievirus A9 was used as the control to optimize the inverse 
PCR reaction. The generation of full-length cDNA followed by restriction enzyme 
digestion was carried out as described in 2.10.2. Varying amounts of cDNA were then 
amplified by inverse PCR as described in 2.10.3. Gel electrophoresis of the products 
showed smearing in each of the wells with no specific bands of the expected size observed.
The reaction was repeated, priming the cDNA synthesis specifically with primer A- 
according to method 2.10.1, using 10 ^  and 10 ^  dilutions of coxsackievirus A9. This would 
produce a double-stranded cDNA template of approximately 600 base pairs.
Enterovirus PCR using the standard primers was performed on this template to ensure that Ti
it was intact after processing. A product of the correct size was observed in all samples 
except for the 10^ dilution that was subjected to the phenol/chloroform extraction 
procedure. Thus the template was intact for all but one sample.
The inverse PCR products generated using these templates are shown in Figure 23. Again, 
the 10^ dilution did not produce any amplification product. Although bands were I; 
observed for each of the other reactions around the expected size (approximately 190 base 
pairs), there were multiple bands present which were not distinct and sequencing of the 
products was not possible. This procedure was therefore deemed unsuitable for use with 
clinical specimens since it was unable to generate useful sequencing material.
3.5.2.2. Long PCR of the enteroviral genome. A full length cDNA template for long PCR 
can be created by priming the RT reaction with a poly-T primer which binds to the poly-A 
tail of the enterovirus genome. Subsequent PCR with extreme 5’ and 3’primers can then 
generate fragments which will be near full-length. Before using the 3’ negative sense 
primers in the long PCR, they were used to prime the synthesis of cDNA in a standard RT 
reaction to ensure that they would bind. The standard 5’ NTR PCR using primers P1+ and 
P4- was then performed to ensure that the cDNA had been successfully generated. Out of 
22 standard viruses tested, a PCR product of the correct size was generated for all virus 
types when the poly-T primer was used to prime the RT reaction
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Known sequence amplified by standard primers
5’ P1+ P4- A-
ds cDNA
Cut with restriction enzymes at * sites 
and religate ends to form circle
P1+
PI- P4+
Linearize circle by cutting the known 
sequence with a restriction enzyme xx
P l- P4+
PCR internal sequence of linearized fragment using 
reverse orientation primers PI - and P4+
Figure 22: Diagrammatic representation of the inverse PCR reaction, showing 
orientation of forward (P1+ and P4-) and reverse (PI- and P4+) primers.
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Figure 23: Agarose gel electrophoresis showing products of inverse PCR. Lane M - 
lOObp DNA ladder, Lanes 1 to 5 -  Inverse PCR using 1.5mM MgCh, Lanes 6 to 10 -  
Inverse PCR jising 3.0mM MgCh. Lanes I and 6 -coxsackie A9 10  ^ (heat- 
inactivated); lanes 2 and 7 -  coxsackie A9 10  ^ (heat inactivated); lanes 3 and 8 -  
coxsackie A9 10  ^ (chloroform extracted); lanes 4 and 9 -  coxsackie A9 10  ^
(chloroform extracted) lanes 5 and 10 -  no template control. The expected 190 base 
pair product is indicated by an arrow.
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PCR products were generated from the RNA of 18 different virus types, including 
coxsackievirus types B1 to B5, A5, A9, A19 and A22, echovirus types 4, 6, 7, 9, 18, 19, 25 
and 30 and enterovirus 69 when primers Y-, prot2- and prot3~ were used in the RT 
reaction. The primers were thus considered to be appropriate for use in the amplification 
of clinical samples.
j
Amplification of the entire genome was carried out according to method 2.12 using 
coxsackievirus A9 as the standard. Because clinical samples are likely to contain low 
levels of enterovirus, as evidenced by the standard EV-PCR, it was necessary to design a 
nested PCR. A number of different primer combinations were used to determine the 
greatest sensitivity. Priming of cDNA synthesis using the poly-T primer followed by a 
first round PCR with primers P1+ and Y- and a nested PCR with primers P4+ and prot2
produced the best sensitivity (see Figure 24A). Long PCR using these primers was :%therefore possible but the sensitivity was low (to 10 T and would therefore not be sufficient
for the detection of enteroviral sequences in the clinical samples from CFS patients. :rs
3.5.2.3. Construction of a cDNA library. RNA molecules can be labile in their natural 
form and difficult to amplify. For this reason, the information encoded by the RNA is 
converted into a stable DNA duplex (cDNA) and then inserted into a self-replicating 
lambda vector (UNI-ZAP XR vector). This can then be used to infect host bacteria which 
can be grown and screened in hybridisation assays for any insert of interest. The cDNA 
library generated represents the information encoded in the messenger RNA of the sample 
and is much easier to manipulate than the parental RNA. The procedure makes use of the 
poly-A tail of the RNA to prime the cDNA synthesis. It was therefore important to ensure 
that samples for cloning could be primed in this way.
Previous positive RNA samples were screened using poly-T to prime the reverse 
transcriptase reaction followed by a standard enterovirus PCR using primers P1/P4 and 
P6/P9. Out of 83 previous positives, only 13 produced a positive band, suggesting that the
I';primer was unable to bind to the A-tail.
If the poly-A tail was reduced or absent in these samples then the primer would not bind. 
Adenosine residues (from ATP) can however, be added to the 3’ end of RNA by the 
enzyme poly-A polymerase (see Method 2.11).
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Four samples were chosen which could not be primed with the poly-T primer. Adenosine 
residues were added using the polymerase enzyme and the resulting product was reverse 
transcribed using the poly-T primer and then amplified using the standard 5’ NTR 
enterovirus primers. The resulting agarose gel (Figure 24B) clearly shows that the samples 
without the tail have not amplified, whereas the same samples with the added tail have 
been amplified, suggesting that the poly-T primer is binding to the additional adenosine 
residues.
For the cloning procedure, two samples with sufficient volume were selected. Five 200 fxl 
aliquots were processed according to method 2.4.2, with the exception that each RNA 
sample was dissolved in 6 ]x\ of DEPC-treated water. The aliquots were then combined to 
produce a more concentrated starting material. An aliquot of RNA (lOfll) was used in the 
standard PCR reaction priming with poly-T to ensure that the sample was still positive. 
Two samples were used in the cloning procedure (2.13) one that could be primed with the 
poly-T primer (sample A) and one that required treatment with poly-A polymerase (sample 
B).
After size fractionation, four fractions of each cDNA were phenol/chloroform extracted 
and quantitated by an ethidium-bromide plate assay (2.14). Three fractions from sample A 
contained 50ng/pl. Each cDNA (lOOng) was ligated into the Uni-ZAP vector (2.14.2) and 
packaged reactions were titred with XLl-Blue MRF’ host bacteria with blue/white 
selection. The ratio of insert to background should be at least 10 times, but in this case the 
ratio was only 2:1. The library was amplified producing titres of 6.1 x 10® pfu/pl to 1.4 x 
10’ pfu/jxl in the fractions. Approximately 500,000 pfu of each fraction was screened with 
different radioactive probes according to methods 2.13.4 and 2.13.5.
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Figure 24: A. Agarose gel electrophoresis of long PCR products from semi-nested PCR. Lane M - Ikb 
DNA ladder; lanes 1 to 4: coxsackievirus A9 10'* to coxsackievirus A9^ (primers Pl+/prot2-: expected 
product size 5000 base pairs approx.); lane 5 - coxsackievirus A9 * (primers Pl+/prot3-: expected 
product size 5300 base pairs approx.). B. Agarose gel showing PCR products obtained using primers 
P6+/P9- from samples with (lanes 6-10) and without (lanes 1-5) treatment with poly-A polymerase. 
Lanes 1-4 and lanes 6-9 represent four samples from CFS patients. Lanes 5 and 10 are products of the 
control, coxsackievirus A9. Expected PCR products are indicated by an arrow.
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There were no positive hybridization spots with either the long coxsackie A9 based probe 
or the protease probe. With the standard P6+/P9- product a possible positive plaque was 
observed which was picked into SM buffer and used to infect new XLl-blue cells. The 
new plates were then screened as before, producing 2 possible positives at this stage. 
These were picked into SM buffer and the process repeated once more, resulting in 100% 
positive plaques on the plate. A number of plaques were picked and screened by PCR 
using primers T3 and T7 to determine if an insert was present. The samples were all 
positive at the same size with these primers suggesting that there was no insert in the vector 
and that the hybridization had been non-specific. This was confirmed by sequencing of 
the purified pBluescript plasmid after excision from the lambda/pBluescript phagemid 
vector.
Similar results were obtained for sample B. The initial ratio of insert to background 
plaques was low, and subsequent screening did not produce any genuine positives.
As a control, all the filters used in the screening process were screened with a PCR product 
obtained by amplification with the ABLl/2 primers. None of these were positive, 
suggesting that the library did not contain enough of the semm RNA of interest to begin 
with to enable it to be detected by hybridization methods.
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4. D iscu ssio n
4,1. Chronic Fatigue Syndrome
Chronic Fatigue Syndrome (CFS) is a poorly understood condition characterized by 
chronic, debilitating fatigue of sudden onset that is defined as lasting longer than six 
months. Common associated findings are myalgia, sore throat, poor concentration, sleep 
disturbance and mood disorders but the presence of other somatic complaints often makes 
the syndrome difficult to distinguish from other organic, psychiatric and poorly understood 
disorders. For example, fibromyalgia is a common rheumatologic condition characterized 
by chronic myalgia, fatigue, disrupted sleep and headaches that occurs mostly in women 
and may follow a viral illness, much like CFS (Buchwald & Garrity, 1994). Likewise, 
patients with depressive illness often have no energy, their concentration is impaired and 
they are under-active and depressive illnesses are also twice as common in women as in 
men (Kendell, 1991). There is also an overlap of symptoms between CFS and 
somatisation disorder where patients present with physical symptoms that are likely to be 
associated with depression or anxiety, rather than physical disease.
However, having said this, the symptoms that define CFS (according to Fukuda et al, 
1994) are reported much more frequently by patients with CFS than by healthy subjects or 
by patients with other diseases that produce chronic fatigue (Komaroff & Buchwald, 1998),
Data from early investigations of CFS was difficult to compare because of the variety of 
names used by different investigators for the condition and the failure to apply uniform 
diagnostic criteria. There was also a lack of objective measures of illness severity and in 
some cases control groups were not tested. This led to the introduction of the Oxford 
criteria (Sharpe et a l,  1991) and the CDC criteria (Holmes et a l,  1988, revised by Fukuda 
et a l,  1994) for the diagnosis of CFS for research purposes which meant that clinical 
groups could then be well-defined. Comparison of data between studies was therefore 
possible, affording a better understanding of the nature of the illness.
The research on CFS has provided many contradictions with few agreed and consistent
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findings regarding the nature of the illness. What has been consistent across studies is the 
mean age at diagnosis (35-41 years) and the preponderance of women. It is acknowledged 
however that many more women than men consult their general practitioner on a regular 
basis and this may account for the difference observed. Other common features include a 
belief in a physical rather than a psychological cause of illness by the patient and a high 
frequency of depression, which is significant (2-3.3 times more frequent) when compared 
to patients with other chronic physical illnesses (Wessely & Powell, 1989). Findings that 
have not been independently confirmed among studies include various immunological and 
virological abnormalities. The presence of these abnormalities does however point to an 
organic rather than a psychiatric basis for the disease although it is likely that elements of 
both are involved. The variety of symptoms and abnormalities observed thus suggest that 
the illness is multifactorial.
The reporting of a sudden onset of CFS following a flu-like illness by many patients, 
suggested involvement of an infectious agent, especially where epidemics of CFS occurred 
in a number of individuals in the same geographical area over a short time span. For 
example, in Lake Tahoe, 150 patients were diagnosed predominantly in 1985 with chronic 
mononucleosis-like syndrome (Barnes, 1986). Additionally, there were ‘outbreaks’ of a 
similar illness in two other communities within a radius of 100 miles at about the same 
time (Komaroff, 1988). Similar outbreaks have been described in Los Angeles (Gilliam, 
1938), London (Ramsay & O’Sullivan, 1956) and Scotland (Fegan et a l ,  1983). A good 
history of an acute onset has been used to distinguish the CFS patient from other patients 
presenting with a complaint of chronic fatigue who are normally vague about the date of 
onset. One difficulty in using these criteria is that patients are not diagnosed until at least 
six months after onset of illness and thus a confirmed laboratoiy diagnosis of infection at 
onset of fatigue is generally not possible. In cases where coiToboration of a viral illness by 
laboratory data is available the illness is classified as a post-infectious/viral fatigue 
syndrome (PIFS/PVFS) (Sharpe et a l,  1991).
Immunological abnormalities have been observed in CFS patients although interpretation 
of results is complicated by lack of standardization of tests compounded with the failure of 
studies to use similar patient groups. The most consistent findings have included IgG 
deficiencies, impaired T-cell function and low NK cell cytotoxicity. It has thus been 
suggested that CFS is associated with an immunological disturbance. This can then permit
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infection by or the reactivation of latent and persistent infectious agents, particularly 
vimses, in the host. Vimses may contribute directly to the illness by damaging certain 
tissues and indirectly by eliciting an immune response. Alternatively, a viral ‘hit and mn’ 
mechanism has been proposed based on the lack of recovery of an infectious agent (Levy,
1994). Here the vims enters the host and infects the target cells causing immune 
abnormalities and the production of inflammatory cytokines, which in turn produce the 
symptoms observed in CFS. As has been stated earlier, the Royal College report which | |
brought together research topics from a wide variety of areas warned against over­
interpreting these immunological abnormalities because of lack of standardization of test 
methods (Royal Colleges, 1996).
1
The search for a common viral agent as a trigger or precipitating factor has included the 
study of herpes vimses, retro vimses and entero vimses. Evidence for and against the 
involvement of these vims types has been presented. Much of this evidence has been 
based on retrospective serological data which cannot be linked directly to the illness. ■ i:
Enterovims neutralizing antibodies for example, can be detected for months to years after | |
the initial infection. Elevated titres of antibodies to a number of different vimses have 
been detected in different groups of CFS patients and this was suggested to be the result of - #
a nonspecific polyclonal immune response. To test this hypothesis, antibody titres to 18 
common viruses (EBV, HHV-6, HSV-1, HSV-2 and 14 enterovimses) were measured 
simultaneously in 20 patients with CFS and compared with age and gender matched 
controls (Manian, 1994). Antibody titres to EBV viral capsid antigen were elevated in
"■ j'-55% of cases compared to 15% of controls but for the 14 enteroviruses, antibodies to only 
coxsackievims types B 1 and B4 were present at significant titres. Additionally there was 
no correlation between elevated titers of EBV viral capsid antigen IgG and IgG to HHV-6, 
HSV-1 and HSV-2 or antibody to coxsackie types B1 and B4. Although only 20 patients 
and controls were sampled, the data did not support the idea that elevation of viral antibody
titres in CFS patients was due to a non-specific polyclonal immune response.
More direct evidence for the involvement of a particular vims in the syndrome can be 
provided by isolation of the vims or detection of viral sequences. Again, conflicting data 
have been presented. Retroviral sequences (DeFreitas et a i ,  1991), HHV-6 replication 
(Buchwald et a l ,  1992) and enteroviral sequences (Archard et al., 1988) have been 
reported in significant numbers of CFS patients compared to control groups, but 
subsequent investigations have not independently confirmed these results (Secchiero et a l ,
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1995; Swanink é ta l ,  1994).
4.2. Enteroviruses and Chronic Fatigue Syndrome
In the United Kingdom, researchers have focused attention on the association of 
enteroviruses with CFS. Investigations centred on the detection of coxsackie B virus 
neutralizing antibodies, which were present in significant proportions of individuals with 
CFS compared to healthy control groups (Fegan et a l,  1983; Keighley and Bell, 1983; Bell 
& McCartney; 1984; Calder et a i,  1984; Behan et a l,  1985). Serological criteria based on 
raised antibody titres had proved useful in demonstrating the role of coxsackie B viruses in 
some cases of adult heart disease (Bell et a l ,  1983; O’Neill et a l, 1983). Early studies 
indicated a link between high antibody titre and recent infection, therefore titres of 256 
were suggestive while titres of 512 and above were indicative of recent infection (Grist et 
a l,  1974). A disadvantage of using this as a measure of infection is that neutralizing 
antibody can remain elevated for many years in an individual and interpretation of static 
titres then becomes difficult.
An ELISA for the detection of coxsackie B virus specific IgM was developed as a more 
useful marker of recent infection (King et a l,  1983). McCartney et a l,  (1986) showed 
that a significant proportion of CFS patients (31% of 118 and 37% of 290) were positive 
for coxsackie B-specific IgM compared to healthy controls (9% positive), while Miller et 
al,  (1991) found no significant difference between 53 patients and 49 controls (24.4% 
versus 22.6% positives respectively). It must also be noted that cross-reactivity of the IgM 
test with other enteroviruses (coxsackie A and echovirus types) and hepatitis A vims has 
been observed (King et a l,  1983; McCartney et a l,  1986). This test has not been routinely 
used since for diagnostic purposes.
Although serological testing only provides indirect evidence for the presence of 
enterovimses, additional molecular studies have provided further direct evidence for the 
association of enterovimses in patients with CFS. Direct isolation of the vims has also 
been shown, although only in a few studies. Using acid dissociation culture of stool 
samples, Yousef et a l  (1988) isolated enterovims from 17 patients and 2 controls. This 
technique removes bound neutralizing antibody from any vims present which would 
normally hinder isolation. Isolates of coxsackievirus types B 1-5 and echovims 1, 9 and 11
   . . .
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were recorded and after 12 months, five patients were still positive, yielding the same virus 
type. More recently, Vedhara et a l ,  (1997) isolated non-polio enterovims using acid- 
culture from two CFS patients on day zero of a poliovirus vaccine trial. Studies from the m
Netherlands (Swanink et a l ,  1994) on 76 patients and 76 controls and from Sweden (Lindh 
et a l ,  1996) on 82 samples from 34 patients failed to isolate vims using acid-culture 
methods. In routine eell culture systems, 25% to 35% of specimens from patients with 
typical enterovirus infections of any serotype are negative (Chonmaitree et a l,  1982), so it 
is not surprising that many virological studies of CFS patients do not yield any positive 1;:isolation results. Indeed, isolation of virus from affected tissue in chronic heart disease, 
where a positive association with enterovimses has been suggested, is rarely successful 
(Morgan-Capner et a l ,  1984). In addition to the problems of vims isolation in general, 
discussed in section 1.4.4., the nature of the chronic illness is such that the virus may 
already have been cleared by the time the investigations are carried out.
Both Swanink and Lindh also failed to detect enterovims in CFS patients using PCR 
techniques apart from one positive sample in the former study from a CFS patient. Neither 
group included an extraction control in the PCR to show that the RNA had been 
successfully extracted from each sample. It is known that stool samples can contain 
inhibitors of the PCR process (Wilde et a l ,  1990) and these must be removed during the |
RNA isolation process. Negative results should therefore be accompanied by a positive :;|
control PCR result indicating that the RNA extraction procedure has been successful. 
Additionally, the Swedish study did not include any control samples and did not supply any 
information regarding the sensitivity of the PCR (Swanink could detect approximately 20 |
pfu).
Concurrent testing of comparison samples for enterovirus by nested PCR in the present 
study showed an overall uniform background level of detection of 5.2% for the years 1990 
to 1996. It is therefore surprising that all the samples (except one) tested by both groups 
discussed above were negative. Perhaps these results reflect a difference in the 
epidemiology of the enterovimses in different countries and as such cannot be used as 
evidence to discount the data from the U.K.
Another marker of enteroviral infection which has been used is the VPl antigen, a capsid 
protein common to all enteroviruses which can be detected by 5-D8/1, a monoclonal 
antibody. VPl antigen was detected in 51% of CFS patients compared to 0% of controls
.3 .  ;
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in a study by Yousef et al. (1988). This finding was confirmed by Halpin and Wessely 
(1989) but disputed by Lynch and Seth (1989) and Swanink et a l,  (1994) who both found 
no difference in the detection of the antigen between patients and controls. The test has 
not been widely used since in the investigation of CFS patients.
3
Early studies using molecular techniques described the detection of enteroviral specific 
RNA in muscle biopsies of a significant number of CFS patients compared to controls iï(Archard et a l,  1988; Bowles and Archard, 1990; Cunningham et a l ,  1991). Additionally, 
Cunningham showed that where enteroviral RNA was detected in biopsies from CFS 
patients, the amounts of positive and negative strands were approximately equal, whereas 
in a lytic infection positive strand is synthesized in approximately 100-fold excess. This 
could be the result of a defect in the control of viral RNA synthesis and together with the 
failure to isolate enterovirus in conventional cell culture this suggested that the enterovirus 
detected in CFS patients was in some way unusual.
I
Further advances led to the development of the polymerase chain reaction which was 
capable of amplifying specific DNA sequences from low levels of starting material. Many 
investigators thus began developing PCR protocols and this technique began to be favoured 
over hybridization and serological methods to study enterovirus involvement in CFS.
The data discussed herein was derived from studies conducted over approximately 7 years.
The preliminary data indicating a positive relationship between enteroviral sequences and 
CFS by PCR was based on samples collected during 1990 and 1991 (Clements et a l,  1995;
Nairn et a l,  1995). Phylogenetic analysis was performed on sequences derived from 
samples obtained during 1992 and 1994 (Galbraith et a l,  1995) and the follow-up study 
which included an investigation into enteroviral persistence (Galbraith et a l,  1997) and a 
clinical evaluation of the patients’ illness, was carried out on samples collected between 
1994 and 1997. :i
,..u
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4.3. Polym erase Chain Reaction
4.3.1. Contamination
PCR is a process capable of amplifying and detecting a target DNA molecule present only 
once in a sample of 10= cells (Saiki et a i,  1988). In approximately 35 cycles of PCR a 
target can be amplified by a factor of more than 10 million. This sensitivity means that 
even a small amount of contamination of target DNA in the starting material will result in a 
positive reaction product. This problem is more pronounced when nested-PCR is used 
since this is more sensitive than one round of PCR.
In this study although all reasonable precautions were taken within the laboratory (see 
methods), contamination was observed occasionally where samples, negative virus controls 
and no template controls were positive. These instances were obvious and the results were 
disregarded. Sequencing of PCR positives throughout the study showed that none of the 
samples were identical in sequence, although many were very similar, and at no time was 
the coxsackievirus A9 positive-control sequence detected in any of the positive clinical 
samples.
Critics have suggested that the significant numbers of PCR positives reported in Clements 
et a l ,  (1995) and Galbraith et at,, (1995) were a result of contamination since this work has 
not been replicated elsewhere. However, samples were only recorded as positive if all the 
controls in that particular run amplified as predicted and if repeated extraction and RT- 
PCR produced a second positive result. Additionally, if contamination from PCR product 
carry-over due to poor technique was responsible for the positive results observed, more
positives would have been expected in the control group. Furthermore, there were no 
positives at all with the VP4/VP2 capsid PCR.
4.3.2. Sensitivity and specificity of PCR
The majority of published PCR protocols for enterovirus detection target the 5’ non- 
translated region (NTR), a highly conserved stretch of approximately 750 base pairs,
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common to the majority of the enteroviruses (Stanway, 1990). Many of the reported PCR
protocols describe a single round PCR followed by hybridization, which can be time 
consuming and often requires the use of radioactive probes. Additionally, under stringent 
reaction conditions for high specificity, hybridization requires almost perfect homology 
between the probe and the product (Severini et ah, 1993). Nested PCR is suited to the 
sensitive and specific detection of a small number of templates against a large background 
of cellular RNA (Erlich et a l ,  1991). It is as sensitive as PCR plus hybridization, more 
rapid and does not require perfect homology except at the 3’ ends of primers. PCR also 
allows for subsequent sequencing of the positive product for identification purposes. A 
number of nested and semi-nested PCR protocols for the 5’ NTR have been described. 
Severini et a l,  (1993) described the detection of coxsackievirus types B1 to B6, poliovirus 
types 1 to 3, and echovirus types 9,19 and 31 using a nested PCR. The sensitivity of the 
reaction was such that close to a single molecule, in as much as Img of tissue could be 
detected. Kammerer et a l  (1994) tested 33 prototype viruses, including the poliovirus and 
coxsackie B types, coxsackie A types 5, 7, 9, 16 and 21, echovirus types 1 to 9, 11,12, 22, 
24 and 33 and rhinovirus types 1, 2b, 14 and 89. With the exception of echovirus 22 
which was not amplified, all the virus types were detected to a sensitivity of 0.05 PFU/ml. 
Nicholson et a l  (1994) used a nested PCR which recognized all poliovirus and coxsackie 
B isolates, coxsackieviruses A9 and A16 and echovirus types 4 , 6 , 7 ,  11, 18 and 30, to a 
sensitivity of 0.1 TCIDso.
:A::
In the present study, coxsackievirus types A6, A24 and echovirus types 23, 29 and 32 were 
not available for testing but all other enteroviruses (59 types) were amplified using the 
nested primers, with the exception of echovirus 22. Echovirus types 22 and 23 have been 
shown to differ considerably from the other enteroviruses in terms of their genome 
sequence, structural proteins and lack of host-cell shut-off. Echovirus 22 has recently been 
classified as the type member of a sixth genus, parechovirus (Mayo & Pringle, 1998).
Many PCR protocols have thus failed to detect these serotypes (Hyypia et a l,  1989; Olive
■
et a l ,  1990; Chapman et a l ,  1990) while others have reported the amplification of smaller 
sized bands (Kammerer et a l ,  1994) or the need for additional cycles for detection 
(Rotbart, 1990). In the latter study echovirus 2 also needed an additional 25 cycles for 
amplification compared to 9 other serotypes of the same titre. Using the microwell 
detection system 27 serotypes were detected at < 1 TCIDso with the exception of coxsackie 
A7 which was detected at 1 TCIDso (Rotbart et a l,  1994). The decreased sensitivity
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observed with these few serotypes is probably a result of differing homologies between the 
primers and the target sequence. The standard enteroviral nested PCR described in this 
thesis detected coxsackievirus A9 control to a dilution of 10 ®, which was equivalent to 0.01 
TCID 5 0 . For this virus type, the sensitivity was similar to other nested protocols that 
expressed the sensitivity in these terms. Endpoint sensitivities for other types were not 
determined.
4.3.3. PCR testing in CFS
PCR was used initially in investigations of CFS to test muscle biopsies and the association ■î‘
with enteroviruses was confirmed with a significant proportion of patients positive (53%) S
compared to controls (15%) (Gow et a l,  1991). Many individuals with CFS report muscle 
pain and fatigue on exercise: the detection of enteroviral sequences in muscle tissue may 
provide evidence for a direct association with chronic fatigue syndrome. The same group |
in a later publication on the results of a larger study, showed no difference in the number of 
enterovirus positive samples between patients with CFS and those with other 
neuromuscular disorders (Gow et a l ,  1994). However, in a further publication it was 
stated that the methods used in the 1994 study were not as specific as had been hoped,
ssuggesting that there were a number of false-positives in the series of samples (Behan et 
a l,  1996). Whether these were in the patient or control groups (or both) was not discussed lij 
but six of the CFS patient positives were shown to be enteroviral in origin by direct 
sequencing of the PCR products. The accuracy of the results previously reported by others 
and by Gow et al (1994) would therefore appear to be in question and there may be no 
convincing evidence of enterovirus positivity in CFS cases. Other groups also failed to 
find a significant difference between patients and controls (Leon-Monzon & Dalakas,
%
1992; Swanink et a l ,  1994; Lindh et a l,  1996), the latter two reports having been 
discussed previously. However, focal localisation is a feature of some enterovirus 
infections (Kandolf et a l,  1987) and if viral particles are sparsely distributed in the muscle f
then they may escape detection and false-negative results may arise (Leon-Monzon &
Dalakas, 1992). Examination of multiple biopsies might prevent this but it is difficult to 
justify obtaining multiple biopsy samples in control patient groups. Would it therefore be 
possible to use samples other than muscle biopsies from these patients? Serum samples
Àwere thus selected and with access to individuals with chronic fatigue syndrome, they were I
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tested for the presence of enterovirus by a nested PCR (Clements et a l ,  1995) previously 
developed in this laboratory (Gow et a l,  1991). The results showed a significant 
difference between the patient and comparison groups for enteroviral RNA sequences and 
demonstrated that serum could be used as an alternative to muscle biopsies for detecting 
enteroviral sequences in CFS patients. Obtaining a serum sample is a less invasive 
procedure than retrieving a muscle biopsy, and consequently obtaining comparison samples 
is less of a problem. Enteroviruses were also detected from stool samples in 48% of 
patients versus 28% of controls but this result was not significant using the ‘Odds ratio’ 
test.
In the Regional Virus Laboratory in Glasgow, serum samples from CFS patients were 
routinely tested for the presence of coxsackievirus B neutralizing antibodies (types B1 to 
B5) because of the historical data indicating an association with CFS. The merits of this 
test (and other serological assays) have been mentioned previously. Using the same 
methods, the neutralization assay was used to test serum samples from CFS patients and 
compare the results with the detection of enteroviral sequences by PCR. The tests were 
performed on 100 CFS and 100 comparison individuals (Nairn et a l ,  1995). Testing for 
coxsackievirus B6 antibodies was not carried out since this serotype is rarely found in 
Glasgow, with only two isolates reported in the 1977-1997 period (Nairn & Clements, 
1999). The results showed that it was not possible to distinguish between patients in the 
CFS and comparison groups using the neutralization test, since equal numbers in both 
groups were positive for one or other of the antibodies (34% versus 41% respectively). 
The PCR results however, were significantly different between the two groups (42% versus 
9% for patients and comparison individuals respectively). In the patient group, sixty six 
results were concordant. Of those that did not correlate the majority were PCR 
positive/coxsackie B antibody negative (21/34), and would have been the result of the PCR 
detecting enterovirus other than the coxsackie B serotype. In the comparison group, 58 
results were concordant and the majority that were not, were PCR negative/coxsackie B 
antibody positive (37/42). The detection of neutralizing antibodies in ‘healthy’ patients is 
not surprising since these are known to persist for months to years following infection. 
The antibody test is therefore not an appropriate measure of recent infection and does not 
provide information regarding the current enteroviral status of the patient. PCR, on the
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other hand provides evidence for the direct detection of enteroviral RNA sequences at a 
given time point and can be used as a marker of enteroviral infection.
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Thus PCR was shown to be a suitable and sensitive technique for the detection of 
enteroviruses in serum and from these two studies the association of enteroviruses with 
CFS, previously shown by serological testing and by PCR of muscle biopsies, was 
strengthened. This prompted the initiation of a study to examine new patients and to 
analyze the sequence of the enterovirus present by direct sequencing of any positive PCR 
products.
4.4. Phylogenetic analysis o f  enteroviral sequences
PCR was used to screen samples from new patients with CFS presenting to the Infectious 
Disease (ID) unit of Ruchill Hospital for the presence of enteroviral sequences. Initially, 
twenty PCR products (13 from serum and 7 from throat swab samples) were subjected to 
manual sequencing and compared to sequences from the GenBank database and laboratory 
isolate sequences using phylogenetic analysis.
Phylogenetic analysis refers to the comparison of sequence data and the construction of 
phylogenetic trees or dendrograms that graphically depict the relationships of sequences. 
It can be used to compare two sequences to determine how similar they are, to trace the 
source of transmission of a particular virus, or to identify an unknown sequence by 
comparison with sequences available in the various databases. There are numerous 
methods for constructing phylogenetic trees from molecular data (Felsenstein 1988; 
Miyamoto and Cracraft, 1991). They can be classified into distance methods and discrete- 
character methods. Distance methods include the neighbour-joining method proposed by 
S ai ton and Nei (1987) and the unweighted pair-group method with arithmetic means 
(UPGMA: Sneath and Sokal, 1973). There are two major groups of discrete character 
methods - maximum parsimony and maximum likelihood methods. No one method has 
been shown to be optimal for inferring phylogenetic trees from alignments. Therefore, the 
consensus of opinion in the literature has been to carry out several different methods of 
comparison and if they yield the same or a virtually identical tree, then this is thought to be 
a reliable representation of the sequence relationships present (Saitou and Imanishi, 1989).
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To ensure that the sequences obtained by manual sequencing were accurate the reliability 
of the procedure was measured by comparing the manual-derived sequence with one 
derived from automated sequencing from a single sample. Manual sequencing relies on 
the operator distinguishing bands across four lanes of a gel and this can be inaccurate at the 
top of the gel where bands are packed closely together. However, only one nucleotide 
difference was observed between the two sequences, suggesting that the sequence obtained 
by the manual methods was reliable and representative of that present in the original 
sample.
Phylogenetic analysis of the 20 sequences derived from the CFS patients showed that all 
but one of the sequences were separate and distinct from the known enteroviruses and from 
other enterovimses and non-CFS sequences derived from laboratory specimens. The 
sequences were also illustrated in dendrogram format and this confirmed the phylogenetic 
tree groupings. Further sequence comparisons showed that a consensus CFS sequence 
was not related to other animal picomavimses (<50% homology) with the exception of 
SVDV (approximately 83% similar) which is closely related to the coxsackie B vimses. 
However, at this time there were only a few enterovimses out of the whole group with 
sequence data available for this region (poliovims types 1-3, coxsackievims types A9, A21, 
A24, B l, B3, B4, B5 and enterovims type 70) thus it is possible that the CFS related 
sequences were derived from known enterovimses whose sequence had not been 
determined. Alternatively, the CFS sequences may have indicated the presence of novel 
enteroviruses or represented sequences from known enterovimses with variant 5’ NTRs. 
The 5’ NTRs of enterovimses and rhinovimses have highly conserved primary and 
secondary stmctures that have been confirmed as being vital for RNA replication and 
translation of viral proteins. Indeed the initiation of translation is mediated by a region 
within the 5’ NTR known as the internal ribosome entry site (1RES) (Rohll et a l, 1994). 
The 5’ NTR also contains determinants of neurovimlence. The base at nucleotide 472 of 
poliovims 3 is the major determinant of vimlence, and in a study of seven different 
echovimses, the less vimlent types (serotypes 2 and 12) exhibited variations in this region 
compared to the vimlent types (Romero & Rotbart, 1995), Similarly, in a study of 
enterovims 71 isolates, variations in the 5’ NTR were revealed between isolates associated 
with hand, foot and mouth disease and those associated with aseptic meningitis (Zheng et 
al,  1995).
Thus if an altered 5’ NTR is a feature of the enteroviruses found in patients with chronic
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fatigue syndrome and inefficient translation and replication result then this might lead to an 
atypical pattern of infection and result in a persistent infection.
An atypical sequence was also obtained from one non-CFS comparison patient (non-CFS 
1). No clinical information was available for this patient. The other non-CFS sequences 
were dissimilar to the CFS patient sequences and grouped with the sequences of the known 
enteroviruses. This is to be expected from non-CFS sequences 2 to 6 which were derived 
from patients with a presumptive diagnosis of myocarditis. Enteroviruses, particularly the 
coxsackie B virus type, have been shown to be associated with human viral heart disease 
(Kandolf & Hofschneider, 1989). Controlled studies of patients with suspected viral heart 
disease showed that at least half the cases of acute myocarditis and one third of the cases of 
non-bacterial pericarditis were associated with coxsackie B virus infection (Grist and Bell, 
1974). More recent summary data has reported the detection of enterovirus sequences in 
45% of hearts by slot-blot hybridization and 25% by PCR or in situ hybridization (Martino 
etaL, 1995).
Gow and colleagues (1994) published a short enteroviral sequence identified from the 
muscle biopsy of a CFS patient. Although only 83 base pairs in length it was also distinct 
from the known enteroviruses (at least 20% difference in nucleotide identity from 
coxsackieviruses B l and B3). Another group showed that sequences obtained from stool 
samples from CFS patients in Cardiff were closely related (>90%) to those described by 
Galbraith et a i ,  (1997) (Han et al., 1998). Both these studies thus provided corroborating 
evidence for the presence of atypical enteroviral sequences associated with CFS. 
However, all the sequences analysed were short and without further corroboration from 
other regions of the viral genome, preferably those coding for the capsid proteins which 
give an indication as to the type of enterovirus, the atypical group identified here could not 
be defined further.
Among the 20 CFS patient sequences subjected to initial phylogenetic analysis were two 
sequences from patient 7 derived from samples obtained 10 months apart. These 
sequences differed by less than 1% suggesting that the virus may have persisted in this 
patient. Persistence has been suggested as being involved in the progression and 
maintenance of the fatigue syndrome because enteroviral antibodies and RNA have been 
detected in patients who have suffered with the syndrome over a long period (McCartney et
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al., 1986; Archard et al,, 1988; Cunningham et a l,  1990; Bowles et a l,  1993). Indeed, the 
study by Cunningham et a l,  (1990) provided evidence for abnormal replication and was 
interpreted as enteroviral persistence. The evidence for (Muir & Archard, 1994) and 
against (Melchers et a l,  1994) enteroviral persistence has been hotly debated. However, 
in most studies evidence for the presence or absence of persistence has been based on 
analysis at one time point only. None of the studies have looked at detecting the virus 
(viral sequences) over time. A follow-up study was thus implemented to examine patients 
over time with respect to their clinical condition (with the aid of the questionnaire) and
their enteroviral PCR status.
4.5. Follow-up Study
4.5.1. Correlation of enteroviral status vrith clinical data
If enteroviruses act as trigger for CFS via a ‘hit and run’ mechanism then they should be 
detected shortly after the onset of fatigue, before they are cleared by the immune system.
If they trigger the syndrome and then persist in the host in some way, then they might be 
expected to be detected throughout the course of the illness. If the vims acts as a 
precipitating factor in causing an exacerbation of symptoms, either through exogenous 
infection or from ‘persistent infection’ then the presence of vims may be associated with 
the clinical course of the illness.
There have been no attempts to follow CFS patients over time to look at the clinical course 
of CFS in relation to the presence or absence of the enteroviruses (or any other vimses), 
although one group did look at the effects of enteroviral infection in CFS patients by |  
exposing the patients to live poliovirus vaccine (Vedhara et a l,  1997). In this study 7 CFS 
patients receiving vaccine were compared to 7 CFS patients receiving placebo and 9 
control patients receiving vaccine in a double-blind study. Patients were monitored at 
intervals up to 8 weeks post-immunization by providing faecal samples for virus isolation |  
studies, blood samples for immunological analysis and undergoing behavioural assessment. 
Administration of the vaccine was not associated with exacerbation of symptoms in CFS 
patients, the behavioural differences present between the groups did not change post­
immunization, the number of cognitive failures did not increase and psychomotor function 
did not decrease. Additionally, there were no immunological abnormalities in the immune Mresponse to poliovirus although the reduced levels of CD28 and CD38 cells observed in
J Î
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CFS patients compared to the control patients prior to immunization were maintained 
through the study. There were also no differences in cytokine release, T-cell responses, 
neutralizing antibodies or secretory IgA. Interestingly, acid culture of stool samples did 
produce differences between the groups, with polioviruses, non-polio enteroviruses and 
unclassified enteroviruses isolated from the CFS-vaccine group compared to only one 
poliovirus isolate in the control group and none in the CFS-placebo group. In addition, 
circulating enterovirus-like sequences were detected by PCR in the first serum sample 
tested of two CFS patients. Thus the data supported the hypothesis that persistent : 
enteroviral shedding following infection was a feature of CFS (Yousef et a l,  1988).
I-
The few long term follow-up studies that have been reported have mainly looked at 
predictors of outcome and have had a psychiatric basis. For example, Sharpe et a l,  (1992) 
followed up patients at 6 weeks to 4 years and showed that for the first year, prognosis was 
poor but long term, the percentage of patients functionally impaired (in terms of walking, 
social activities, hobbies and occupation) reduced, although most still complained of àfatigue. Age, sex and marital status was not related to functional impairment but belief in 
a viral cause, coping skills, changing job and joining a patient organization were related. 
Bonner et a l,  (1994) studied 43 patients who were followed up after 4 years. This group 
of patients had been offered treatment in the form of cognitive behaviour therapy. Of the 
23 who completed treatment, 87% were well compared to only 13% who had made a 
spontaneous recovery without receiving or completing treatment. Those that were still 
fatigued after 4 years (only 1/3) were likely to have had more somatic disorders, were more 
fatigued and had a previous psyehiatric history when assessed. Wilson et a l,  (1994) also 
showed psychiatric involvement, with a significantly higher rate of primary psychiatric 
diagnosis at follow-up in those patients who had not improved, but in this case there was 
no difference in premorbid psychiatric diagnoses at entry to the trial. A poor outcome for 
patients was also predicted for those with a high score on the disease conviction scale and 
those who did not believe that psychosocial factors played a role in their illness.
In the present study, patients were referred initially to the Infectious Disease Department at 
Ruchill Hospital by their General Practitioner. A number of patients were referred from 
the same practice and thus the interest and/or expertise of the G.P. in this field may have 
determined which patients were referred further and this does add some selection bias to 
the study group. A diagnosis of CFS was then confirmed by the Infectious Disease 
consultants and the patients were put forward for inclusion in the study. A psychiatric
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evaluation was not performed on the patients, but they all fulfilled the Oxford Criteria
which made them suitable for analysis. All patients were asked to complete a
questionnaire at entry to the study and annually subsequently.
Patients were followed up to correlate clinical presentation (derived from the questionnaire 
data) with enteroviral PCR status over a four-year period. The number of patients 
participating each year decreased, due to a number of factors; failure to contact the 
G.P./patient due to a change in address, refusal of G.P. to take part, recovery of the patient 
and unwillingness to continue or general loss of interest in the study. Thus only 19 
patients completed four questionnaires and provided four blood samples compared to 130 
who completed two.
An overall view of the group regarding their health status prior to the illness and their 
clinical condition afterwards was gathered from the 333 ‘first’ questionnaires completed by 
patients on first attendance at the clinic. There was nothing remarkable about the patient 
group prior to the onset of illness, for example travel abroad, immunizations, allergies etc.
The age distribution showed an approximately normal distribution and the female to male 
preponderance observed in other studies was repeated here. The distribution of the month 
of onset of fatigue is interesting when compared to the distribution of isolation of 
enteroviruses in Glasgow (based on figures from 1994-1997). The peak of enterovirus 
isolation occurs in July and August while the onset of fatigue is fairly constant throughout 
the year with slight peaks in November/December and February when enteroviral activity 
is low. The majority of patients (81%) reported an acute illness (within 2 weeks) prior to 
the onset of fatigue and thus the peak of onset would be expected to match the peak of 
enterovirus activity if enteroviruses were a major factor in this illness. However, although 
some patients were definite about the date of onset (to the day) others could not remember 
so accurately, especially those who had been ill long-term and this may have altered the 
distribution.
The ten symptoms reported most often (after fatigue and post-exertion weakness in 
muscles, which were virtually 100%) by this group of patients included many symptoms 
which are common secondary manifestations of depression or anxiety, including myalgia, 
sleep disorder and headache for example (Komaroff, 1993). Those symptoms that cannot 
easily be ascribed to a primary psychiatric illness including fevers, coughs, night sweats 
and joint pain were reported at lower frequencies by patients (14% for cough to 58% for
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joint pain). Perhaps this indicates that in this group of patients the psychiatric component 
of the illness is greater than the physical component.
Of the 333 patients completing one questionnaire, 36% were enterovirus PCR positive. 
The patient responses to all of the questions were analysed (where possible) on the basis of 
the PCR results, thus two groups were identified for each question and the percentage in 
each group determined, hi all cases, the percentages reporting a particular symptom or a 
specific type of illness at onset for example, mirrored the PCR results. Thus the patient 
responses to the questions were similar regardless of their PCR status. However, this 
analysis was performed on one group of samples only at one time-point, providing a 
snapshot only of a chronic illness.
Thus, patients were followed up at twelve monthly intervals to extend the questionnaire 
analysis and compare the data with the PCR results over the course of the illness. One 
hundred and thirty patients were compared in this analysis in which the severity of disease 
was measured objectively by a number of markers for example, ability to work (both in 
employment and in domestic terms) and physical activity. This was compared with 
enteroviral PCR status over time.
Analysis of data from the initial questionnaires and initial PCR testing of this cohort 
showed that 51.5% of the 130 patients were enteroviral PCR positive. Comparison of the 
PCR positive and negative groups showed a significant association between PCR positivity 
and severity of disease. That is, those individuals with a PCR positive result were less 
likely to be at work or school, less likely to be able to carry out their domestic work, less 
able to walk distances and more likely to have taken time off work. This suggested that 
the presence of the enterovirus was a major factor in influencing the severity of illness at 
this time.
The second set of questionnaires (obtained after twelve months) was similarly analysed. 
The number of patients who were enteroviral PCR positive had reduced to 16%. If the 
two groups of patients at this time were compared (21 positives and 109 negatives) there 
was no difference between the positive and negative groups in terms of ability to work, 
physical activity etc. Similarly, if the patients were divided into four groups based on their 
PCR status over time (EV-PCR +/+, +/-, -/+, -/-) there was no correlation between 
enteroviral positivity and ability to work or physical activity. The group with the most
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time off work though had two enterovims PCR positive results, whereas the group with 
least time off work had two negative results over time. However, the number of 
respondents in the PCR +/+ group was too low (4) for this result to be regarded as 
significant. After 12 months then, the continued presence of virus did not appear to play a 
part in the severity of illness.
From this data there was a positive correlation between overt clinical symptoms and 
enteroviral PCR status on examination of the first questionnaire from a cohort of patients. 
The mean duration of fatigue for this group of patients was 3.9 years (with no difference 
between the PCR negative and positive groups). Therefore, the virus could have triggered 
the syndrome and persisted for nearly 4 years, the exacerbation of symptoms being due to 
its reappearance in the circulation. Alternatively, the symptoms may have been 
precipitated by a recent episode of infection. With no pre-fatigue samples available for 
testing it is not possible to determine which of the two possibilities is correct. However, 
subsequent analysis of a second questionnaire at 12 months compared with PCR results did 
not support the positive correlation between symptoms and PCR status, while combined 
analysis of the sequential enteroviral PCR results compared with clinical symptoms, 
suggested that enteroviral persistence did not play a role in the maintenance of chronic 
fatigue syndrome. The condition of the majority of patients had not improved but only 
16% of second samples were positive. However, the nature of the infection may be such 
that the enteroviral sequences are present in the individual at particular localized sites, for A
example the muscle (detection of which has been reported in other studies (Cunningham et 
al,, 1991, Gow et al., 1991)) and shedding into the bloodstream may occur only at 
intervals. Therefore more frequent testing of patients would be required to maximize the 
chances of detecting the enteroviral sequences if this is occurring.
The use of self-administered questionnaires to obtain clinical information can be a 
problem. In this case, forms were completed at home by the patient, as closely as possible 
to the time of blood donation to enable a correlation of clinical symptoms and enteroviral 
PCR status to be made. This was not always possible owing to difficulties in obtaining 
appointments at health clinics to donate the sample and thus many questionnaires could not 
be included in this cohort, but in most of the 130 cases the difference was a matter of 
weeks at most. There are also difficulties associated in using questionnaires in CFS 
research due to the length of time since the onset of symptoms. Many patients simply
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cannot remember details prior to their illness and they often misinterpret questions. In a 
number of cases a question with a ‘yes or no’ choice (for the list of current symptoms) was 
answered with ‘sometimes’ or ‘occasionally’. Recall bias is also a feature of this 
syndrome with patients highly motivated to remember viral infections as many attribute 
this as the cause of their illness. Of all the patients who completed a first questionnaire in 
this study, approximately 50% answered ‘yes’ to ever having been diagnosed with a 
particular virus infection. The viruses involved were either coxsackieviruses or EBV in 
equal numbers apart from a few ‘mystery’ or ‘ME’ virus reports.
4.5.2. Enteroviral persistence
4.5.2.1 Evidence of enteroviral persistence in vitro and in vivo. Enteroviruses are 
known to be the aetiological agents in many acute conditions such as aseptic meningitis 
and poliomyelitis. With the exception of some cases of immunodeficiency it is not 
generally accepted that enteroviruses can cause persistent infections (Melchers et al.,
1995).
To persist in a host, the virus must be able to cause infection without being cytopathic and 
must be able to avoid detection and elimination by the immune system of the host. 
Avoidance of the immune system can be achieved by restricting viral gene expression for 
example as in the case of HSV, or by infection of tissues and cell types that are not readily 
accessible to the immune system such as the central nervous system, for example measles 
virus in the case of SSPE (sub-acute sclerosing pan-encephalitis). Non-lytic viruses are 
suited to persistence and can establish chronic infections but for lytic viruses, the 
cytopathic effect has to be limited. This can be achieved by a number of means including 
infection of non-permissive cells or by the vims adopting a strategy of non-lytic 
replication, by producing incomplete or defective viruses or generating mutants and 
variants (Torre et a l ,  199\).
Persistent enterovims infections have been demonstrated in cell lines and experimental 
animals. A persistent steady-state infection of cloned human WISH cells by echovims 6 
has been maintained for over 7 years with the production of defective vims particles 
(Gibson & Righthand, 1985). The vims particles only contained capsid proteins, VPO,
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VPl and VP3, thus processing of VPO to VP2 and VP4 had not occurred. Most of the
cells were infected and expressed viral antigen, and viras was released continuously 
without cellular destruction. The viral RNA was not able to produce a lytic infection when |;
transfected into uninfected susceptible cells but could be used to convert uninfected cells to 
a persistently infected cell line (Righthand & Blackburn, 1989; Righthand, 1991).
Coxsackie B viruses have also been shown to establish persistent infections (McLaren et 
a l,  1993; Gow et a l,  1997b). An in vitro carrier cell model of persistent coxsackie B5 
infection, where only a small proportion of cells cany the viral genome, was developed in 
rhabdomyosarcoma (RD) cells and maintained for over 100 passages. No cytopathic 
effect was detected, cellular protein synthesis was inhibited and two virus proteins (p33 
and p39) had altered electrophoretic mobility suggesting that mutations had occurred. 
Coxsackie B viruses are widely accepted as aetiological agents of myocarditis and it has 
been suggested that dilated cardiomyopathy (DCM) is the result of a previous viral 
myocarditis, although there are numerous reports that discount the role of enteroviruses in 
DCM. The positive association has been supported by the detection of enteroviral RNA in 
the myocardium of patients with end-stage disease requiring transplantation (Bowles et a l , 1
1989). Persistence of enterovirus in the myocardium of patients with DCM has been 
shown to be a powerful indicator of poor prognosis (Why et a l ,  1994). Conaldi et al,
'V:(1997) looked at the interaction of coxsackieviruses with murine vascular endothelial cells.
'^1All 6 types infected the endothelial cells without producing any cytopathic effect, with the 
replication of coxsackie B types 3 and 5 persisting for an undefined period. Detection of |
virus in the cell supernatant and demonstration of the presence of the minus strand of the 
RNA indicated that continued virus replication was occurring. In this case only a small 
proportion of cells were involved, persistence being maintained through a carrier-state
■I'culture.
One example of enteroviral persistence in vivo is in patients with agammaglobulinemia |
who are susceptible to chronic enteroviral infection of the central nervous system, |
developing chronic meningoencephalitis as part of the syndrome. Wilfert et a l,  (1977) f
showed that virus could be isolated from the CSF of 5 such patients. Echovirus types 9,
19, 30 and 33 were recovered for periods ranging from 2 months to 3 years. O’Neill et al,
(1988) described a case study where enterovims was isolated from stool samples over a 
period of approximately 5 years. Coxsackievirus A15 was isolated up until 1984, then 
coxsackievirus A4 was isolated in 1985. Oligonucleotide fingerprint maps of 5 of each of
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these showed that isolates of the same serotype were similar to each other but markedly 
different from the other serotype. Two isolates with identical prints were obtained from 
stools taken within eight days of each other. The degree of change was estimated at 1 % of 
the genome over a period of 2 to 6 years. This case study showed that virus culture 
negative intervals were common in this syndrome although the signs and symptoms of the 
infection could persist for months to years. Rotbart et a l  (1990) showed that by using 
PCR, enteroviral RNA could be detected in the CSF of patients with agammaglobulinemia 
through the culture negative periods. Leparc et a l  (1994) also showed that while 
enteroviruses could not be isolated from CSF they could be detected by PCR in faeces and 
throat-swab samples.
4.5.2.2. Enteroviral persistence in patients with CFS. The majority of studies 
citing evidence for enteroviral persistence have based their findings on detecting 
enterovirus in one sample from patients who had been ill for a number of years. In the 
present study, persistence of enterovirus in CFS was assessed by identifying samples 
containing enteroviral RNA sequences, as detected by RT-PCR, from individual patients 
over time. The percentage identity between the sequences derived from the PCR 
amplicons was then determined. RT-nested PCR coupled with direct sequencing is a 
multiple step enzymatic process involving reverse transcriptase and Taq polymerase. 
These enzymes lack a 3’ to 5’ exonuclease activity and thus errors can occur during 
processing. Base substitution errors during reverse transcription have been measured at 
between 1/30000 to 1/2000 for every nucleotide polymerized (Preston et a l ,  1988; Roberts 
et a l ,  1989) and the mis-incorporation rate per nucleotide per cycle for Taq polymerase is 
estimated at 2x10 \  if constant over 30 cycles (Saiki et a l,  1988). It is generally believed 
that direct sequencing of PCR products generates reliable consensus sequences compared 
to sequencing cloned DNA of PCR products since the latter represents single amplicons 
that may contain random errors of the two enzymes. Base mis-incoiporation in single 
amplicons should be masked by correct bases in the majority of the amplicons (Zhang et 
al,  1997). Zhang assessed the reliability of direct sequencing by sequencing amplified 
products from coxsackie B3 infected mouse heart, on days 1 to 13 post inoculation and 
showed them to be identical to the published sequence of coxsackie B3 (Nancy strain). 
Three tissue samples from the same infected mouse heart were also processed 
independently and these sequences were identical to each other as well as to the published 
sequence. Thus coupling RT-PCR with direct sequencing of nested PCR products
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generated accurate consensus sequence data.
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RNA virus populations are thought to consist of a heterogeneous mixture of related 
genomes (quasispecies) rather than a single genome species (Domingo et a l, 1985). Thus 
in a virus stock consisting of quasispecies the population of genomes share a consensus 
sequence while differing from each other and the consensus sequence by one or a number 
of bases. The evidence for quasispecies has come from studies on clonal populations 
obtained at limiting dilution which have shown the occurrence of antigenic variants and 
mutant virus types. This is true for the enteroviruses; point mutations have been 
sequenced in antigenic variants of the Sabin type 1 vaccine strain derived from children 
post-immunization. Additionally, a single nucleotide change at position 472 in type 3 
Sabin vaccine, which occurs on passage through the immunized individual, is associated 
with an increase in neurovirulence (Evans et a l, 1985).
An average nucleotide sequence then, results from assigning to each residue the nucleotide 
most frequently found at the corresponding position, and will in general coincide with the 
most abundant sequence. In the present study, the accuracy of automated sequencing 
following RT-PCR was determined by obtaining 5 independent sequences of the 5’ NTR of 
the positive control virus coxsackie A9. Only one base pair difference in sequence 4 was 
noted which is probably not significant since the first few bases from either direction of a 
sequence usually contain several ambiguous base calls. This would suggest that 
sequencing of products is accurate and that the sequence obtained is representative of that 
present in the sample itself. Additionally, sequencing was carried out in both directions to 
confirm the bases identified.
Sixteen CFS patients provided two positive samples over time and these were sequenced 
and compared (Table 25 & Figure 13). Initial sequence comparisons based on 8 pairs of 
sequences suggested that 4/8 pairs (TI, PA, HA and MO) had evidence for enteroviral 
persistence based on a high sequence identity between the pairs and the presence of unique 
shared base pairs that were different from the consensus sequence (Galbraith et a l, 1997).
Two very different enteroviral sequences were derived over time from one patient (HO) 
which was strong evidence for a re-infection with a different enterovirus type. This is not 
surprising since the samples were obtained over 3 years apart. A further eight pairs of 
sequences were included in the comparison and only one further pair (HV) had a high
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enough sequence identity to suggest persistence, but it lacked any unique shared features. 
The remaining pairs were similar to each other but not at a high enough level to suggest 
that persistence had occurred. When the comparison was viewed as a whole, similarities 
were observed between sequences from different patients obtained in the same year. In 
fact, the percentage identities often exceeded those observed between consecutive pairs. 
Only two of the ‘persistent’ pairs identified initially (TI and PA) were closest in identity to 
their respective pair when compared to all the other CFS sequences and could be regarded 
as having persisted. Thus, if sequences from different patients are more similar to each 
other than to their respective pair then the high sequence identity in this region cannot be 
regarded as evidence for persistence. Additionally, comparison of three consecutive 
samples from one patient (HM) showed no pattern of evolution over time and thus no 
evidence for persistence.
From this follow-up data, only a minority of CFS patients provided two (or three) 
enteroviral positive samples over time, indicating that enteroviral persistence, as assessed sby RT-PCR, is not a major factor in this syndrome. Within this small group, analysis of 
the 5’ NTR enteroviral sequence of the positive samples did not provide an ideal means of 
assessing persistence because of the highly conserved nature of this region and the 
possibility that the variation is due to the quasispecies nature of the genome. Again l
corroboration from other regions of the genome is required, which might show that the 
same type had been detected over time.
Enteroviruses were consistently detected in a greater proportion of CFS patients than 
comparison patients throughout the study, although the proportion of CFS patients who 
were enterovirus PCR positive varied each year with 52.2% positives in 1990 compared to 
0% (out of 136 samples tested) in 1997. These figures included new patients and those 
participating in the follow-up study. No control samples were processed for 1997 due to 
time constraints although controls for the years 1990 to 1996 had shown a mean 
background level of 5.2% that varied little over the years. Additionally, enteroviral PCR 
carried out in 1997 by staff of the routine diagnostic laboratory produced positive results in 
6.5% of cerebrospinal fluid specimens and in a parallel study on juvenile-onset type 1 
diabetes-mellitus, 27% of serum samples were positive for enteroviral sequences (Nairn et 
al., 1999). Thus enterovimses were still detectable from clinical samples by PCR in 1997 
suggesting that the figure for the CFS patients was genuine and that at this time, there was
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no evidence of enteroviral sequences in these individuals. This demonstrates the variation 
present within a sample population and underscores the need to submit patients to multiple 
testing over time rather than to single point testing.
Interestingly, the greatest proportion of CFS patient PCR positives over this study period f
was recorded in the same year (1990) as a large outbreak of echovirus 4. Sixty-four 
percent of PCR-positive patients reported a date of onset of fatigue of 1990 following a flu­
like illness, suggesting that these patients were suffering from a post-infectious fatigue I
'Asyndrome. For one patient with chronic fatigue, symptoms of meningitis accompanied by 
isolation of echovirus 4 were followed by persistent lethargy. A serum sample obtained 
two months later tested positive by PCR. According to the Oxford criteria, a patient must 
have persisting fatigue as a new symptom for at least six months before a diagnosis of CFS 
can be made. In this case, the criteria could not be met at the time of sampling although 
the patient had severe chronic fatigue. For many of the patients in this initial cohort 
(Clements et a l, 1995), PCR positive samples were obtained within months of onset of ;;;
fatigue and as such many would not fulfil the Oxford criteria as was originally stated: the 
mean duration of fatigue was approximately six months. However, it would seem that 
because the patients were tested shortly after a presumed viral episode and shortly after the 
onset of fatigue, the triggering factor may have been detected in a high proportion of cases. 
Additionally, a number of the enterovirus positives were identified after one round of PCR 
only (5/88 serum samples, 2/32 stool samples and 6/62 buffy coat samples) reflecting a 
higher level of enteroviral RNA in the serum. In contrast, the comparison group samples 
required nested PCR for detection. Unfortunately, apart from the one report of an isolate 
from a CFS patient mentioned above, no other enterovimses were isolated from these 
patients to confirm that the echovirus 4 outbreak had caused an outbreak of post-infectious 
fatigue syndrome. Additionally, sequencing of PCR products and echovims 4 isolates 
which might have confirmed the relationship was not performed at this time.
All subsequent samples from CFS patients in the follow-up study required nested PCR for 
detection, suggesting a low level of enteroviral RNA in these samples. These patients 
were tested on average, approximately 4 years after the onset of fatigue, a figure which has 
been noted elsewhere. The mean duration of illness at presentation from 15 studies was 
37.1 months (Klonoff, 1992).
j;’-
Discussion  -----In summary, PCR testing of CFS patients over a number of years showed that two different :populations of CFS patients were present. Patients tested in 1990 and 1991 presented 
within months of the onset of fatigue and appeared to form an outbreak of post-infectious 
fatigue syndrome. A high percentage of these patients were enterovirus PCR positive and 
the timing coincided with a large outbreak of echovirus 4. This prompted the prospective 
study of patients attending the infectious disease clinic, for the presence of enteroviral 
sequences. These further samples were obtained from patients who had been ill for an 
average of 3.9 years. The percentage of PCR positives each year (16% to 31%) was still 
greater than that detected in the comparison patients (1.6% to 8.6%) but the difference was 
not as high as that observed in 1990-1991. Sequence analysis of a number of PCR 
products derived from the 5’ NTR confirmed that the sequences were enteroviral-like but I  
was unable to determine the serotype involved. The highly conserved nature of the 5’
NTR made it difficult to determine whether persistence of sequence had occurred (apart 
from 2 cases) in a group of 16 patients who provided 2 samples over time.
4.6. Further com parison o f  CFS sequences
One of the questions raised from the initial phylogenetic analysis was the possibility that 
the atypical sequences observed were in fact known enteroviruses for which there was no
.sequence data available. To address this, a number of enteroviral sequences derived from '
clinical specimens in the laboratory were sequenced. These included one echovirus 4 |
isolate from the 1990 outbreak, which was 82% similar to the published echovirus 4 
sequence. Also at this time, a number of additional sequences were obtained from the 
GenBank database, which were not available at the time of the initial comparisons. The 
four CFS sequences from the initial phylogenetic analysis still grouped apart from the rest, ■Sforming a cluster on their own with differences of approximately 13% from the closest 
match of echovirus 6. These CFS sequences were obtained by manual sequencing and as A
such contained a number of N ’s representing bases where a single nucleotide could not be 
assigned at these positions. This may be why they group together, apart from the 
remaining sequences. The other CFS sequences were spread throughout the 
coxsackie/echovirus-like group. Two sequences, MCN94 and SE95, were greater than 
95% similar to echovirus 19 and echovirus 7 respectively and could probably be typed as
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such. Others were still 10-12% different which makes them difficult to type as one 
serotype or another. Sequences derived from samples obtained from three patients with a 
date of onset in 1990 were compared with the 1990 echovirus 4 sequence but similarities 
ranged from 78 to 88% only.
The variation present naturally within groups of clinical isolates representing epidemic and 
endemic types was also examined. Coxsackie B3, which was dominant in 1997, had not 
been isolated in Glasgow since 1991 and 63% of the isolates were from one geographical 
region. The isolates were obtained within a five month period and differed from each 
other by very little (3%) but differed from the published coxsackie B3 isolates by as much 
as 15%, which may have been why this type caused a small outbreak after being out of 
circulation for 6 years. Similaiiy, echovirus 6 isolates from 1994 were very similar to each 
other but were up to 20% different from the published sequences. Other multiple isolates 
(echovirus 30 and coxsackie B5) representing enteroviruses isolated almost every year, 
clustered according to the time of isolation and showed considerable variation over time. 
High sequence identity between echovims 30 isolates and coxsackievims B l isolates 
obtained in the same year has been observed elsewhere with the observation that prototype 
strains were significantly different (Drebot et a l,  1994; Diedrich et a l, 1995).
Since isolates of the same serotype can vary by up to 20% in the 5’ NTR it is very likely 
that the CFS 5’ NTR sequences observed were not ‘atypical’, but were from variants of the 
known enteroviruses. However, without corroboration using sequence from other regions, 
for example the capsid region which provides a more accurate indication of serotype (Arola 
et a l, 1996) this could not be confirmed.
#
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4.7, Obtaining additional sequence
4.7.1. Standard PCR of the capsid region
The 5’ NTR sequence of hepatitis C virus is very highly conserved and in many cases, 
different subtypes are indistinguishable, although major genotypes are reliably identified 
(Simmonds et a l, 1994). As an alternative, sequence from at least two separate coding 
regions, for example the E l and NS-5 regions can be examined, identifying each of the 11 
or 12 known types or serotypes. With the enteroviruses, the capsid coding region is 
suitable for amplification being relatively conserved among the different types and also 
because neutralizing antigens are present in this region and form the basis for serotyping. 
Therefore sequence information from this region should be more useful for distinguishing 
the serotype of the viral sequences identified, than that from the 5’ NTR.
Primers for a semi-nested PCR were designed to amplify a portion of the capsid region 
(nucleotides 581-1191). Primer 4+ was the reverse sequence of the first round primer used 
in the standard PCR in this study, which has been shown to amplify all the known 
enteroviruses and sequences from CFS patients. Primer A+ was the reverse of primer 3 
described by Zoll et a l, (1991) which had 100% homology with all the sequenced 
enteroviruses. As with the 5’ NTR a number of clinical isolates were available for 
sequencing and analysis of this region produced a dendrogram in which individual 
serotypes grouped together in general. The reaction was optimized with coxsackievirus 
A9, but these conditions did not produce any correctly sized amplification products from 
samples obtained from CFS patients, even though they were positive for the 5’ NTR 
sequence. Either the PCR was not sensitive enough, being 100-fold less sensitive than the 
standard 5’ NTR-PCR or the sequence of this region is so different that the primers will not 
bind and therefore no amplification occurs.
The failure to amplify this region could also be explained by a deletion in the target 
sequence. Defective-interfering (DI) particles are naturally occurring deletion mutants that 
have been recognized for almost all groups of infectious viruses (Kuge et a l, 1986). The 
generation of DI particles of poliovirus type 1 (Mahoney) has been reported. These
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4.7.2. Inverse PCR
If other regions of the genome are so variable or absent that it is difficult to design primers 
that will anneal, then alternative techniques for amplification needed to be employed. It is 
possible to take advantage of the known sequence to which the standard primers will bind 
and design an inverse PCR reaction. In this study, primers in an inverse orientation to 
those which could amplify the 5’ NTR region were used to amplify the flanking regions of 
the known 264 base pair sequence.
Preparation of the template for inverse PCR was attempted with various combinations of 
heat and chemical inactivation of enzymes all of which involved a number of different 
stages. No part of the process will result in 100% recovery of the DNA sample and thus 
the greater the number of steps to the protocol, the less DNA will be available for the PCR 
process. With clinical material, the starting copy number is low and the chances of 
retaining enough to have sufficient template for the PCR process are poor. The inverse 
PCR procedure was not successful. Even with coxsackievirus A9 as the control, no bands
initiated normal poliovirus replication but were unable to synthesize capsid proteins (Cole 
et a l, 1971), suggesting that they lacked the region encoding these proteins. Additionally, 
almost all the deletions were shown to be located at bases 1300 to 3100, the region coding 
for the capsid proteins. A similar result was observed with Sabin type 1 poliovirus with 
deletions between positions 1307 and 2630 (Kajigaya et a l, 1985). Secondary structure 
was discovered to be common to all the deletion sites and it was proposed that a portion of 
the template looped out due to structural interactions and that the polymerase bypassed this 
portion, resulting in the synthesis of deleted daughter chains.
In this study, the VP4/VP2 region amplified by primers A+/B- is slightly upstream (ending 
at position 1200) of the deletion sites referred to above but it is still possible that the lack 
of amplification observed with the clinical samples is explained by a deletion in this 
region. This would result in the production of defective particles which, lacking part of #  
the capsid might be unable to establish a productive infection. Only one study has in fact 
been successful in isolating virus from a number of patients with CFS (Yousef et a l,
1988).
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were produced which were suitable for sequencing. It was difficult to optimize the system 
because of the lack of a positive control for the PCR reaction and time constraints 
prevented this being pursued further. Only a limited amount of enterovirus positive 
clinical material was available and it was decided not to use it in this system.
4.7.3. Long PCR
The complete nucleotide sequence of only a small number of picomavirus genomes is 
known. These have generally been elucidated by traditional cloning strategies that are 
time consuming and usually do not produce cDNA clones of full length. For example, 
Kandolf and Hofschneider (1985) screened nearly 5000 cDNA clones before isolating a 
full-length coxsackie B3 clone. Improvements in the PCR process have permitted the 
synthesis of amplicons up to 40kb. This is generally facilitated by the combination of 
thermostable DNA polymerases with and without proofreading activity (3’ to 5’ 
exonuclease activity). The limiting factor in RT-PCR is the reverse-transcription stage: 
standard RT-enzymes generally do not produce full-length cDNAs, The use of a 
recombinant reverse transcriptase enzyme which has been engineered without RNase H 
activity, which would normally degrade template RNA, enables the synthesis of full-length 
product to a reasonable efficiency (Lindberg et a i, 1997). Using a combination of RT and 
polymerase enzymes, long PCR has been achieved for hepatitis genomes (Teilier et a l, 
1996), coxsackie B2 (Gow et a l, 1996) and 14 prototype strains of group B 
coxsackieviruses and echoviruses (Lindberg et a i, 1997). Nested long PCR of the 
hepatitis B genome was sensitive to 10^  TCIDso for the first round and 10 TCIDso for the 
second which corresponded to 100 genome copies (Teilier et a l, 1996).
In this study approximately 5kb of the standard coxsackievirus A9 genome was amplified 
using a nested PCR system. The sensitivity of the nested reaction however was low, with 
the standard not detected below 10^  TCID50 and again this was unsuitable for use with 
clinical samples which contain less than 1 TCID50 (based on the standard 5’ NTR PCR). 
The problem with optimizing long PCR and especially a nested reaction is that it is time 
consuming with 35 cycles taking approximately 6 hours. These problems may be 
overcome by the recent introduction of the lightcycler system (Idaho Technologies) for 
PCR which uses glass capillary tubes as the reaction vessels. This allows the processes of
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heating and cooling to be extremely rapid, and 35 cycles of standard PCR can be completed 
within 15 minutes. This would allow optimization of PCR to be carried out more quickly 
and because the volumes used in each reaction are small (less than 10|il) the cost of such a 
procedure would be minimized. It may then be possible to optimize the reaction to a level 
comparable with that described for hepatitis B.
One interesting fact that emerged from this procedure was that 85% of enterovirus positive 
clinical samples (by standard PCR) could not be primed with a poly-T primer. The 
subsequent addition of poly-A residues by enzymatic methods enabled priming to occur 
suggesting that the poly-A tail was either reduced or absent from the RNA in these 
samples. Alternatively, the genome may be present as fragments only due to degradation. 
Another group (Gow et a l, 1997) could only amplify 7/23 samples from muscle biopsies 
using a poly-T primer. The lack of a poly-A tail has been shown to have an effect on the 
infectivity of the virus. Early studies had shown that adenine sequences shorter than 20 
nucleotides reduced the infectivity of virion RNA 20-fold (Spector & Baltimore, 1974).
This was confirmed by Sarnow (1989) who showed that poliovirus RNAs with long 
homopolymeric adenine sequences at the 3’ end were more infective than those with short 7
adenine sequences. It was suggested that these RNA molecules were unstable or poor 
templates for translation or initiation of minus strand RNA synthesis. This might go some 
way to explaining why there is a distinct lack of success in isolating virus from CFS 
patients and why in most cases, nested PCR is required for the detection of RNA indicating I
a low level of infection. Again, because of limited sample volume, the implications of this 
finding could not be pursued further.
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4.7.4. Construction and screening of a cDNA library
One final approach to obtain full length sequence was the cloning of cDNA derived from a 
positive sample, into a vector, creating a cDNA library which could then be screened for I
the appropriate cDNA of interest. The vector system used combines the high efficiency of
,1;'lambda library construction and convenience of a plasmid system with blue-white colour Iselection and can accommodate DNA inserts up to lOkb in length. This process relies on 
the generation of full-length cDNA by priming with a poly-T primer and having sufficient 
RNA (optimum 5 jiig) as starting material. As has been stated earlier, nested PCR is |
required to obtain a signal from most CFS samples and a number of samples could not be
Î
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primed by the poly-T primer. It was therefore difficult obtaining a sample that had 
sufficient volume to maximize the amount of RNA available that was also poly-A (+). If 
the samples had been received shortly after the onset of fatigue rather than after at least 6 
months when CFS has been formally diagnosed, this might have improved the chances of 
picking up the virus at a higher level. As has been mentioned earlier, samples obtained in 
1990 were received 2 to 6 months after the onset of illness and a number were positive 
after 35 cycles of amplification and did not require nested PCR for detection, reflecting a 
higher level of RNA in the sample. Subsequent samples which were in general obtained 
approximately 4 years after onset all required nested PCR for detection.
The cloning procedure involves the incorporation of ^^ P at an early stage which means that 
subsequent stages must be carried out behind a protective screen and dedicated centrifuges 
and equipment must be used for safety reasons. The column used for size fractionation of 
the cDNA had to be assembled from various components and the column loaded with gel 
filtration medium. This was not easy to do and was very time consuming (previous 
versions of this kit provided a fractionation column). Again, working with the column 
behind a protective screen was restricting. After packaging of the cDNA/vector construct 
the number of recombinant plaques containing the insert should have been 10 to 100-fold 
above the background plaques, without the insert, but in this case the ratio was only 
approximately 2:1. Thus the recombinants were only present in 50% of plaques and the 
insert of interest was only present in very small quantities to begin with, making it very 
difficult to detect. The procedure was indeed completed without the identification of a 
positive plaque and screening the library with control PCR product representing the human 
ableson thymidine kinase mRNA produced no positives. This suggested that the libraiy 
did not contain sufficient cDNA inserts at the beginning due to the low quantities of RNA 
present in the original sample. Thus this method was not sensitive enough to pick up the 
cDNA of interest.
Techniques such as subtractive hybridization can be used to enrich for the RNA species of 
interest (Diatchenko et a l, 1996). In theory, two populations of similar mRNA are used, 
with one containing RNA not expressed in the other (for example enterovirus positive 
RNA from a CFS patient and enterovirus negative RNA from a control patient). Both 
RNA species are converted into cDNA and then hybridized together. The hybrid 
sequences are then removed thus leaving behind cDNAs that are not hybridized and are
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present in one sample only, which should be the enterovims RNA (presuming the control 
RNA is negative for other viruses also). The population of mRNA is thus enriched for the 
enterovirus RNA and this might just provide enough starting material for the cloning 
techniques to work. This is a technique which could be tried in the future.
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4.8. Conclusions
From the existing literature, what is clear about the illness described as Chronic Fatigue 
Syndrome (CFS) is that no one common factor can be considered to be the cause of all 
cases. Various aetiologies have been suggested but no consensus has emerged. It has 
proven difficult to design studies to address the problem because of the nature of the 
illness. Only studies set up with appropriate controls and employing recognized testing 
methods can be considered as valid and providing reliable results. This illness is almost 
certainly multifactorial in origin and as such different groups of patients examined at 
different times and locations, are likely to produce different results. Instead of dismissing 
data that is not confirmed by others, results should be viewed as pertinent data for the 
patients of study. For example, the conflicting evidence for the association of various 
viruses in a significant number of patients may be a result of epidemiological differences. 
Borna disease vims has been associated with CFS in Japan but not in the USA or UK while 
enteroviruses have been associated with CFS in the UK but not elsewhere.
Previous data from the UK had shown a significant association between enterovimses and 
CFS based on serological and nucleic acid hybridization studies. Detection of enteroviral 
RNA in muscle biopsies also confirmed this association. A number of investigators had 
shown that the polymerase chain reaction was more sensitive than isolation and 
hybridization techniques for the detection of enterovimses from clinical samples. This 
technique was optimized in this laboratory and a preliminary study on samples collected 
during 1990 and 1991 indicated that a significant proportion of patients with CFS were 
positive by PCR for enteroviral sequences compared with comparison patients. PCR was 
thus shown to be an appropriate technique for the detection of enterovims in patients with 
CFS. Further investigation suggested that the trigger for CFS in this cohort may have been 
echovims type 4, which was predominant in Glasgow that year and was responsible for a 
large outbreak of aseptic meningitis. This was tme for one patient, with a confirmed 
echovirus 4 isolate followed by a persistent fatigue and the detection of enteroviral 
sequences in the serum approximately 2 months later. As such, this patient and a number 
of others (with a mean duration of fatigue of six months) did not fulfil the Oxford criteria 
of a minimum of six months fatigue for a formal diagnosis of CFS. This may be the 
reason why such a high proportion were enteroviral PCR positive, since they were tested
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shortly after onset following an episode of flu-like illness. Additionally, a number of 
samples required only one round of PCR before enteroviral sequences were detected, 
which implies a greater quantity of viral sequences present in the original sample than f
those samples that required nested PCR for detection. With no sequence data from the f
PCR positives collected at this time or the echovirus 4 isolates it has not been possible to 
confirm that the echovirus 4 was the triggering agent in these cases.
Subsequent testing of new patients with CFS from 1992 onwards showed that 
enteroviruses were still detected by nested PCR in higher numbers (16-31%) compared to 
comparison samples (1.6-8.6%) although the figures were reduced. The majority of 
patients included in the follow-up study were on average tested 3.9 years after the onset of 
fatigue and if the virus was involved as a trigger via a ‘hit and run’ mechanism it would ;i3
most likely have been cleared long before any testing was carried out. In 1997 there were 
no new PCR positive samples detected among the CFS patients. This was not the result of 
any changes in testing procedure since enteroviral PCR positive samples were still being 
detected by PCR in a parallel study on juvenile-onset type 1 diabetes mellitus (Nairn et al.,
1999). Additionally, results from the routine virological service in the laboratory showed 
that 6.5% of clinical samples were positive for enteroviral PCR.
Initial sequencing of 20 new enteroviral PCR positives demonstrated the presence of 
‘atypical’ enteroviral sequences that on phylogenetic analysis grouped apart from the 
known enteroviral sequences and the non-CFS comparison sequences. This could be I
because the sequences represented ‘novel’ enteroviruses, or known enteroviruses for which |
no sequence data was available or known enteroviruses with abnormal 5’ NTRs. The 
latter has implications for the functioning of the virus since this region contains the internal %
ribosome entry site (1RES). This area of highly structured RNA is important for the ?|
replication and translation functions of the genome and alterations can lead to reduced 
efficiency of both. ‘Atypical’ 5’ NTR sequence has also been reported elsewhere (Han et 
a l, 1998).
Further sequence analysis of the 5’ NTR of a number of clinical enterovirus isolates was 
carried out to examine the natural variation between isolates of the same serotype. The 
results showed that sequences from isolates of the same serotype collected within a short 
time span of each other were very closely related, whereas sequences from serotypes
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isolated years apart differed greatly. The variation observed was of the same order as that
between the CFS ‘atypical’ sequences and the known enteroviruses at the time. Therefore, J
this suggests that the ‘atypical’ sequences are probably known enteroviruses with variable
5’ NTRs, and this is probably true for the sequences identified by Han et al. (1998). The
5’ NTR is therefore not a suitable region for determining the type of the virus present
because of the high degree of conservation.
Sequencing of other regions of the genome, especially those coding for the capsid proteins
would give an indication of serotype. Primers were therefore designed to anneal to part of
the VP4/VP2 region and could amplify the majority of the enterovirus types. Sequencing
of clinical isolates and subsequent phylogenetic analysis showed that the different
serotypes could be distinguished in this region. However, none of the samples that were
previously positive using the standard 5’ NTR primers were positive for the VP4/VP2
region. This could either have been due to a lack of sensitivity of this PCR (100-fold less
sensitive than the standard), a high variability of sequence in this region that prevented the
primers from annealing or a deletion in this region of the genome. Deletions downstream fi
of the region amplified here have been demonstrated in defective-interfering particles 
.which have been recognized for a number of virus types and have been shown to play a 
role in the establishment of persistent infection in tissue culture and in vivo (Holland & 
Villareal, 1975; Holland e ta l ,  1979; Holland e ta l,  1980).
The use of other techniques including inverse and long PCR and the construction of a 
cDNA library all failed to elucidate any further sequence information from any of the CFS 
patients. It was thought that this was the result of sensitivity problems. The samples 
detected by one round of PCR only, from the 1990-1991 cohort may have provided better 
starting material for the less sensitive PCR of the other regions of the genome and cloning 
techniques which are also less sensitive than nested PCR. However, these results could 
also be due to the sequence being very different from the conventional viruses in the other 
regions studied. Indeed, the interesting discovery that a number of enteroviral RNA 
sequences had little or no poly-A tail at their 3’ end points to some differences between 
these sequences and conventional enterovirus isolates. The inability to prime from the 3’ 
end has also been reported by another group (Gow, 1997) and the lack of poly-A tail has 
been shown to relate to the infectivity of the virus. This may be the reason why the RNA 
is present at low levels in the serum, requiring nested PCR for detection and why isolation
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of enterovimses has been generally unsuccessful. Again, with very little sample volume 
available for these cases, this finding and its implications could not be pursued.
The idea of enteroviral persistence was explored in this thesis by identifying patients with 
more than one enterovirus PCR positive sample over time. Initial sequence analysis of i;
eight pairs of sequences suggested that 4/8 had evidence for persistence based on a high f
level of sequence identity and the presence of unique shared features which were not 
observed in a consensus sequence. However, subsequently a further eight pairs of | |
sequences were included in the analysis and this highlighted identities between samples 
obtained in the same year. These identities were in most cases greater than those observed 
between consecutive pairs, except for two patients whose sequences maintained their
■■Hunique shared bases that were not observed in any other sequence. From this data, 
persistence was not evident in the majority of paired samples, but the 5’ NTR was not an 
ideal region to explore this idea, being very highly conserved.
Comparison of clinical data derived from a patient questionnaire with enterovirus PCR 
results did however indicate that persistence did not contribute to the maintenance of CFS 
in the majority of patients, although data from the first questionnaire did support a 
relationship between enterovirus positivity and severity of symptoms as measured by 
ability to work and time spent walking etc.
Thus, the study of enterovimses in a number of patients with chronic fatigue syndrome has 
proven difficult, mainly because of sensitivity problems and the small volumes of sample 
available for study. The results do not rule out a role for the enterovimses in CFS, but the 
methods employed to study the enteroviruses and their nature did not provide a definitive 
answer. It has been shown that results of PCR testing for enterovimses can vary over the 
years and therefore it is important that studies test patients more than once to gain more Ithan a snapshot view of what is occurring. Testing patients shortly after the onset of ; : 
fatigue may prove more fruitful in detecting potential triggering agents, even though the 
patients have not been formally diagnosed by this time. Additionally, patients may be able 
to recall more clearly their health etc. prior to the onset of fatigue. It is also important to 
treat every case of CFS as an individual illness, since the aetiology may involve a 
combination of environmental, psychological and biological factors. The heterogeneity of 
the patient group probably contributes to the great variety of data observed in this 
interesting syndrome. NS;
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Should the investigation of enterovimses and CFS be pursued? Those individuals with a 
recent history of onset of symptoms following a flu-like illness would be worth 
investigating further to determine whether enteroviral sequences were present, whether 
there was evidence of active replication (by looking for the presence of the negative sense 
strand of the viral genome for example) and attempting to isolate the virus from stool 
samples after acid-culture since this has proved successful recently. Additionally, the 
analysis of the amounts of positive and negative strands could be carried out to attempt to 
repeat the work of Cunningham et al., (1990) who concluded that the equal amounts of 
positive and negative strand were the result of a persistent infection. These individuals 
could also be monitored at more frequent intervals and clinical information obtained by 
interview rather than by questionnaire. For those cases, who have been ill for some time, 
it is difficult to determine (without a pre-fatigue sample) whether a viral sequence detected 
a number of years after onset has any bearing on the initiation of the syndrome.
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